Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol:  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 1 of 115  Version 7 (15 April  2022) 
   
 
CLINICAL STUDY PROTOCOL  
Protocol Title A Phase 1b -2 Study of the ROR1-Targeting Monoclonal 
Antibody, Cirmtuzumab (UC -961), and the Bruton Tyrosine 
Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid 
Malignancies  
Investigational Product  Cirmtuzumab  (UC-961) (INN: zilovertamab)  
Protocol Number  CIRM -0001 (Oncternal Therapeutics, Inc)  
Developmental Phase  Phase 1b -2 (Clinical Safety and Efficacy)  
US IND Number  133131  
Sponsor Name [CONTACT_512988], Inc 
[ZIP_CODE] El Camino Real, Ste 230 
San Diego, CA [ZIP_CODE]  
Protocol Version s (Date s)  
Version 1 (31 January  2017) 
Version 2 (22 March 2017) Version 3 (19 April 2017) Version 4 (27 April  2018) 
Version 5 (19 July 2019) Version 6 (05 February  2021) 
Version 6.1 (15 March 2021) 
Version 7.0 ( 15 April 2022)  
 
  
Confidentiality Statement 
This document contains confidential information belonging to the study sponsors . Except as may be 
otherwise permitted in writing, by [CONTACT_99458], it is agreed that this 
information should not be disclosed to others (except if required by [CONTACT_65855]) and 
should not be used for unauthorized purposes.  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37

Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 2 of 115  Version 7 ( 15 April  2022 ) 
 ONCTERNAL PROJECT PERSONNEL  
 
Oncternal Therapeutics, Inc 
Chief Medical Officer  Salim Ya zji, MD  
San Diego, CA , [LOCATION_003] 
Telephone: +1( 858) 434- 1113 x223 
Email: CIRM -[EMAIL_9745]  
  
Oncternal Therapeutics, Inc Clinical Operations  Angela Pi[INVESTIGATOR_512906], CA, [LOCATION_003]  
Telephone: +1 ( 858) 434 -1113 x210 
E-mail: CIRM -[EMAIL_9745]   
 
 
ONCTERNAL SIGNATURE   
  
[CONTACT_512989] , MD  
Chief Medical Officer   
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37

Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol:  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 3 of 115  Version 7 (15 April  2022) 
 INVESTIGATOR’S SIGNATURE [CONTACT_317924]:       
Study Number:  CIRM -[ADDRESS_664047] Name(s):  Cirmtuzumab (UC -961) (INN: zilovertamab)  
Study Title:  A Phase 1b -2 Study of the ROR1-Targeting Monoclonal Antibody, 
Cirmtuzumab (UC -961), and the Bruton Tyrosine Kinase Inhibitor, 
Ibrutinib, in Patients with B -Cell Lymphoid Malignancies 
Document Date:  15 April 2022 
 
As Principal Investigator, I agree:  
• To keep all documentation supplied to me or developed by [CONTACT_512930], and 
that has not been previously published, in the strictest confidence. This documentation includes, but is not limited to, the Investigator’s Brochure and Case Report Forms (CRFs) 
• That the study will not commence without prior written approval of a properly 
constituted Institutional Review Board. No changes will be made to the study Protocol 
without prior written approval of Oncternal Therapeutics, Inc.  and the Institutional 
Review Board, except where necessary to eliminate an immediate hazard to patients  
• To implement and  conduct the study diligently and in strict compliance with the protocol, 
good clinical practices and all applicable laws and regulations  
• To accurately transfer all required data from each patient’s source document to the CRFs. 
The original CRFs will be submitted to the Sponsor in a timely manner at the completion of the trial, or as otherwise specified by [CONTACT_1034] 
• To keep a complete and accurate accounting during and at the completion of the trial of 
all procedures performed with the drug provided by [CONTACT_1034] 
• To allow authorized representatives of Oncternal Therapeutics, Inc.  or regulatory 
authority representatives to conduct on- site visits to review, audit and copy trial 
documents. I will personally meet with these representatives at mutually convenient times to answer any trial -related questions 
• To provide the Sponsor with an investigator’s summary within [ADDRESS_664048] patient enrolled, or as designated by [CONTACT_2728] 
• To maintain all information supplied by [CONTACT_512931], when this 
information is submitted to an Institutional Review Board (IRB), Ethical Review Committee, or another group, it will be submitted with a designation that the material is confidential. 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol:  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 4 of 115  Version 7 (15 April  2022) 
 This protocol was designed and will be conducted, recorded, and reported in compliance with the 
principles of Good Clinical Practice (GCP) guidelines. These guidelines are stated in [LOCATION_002] federal regulations as well as “Guidance for Good Clinical Practice,” International 
Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. 
 
I have read this protocol in its entirety, including the preceding statements, and I agree to comply with all aspects of this trial.  
 
 
   
Investigator Printed Name 
  
    
[CONTACT_512990]: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 5 of 115  Version 7 ( 15 April  2022 ) 
 TABLE OF CONTENTS  
ONCTERNAL PROJECT PERSONNEL  .......................................................................................2  
INVESTIGATOR’S SIGNATURE [CONTACT_1783] ......................................................................................[ADDRESS_664049] OF ABBREVIATIONS AND DEFINITIONS OF TERMS  ................................................11  
STATEMENT OF COMPLIANCE  ...............................................................................................14  
1. PROTOCOL SUMMARY ...................................................................................................15  
1.1. Synopsis  ...........................................................................................................................15  
1.2. Schema  ............................................................................................................................18  
1.3. Schedule of  Activities  ......................................................................................................18  
2. INTRODUCTION  ................................................................................................................19  
2.1. Lymphoid Cancers  ...........................................................................................................19  
2.2. Inhibition of Bruton Tyrosine Kinase in Lymphoid Cancers  ..........................................19  
2.3. Receptor Tyrosine Kinase -like Orphan Receptor 1 (ROR1)  ...........................................20  
2.4. Cirmtuzumab  ...................................................................................................................22  
2.4.1.  Discovery  ....................................................................................................................22  
2.4.2.  Chemi stry ....................................................................................................................23  
2.4.3.  Clinical Experience with Cirmtuzumab  ......................................................................23  
2.4.4.  Combination Studies of Cirmtuzumab and Ibrutinib..................................................23  
2.5. Conclusions/Study Rationale  ...........................................................................................24  
3. OBJECTIVES AND ENDPOINTS  .....................................................................................26  
3.1. Primary Objectives  ..........................................................................................................26  
3.2. Secondary Objectives  ......................................................................................................26  
3.3. Primary Study Endpoints  .................................................................................................26  
3.4. Secondary Study Endpoints  .............................................................................................26  
3.4.1.  Antitumor Activity and Survival  ................................................................................26  
3.4.2.  Safety Profile  ..............................................................................................................27  
3.4.3.  Pharmacokinetics  ........................................................................................................27  
3.4.4.  Pharmacodynamics/Exploratory Biomarkers  .............................................................27  
3.4.5.  Immunogenicity  ..........................................................................................................28  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 6 of 115  Version 7 ( 15 April  2022 ) 
 4. STUDY DESIGN  .................................................................................................................29  
4.1. Part 1 – Dose -Finding (Cirmtuzumab → Cirmtuzumab + Ibrutinib)  ..............................29  
4.2. Part 2 – Cohort Expansion (Cirmtuzumab + Ibrutinib)  ...................................................30  
4.3. Part 3 – Efficacy Evaluation (Cirmtuzumab + Ibrutinib versus Ibrutinib)  ......................30  
4.4. Rationale for Study Design .............................................................................................31  
4.5. Rationale for Study Drug Doses  ......................................................................................32  
5. STUDY POPULATION: RECRUITMENT AND SELECTION OF STUDY 
PATIENTS  ...........................................................................................................................33  
5.1. Planned Number of Patients  ............................................................................................33  
5.1.1.  Part 1 (Cirmtuzumab → Cirmtuzumab + Ibrutinib)  ...................................................33  
5.1.2.  Part 2 (Cirmtuzumab + Ibrutinib)  ...............................................................................33  
5.1.3.  Part 3 (Cirmtuzumab + Ibrutinib versus Ibrutinib)  .....................................................33  
5.2. Enrollment of Study Patients  ...........................................................................................33  
5.3. Patient Selection Criteria  .................................................................................................33  
5.3.1.  Inclusion Criteria  ........................................................................................................34  
5.3.2.  Exclusion Criteria  .......................................................................................................36  
6. STUDY INTERVENTION ..................................................................................................38  
6.1. Cirmtuzumab  ...................................................................................................................38  
6.1.1.  Known Potential Risks: Cirmtuzumab (zilovertamab)  ...............................................38  
6.1.2.  Known potential benefits: Cirmtuzumab (zilovertamab)  ...........................................38  
6.1.3.  Description  ..................................................................................................................38  
6.1.4.  Source  .........................................................................................................................39  
6.1.5.  Packaging and Labelling .............................................................................................39  
6.1.6.  Shippi[INVESTIGATOR_007], Storage, and Stability .................................................................................39  
6.1.7.  Cirmtuzumab Administration  .....................................................................................39  
6.2. Ibrutinib  ...........................................................................................................................41  
6.2.1.  Known potential risks: Ibrutinib .................................................................................41  
6.2.2.  Description  ..................................................................................................................42  
6.2.3.  Source  .........................................................................................................................42  
6.2.4.  Packaging and Labelling .............................................................................................42  
6.2.5.  Shippi[INVESTIGATOR_007], Storage, and Stability .................................................................................42  
6.2.6.  Dispensing ..................................................................................................................42  
6.2.7.  Return and Compliance Assessment  ..........................................................................42  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 7 of 115  Version 7 ( 15 April  2022 ) 
 6.2.8.  Ibrutinib Administration  .............................................................................................43  
6.3. Dose Modifications  .........................................................................................................44  
6.3.1.  Dose adjustments for Cirmtuzumab  ...........................................................................44  
6.3.2.  Treatment interruptions for Cirmtuzumab  ..................................................................44  
6.3.3.  Dose modifications for Ibrutinib ................................................................................45  
6.4. Concomitant Therapy  ......................................................................................................46  
6.4.1.  Cirmtuzumab Infusion- Reaction Prophylaxis  ............................................................46  
6.4.2.  Tumor Lysis Syndrome (TLS) Prophylaxis  ...............................................................47  
6.4.3.  TLS Management  .......................................................................................................47  
6.4.4.  Anticancer Therapi[INVESTIGATOR_512907]  .....................................................47  
6.4.5.  Anticoagulants  ............................................................................................................48  
6.4.6.  Drugs with Potential for Drug- Drug Interactions with Ibrutinib  ................................48  
6.4.7.  Drugs Known to Prolong the QT Interval  ..................................................................49  
6.4.8.  Procedures/Surgery  .....................................................................................................[ADDRESS_664050] Feeding  ............................................................................................................49  
6.5.2.  Contraception  ..............................................................................................................49  
6.5.3.  Diet .............................................................................................................................50  
7. STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  ............................................................................51  
7.1. Duration of Study Drug Administration and Study Participation ...................................51  
7.2. Patient Replacement  ........................................................................................................52  
7.3. Study Discontinuation  .....................................................................................................52  
8. STUDY ASSESSMENTS AND PROCEDURES  ...............................................................53  
8.1. Study Activities  ...............................................................................................................53  
8.2. Schedule of Activities – Part 1 MCL and CLL/SLL (Cirmtuzumab → Cirmtuzumab + Ibrutinib)  ................................................................................................54
 
8.3. Schedule of Activities – Part 2 MCL, MZL and CLL/SLL (Cirmtuzumab + Ibrutinib)  ..........................................................................................................................57
 
8.4. Schedule of Activities – Part 3 CLL/SLL (Cirmtuzumab + Ibrutinib versus Ibrutinib)  ..........................................................................................................................60
 
8.5. Efficacy Assessments  ......................................................................................................63  
8.5.1.  Overview  .....................................................................................................................63  
8.5.2.  Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma  ............................63  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 8 of 115  Version 7 ( 15 April  2022 ) 
 8.5.3.  Lymphoma  ..................................................................................................................64  
8.6. Safety Assessments  .........................................................................................................65  
8.6.1.  Definitions  ..................................................................................................................65  
8.6.2.  Grading of the Severity of an Adverse Event  .............................................................67  
8.6.3.  Describing Adverse Event Relationship to Study Drug  .............................................68  
8.6.4.  Adverse Event Reporting Period ................................................................................69  
8.6.5.  Adverse Event Reporting Requirements  ....................................................................69  
8.6.6.  Pregnancy and Reporting ............................................................................................70  
8.6.7.  Sponsor Reporting Requirements  ...............................................................................71  
9. STATISTICAL CONSIDERATIONS  .................................................................................72  
9.1. Analysis Plan  ...................................................................................................................72  
9.1.1.  Pharmacokinetics  ........................................................................................................72  
9.1.2.  Pharmacodynamics  .....................................................................................................72  
9.1.3.  Efficacy Analyses  .......................................................................................................72  
9.1.4.  Other Analyses  ............................................................................................................72  
9.2. Timing of Analyses  .........................................................................................................73  
9.2.1.  Interim Analyses  .........................................................................................................73  
9.2.2.  Final Analyses  ............................................................................................................74  
9.3. Basis for the Planned Sample Sizes  .................................................................................74  
9.3.1.  Part 1 (Cirmtuzumab → Cirmtuzumab + Ibrutinib) and 
Part 2 (Cirmtuzumab  + Ibrutinib)  ...............................................................................74  
9.3.2.  Part 3 (Cirmtuzumab + Ibrutinib versus Ibrutinib)  .....................................................[ADDRESS_664051] (IRB)  ...................................................................................75  
10.5.  Informed Consent  ............................................................................................................76  
10.6.  Confidentiality  .................................................................................................................76  
10.7.  Sample Shippi[INVESTIGATOR_007], Storage, and Retention  .......................................................................77  
10.8.  Study Files and Retention of Records and Biological Samples  ......................................77  
10.9.  Modifications of the Protocol  ..........................................................................................78  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 9 of 115  Version 7 ( 15 April  2022 ) 
 10.10.  Case Report Forms  ..........................................................................................................[ADDRESS_664052]  .............................................................................81  
10.17.  Study Reporting and Publication .....................................................................................81  
11. BIBLIOGRAPHY  ................................................................................................................83  
12. APPENDICES  ......................................................................................................................97  
12.1.  ECOG Per formance Status  ..............................................................................................98  
12.2.  Cockcroft -Gault Method for Estimating Creatinine Clearance  .......................................99  
12.3.  Potent Inhibitors and Inducers of CYP3A4  ...................................................................100  
12.4.  RAI Staging System for CLL/SLL  ................................................................................101  
12.5.  Efficacy Assessments – CLL/SLL  ................................................................................101  
12.5.1.  Identification and Measurement of Tumor Lesions and Organomegaly  ..................101  
12.5.2.  Definitions of Tumor Response and Progression  .....................................................103  
12.6.  Efficacy Assessment – Lymphoma  ...............................................................................107  
12.6.1.  Identification and Fol low-up of Tumor Lesions and Organomegaly .......................108  
12.6.2.  Definitions of Tumor Response and Progression  .....................................................110  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 10 of 115  Version 7 ( 15 April  2022 ) 
 LIST OF IN -TEXT TABLES  
Table 1:  Dose Adjustments for Ibrutinib  ..................................................................................46  
Table 2:  Grading of Adverse Event Severity ............................................................................68  
Table 3:  Relationship of Study Drug to Adverse Event  ...........................................................69  
Table 4:  Contact [CONTACT_512932]  .............70  
Table 5:  Summary of Response Criteria for CLL/SLL Patients  ............................................104  
Table 6:  Summary of Response Criteria for MCL and MZL Patients  ...................................[ADDRESS_664053] OF IN -TEXT FIGURES  
Figure  1: Part 1 – Dose -Finding (Cirmtuzumab → Cirmtuzumab + Ibrutinib)  .........................18  
Figure  2: Part 2 – Cohort Expansion (Cirmtuzumab + Ibrutinib)  ..............................................18  
Figure  3: Part 3 – Efficacy Evaluation (Cirmtuzumab + Ibrutinib versus Ibrutinib)  .................18  
Figure  4. Structure of ROR1  ......................................................................................................21  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 11 of 115  Version 7 ( 15 April  2022 ) 
 LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS  
Abbreviation  Definition  
AE adverse event  
ALC  absolute lymphocyte count  
ALP  alkaline phosphatase  
ALT  alanine aminotransferase  
ANC  absolute neutrophil count  
ANCOVA  analysis of covariance  
aPTT  activated partial thromboplastin time  
AST  aspartate aminotransferase  
AUC  area under the concentration -time curve  
AV Atrioventricular  
Bcl2  B-cell lymphoma 2 (protein)  
BTK  Bruton tyrosine kinase  
BUN  blood urea nitrogen  
CD cluster of differentiation  
CFR  Code of Federal Regulations  
cGMP  Current Good Manufacturing Practices  
CHO  Chinese hamster ovary (cells)  
CI confidence interval  
CK creatine kinase  
Cl clearance  
CLL  chronic lymphocytic leukemia  
Cmax maximum concentration  
CMR  complete metabolic response  
CR complete response  
CRi complete response with incomplete blood count recovery  
CRO  contract research organization  
CT computed tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
CYP  cytochrome P450 (enzyme)  
DLBCL  diffuse large B -cell lymphoma  
DLT  dose-limiting toxicity  
DNA  deoxyribonucleic acid  
DOR  duration of response  
ECG  Electrocardiogram, electrocardiographic  
eCl CR estimated creatinine clearance  
ECOG  Eastern Cooperative Oncology Group  
eCRF  electronic case report form  
EDC  electronic data capture  
EMT  epi[INVESTIGATOR_018] -mesenchymal transition  
EU European Union  
FDA  Food and Drug Administration  
FDAMA  Food and Drug Modernization Act of [ADDRESS_664054] disease  
HBc hepatitis B core (antibody)  
HBsAg  hepatitis B surface antigen  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 12 of 115  Version 7 ( 15 April  2022 ) 
 Abbreviation  Definition  
HBV  hepatitis B virus  
HCV  hepatitis C virus  
HDPE  high-density polyethylene  
HIV human immunodeficiency virus  
ICH International Conference on Harmonization  
ICMJE  International Committee of Medical Journal Editors  
Ig Immunoglobulin  
IL Interleukin  
IND investigational new drug application  
INN International Nonproprietary Name  
[CONTACT_512991], intravenously  
LD or LDi  longest  dimension  
LDH  lactate dehydrogenase  
LLQ  lower limit of quantitation  
LPD  longest perpendicular dimension  
LVD  longest vertical dimension  
MCL  mantle cell lymphoma  
MFI mean fluorescent intensity  
MRD  minimal residual disease  
MRI  magnetic resonance imaging  
MTD  maximum tolerated dose  
MZL  marginal zone lymphoma  
Na-EDTA  sodium -ethylenediaminetetraacetic acid  
NCI National Cancer Institute  
NE Nonevaluable  
NHL  non-Hodgkin lymphoma  
NK natural killer (cells)  
ORR  objective  response rate  
OS overall survival  
PCR  polymerase chain reaction  
PD progressive disease  
PET positron emission tomography  
PFS progression -free survival  
[COMPANY_003] product of the perpendicular diameters  
PR partial response  
PR-L partial response with lymphocytosis  
PT prothrombin time  
Q4 once every  
QD once per day  
QTc cardiac QT interval corrected for heart rate  
Rac1  Ras-related C3 botulinum toxin substrate  
RDR  recommended dosing regimen  
RhoA  Ras homolog gene family member A  
RNA  ribonucleic acid  
ROR1  receptor tyrosine kinase -like orphan receptor 1  
R/R Relapsed  or Refractory  
SAE  serious adverse event  
SD stable disease  
SDi shortest dimension  
siRNA  small interfering ribonucleic acid  
SLL small lymphocytic lymphoma  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 13 of 115  Version 7 ( 15 April  2022 ) 
 Abbreviation  Definition  
SPD sum of the products of the diameters  
SRC  safety review committee  
S[LOCATION_003]R  suspected, unexpected, serious adverse reaction  
t1/[ADDRESS_664055]  upper limit of normal  
Vd volume of distribution  
βHCG  beta human chorionic gonadotropin  
λz terminal elimination rate constant  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 14 of 115  Version 7 ( 15 April  2022 ) 
 STATEMENT OF COMPLIANCE  
The study will be performed in accordance with the principles as set forth under the requirements 
of 21 Code of Federal Regulations (CFR) 50 and the ICH E6 GCP guideline.  
The investigator will ensure that this study is conducted in accordance with 21 CFR parts 50 and 
54 and ICH guidelines. For studies conducted under a US IND, the investigator will ensure 
adherence to the basic principles of GCP as outlined in 21 CFR 312, subpart D, “Responsibilities of Sponsors and Investigators,” [ADDRESS_664056] to and will be conducted in accordance with 21 CFR, Part 320, 1993, “Retention of Bioavailability and Bioequivalence Testing Samples.”  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 15 of 115  Version 7 ( 15 April  2022 ) 
 1. PROTOCOL SUMMARY  
1.1. Synopsis  
Investigational Product  Cirmtuzumab (UC -961) (INN: Zilovertamab)  
Coadministered Drug  Ibrutinib  
Study Title  A Phase 1b -2 Study of the ROR1- Targeting Monoclonal Antibody, 
Cirmtuzumab (UC -961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, 
in Patients with B -Cell Lymphoid Malignancies  
Protocol Number  CIRM -0001 (Oncternal Therapeutics, Inc)  
Study Background  Among the agents approved for the therapy of chronic lymphocytic 
leukemia/small lymphocytic lymphoma ( CLL/SLL ), mantle cell lymphoma 
(MCL ) or marginal zone lymphoma (MZ L) is the Bruton tyrosine kinase 
(BTK) inhibitor, ibrutinib, which has provided durable tumor regressions in 
the majority of patients with these disorders. However, the proportion of 
patients experiencing complete response (CR) to ibrutinib monotherapy is 
low (<7% in CLL/SLL,  ~15% in MCL  and ~3% for MZL ) and resistance to 
ibrutinib eventually develops in many patients. Collectively, these data support development of a new agent with a complementary mechanism of 
action that can safely combine with ibrutinib to enhance disease clearance 
and circumvent dise ase resistance.  
Receptor tyrosine kinase -like orphan receptor 1 (ROR1) is a cell surface 
protein that mediates signals from its ligand, the secreted glycoprotein, 
Wnt5a. Consistent with its role in influencing the fate of stem cells during 
embryogenesis, ROR1 expression is observed on invasive malignancies that 
revert to an embryonic transcriptional program, but is not observed on normal 
adult tissues, offering a favorable selectivity profile as a therapeutic target. 
ROR1 is expressed on the malignant cell s in >90% of patients with CLL/SLL  
and >95% of patients with MCL  and is also expressed  on MZL [ Barna 2011 ]. 
Oncternal Therapeutics, Inc. (Oncternal) , in collaboration with The 
University of [LOCATION_004], San Diego (UCSD) is  devel opi[INVESTIGATOR_512908], cirmtuzumab, for selective targeting of hematological and other cancers with high ROR1 expression. Cirmtuzumab is a humanized 
immunoglobulin (Ig)  G1 monoclonal that shows high- affinity binding to 
ROR1. Cirmtuzumab  is synergistic w hen tested together with ibrutinib, 
inhibiting the growth of CLL  and MCL  cells in vitro, and combination 
therapy was associated with substantially greater reductions in splenomegaly 
and leukemia -cell infiltration in splenic tissue  in a murine CLL model  than 
either single agent given alone.  
Clinical evaluation of cirmtuzumab has comprised a Phase 1a, sequential 
dose-escalation study in patients with CLL/SLL . Cirmtuzumab was very well 
tolerated over a dose range of 0.015 to 20 mg/kg . Adverse events (AEs) were 
largely attributable to patients’ cancers or comorbidities and were primarily Grade 1 or 2 in intensity. No DLTs were observed, no serious adverse events 
(SAEs) occurred, and no maximum tolerated dose (MTD) was identified 
within  the tested dose range. P harmacodynamic data indicted decreases in 
ROR1 -mediated signaling as manifest by [CONTACT_512933]1 and RhoA 
expression in circulating CLL cells. Individual signs of disease control over 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 16 of 115  Version 7 ( 15 April  2022 ) 
 the 8 -week drug administration period were obser ved, including reductions in 
circulating CLL cell numbers, lymphadenopathy, splenomegaly, and/or bone 
marrow infiltration. Many patients had persistent post -therapy disease 
stabilization.  
Collectively, these data provide context for the clinical developme nt of the 
combination of cirmtuzumab and ibrutinib as therapy of CLL/SLL , MCL  and 
MZL. It is hypothesized that coadministration of these 2 drugs will result in a higher proportion of patients achieving CR and experiencing longer 
progression- free survival ( PFS). Given the exceptional clinical safety of both 
drugs, the combination is expected to be well tolerated. Accordingly, this clinical protocol will further characterize the safety, pharmacology, and 
activity of cirmtuzumab alone and when co -administered with ibrutinib in 
patients with recurrent or treatment -refractory CLL/SLL , MCL  or MZL.  
 
Study Design  This clinical trial is a Phase 1b -2 study of the safety, pharmacokinetics, 
pharmacodynamics, immunogenicity, and antitumor activity of the 
combination of cirmtuzumab and ibrutinib. The study will be conducted in 3 parts.  
 Part 1 Dose -Finding  
Cirmtuzumab →  
Cirmtuzumab + 
Ibrutinib  Part 1 comprises a Phase 1b, open -label, sequential allocation, dose -finding 
evaluation of the sequential administration of cirmtuzumab monotherapy 
followed by [CONTACT_512934] + ibrutinib combination therapy in patient s with 
CLL/SLL or MCL.  
  At the conclusion of Part 1 of the study, a recommended dosing regimen (RDR) of cirmtuzumab will be selected based primarily on safety, 
pharmacokinetic, and pharmacodynamic findings.  
 Part 2  
Cohort Expansion  
Cirmtuzumab + 
Ibrutinib  Part [ADDRESS_664057] 
derived from Part 1. Up to 18 evaluable patient s with CLL /SLL will be 
enrolled . Up to 20 evaluable patients with MCL  and up to 10 patients with 
relapsed/refractory ( R/R) MZL will be enrolled into Part 2; a clinical review 
will then be performed to determine if additional patient s are required  to 
assess safety, efficacy, and exploratory biomark ers for further development . 
 Part 3  
Efficacy Evaluation  
Cirmtuzumab + 
Ibrutinib versus 
Ibrutinib  Part 3 comprises a Phase 2 open -label, randomized, controlled, 2- arm, 
parallel -group evaluation of the clinical activity and safety of cirmtuzumab  + 
ibrutin ib versus ibrutinib alone. Patient s with CLL/SLL will be randomized 
2:1 to one of the following 2 regimens : 
• Arm A: cirmtuzumab  + ibrutinib  
• Arm B:  ibrutinib alone  
Approximately 30 patient s will be enrolled and randomized into Part 3 .  
   
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 17 of 115  Version 7 ( 15 April  2022 ) 
 Study Objectives   
 Primary Objectives  • Part 1 (cirmtuzumab → cirmtuzumab + ibrutinib): To determine the RD R 
of cirmtuzumab when given alone and in combination with ibrutinib in 
patient s with CLL/SLL or MCL 
  • Part 2 (cirmtuzumab + ibrutinib): To further characterize the safety , 
pharmacology, and clinical responses of cirmtuzumab  + ibrutinib when 
administered using the RDR  in patients with CLL /SLL , MCL , or MZL  
  • Part 3 (cirmtuzumab + ibrutinib versus ibrutinib): To further evaluate the 
CR rate associated with cirmtuzumab  + ibrutinib when administered using 
the RDR  in patients with CLL /SLL  
 
 Secondary Objectives  • To determine the drug administration, safety, and supportive care profiles of cirmtuzumab and the combination of cirmtuzumab + ibrutinib  
  
• To evaluate the pharmacokinetic profile of cirmtuzumab alone and in 
combination with ibrutinib  
  • To assess the effects of cirmtuzumab and cirmtuzumab  + ibrutinib on 
exploratory biomarker s/pharmacodynamic markers relating to drug 
mechanism, immune profile, and disease manifestations 
  • To characterize the immunogenicity of cirmtuzumab  
  • To characterize the antitumor activity of cirmtuzumab monotherapy and 
cirmtuzumab  + ibrutinib combination therapy  
 
Selection and Enrollment of Study Patient s 
 Planned Number of Patient s Part 1 (Cirmtuzumab → Cirmtuzumab + Ibrutinib)  
 If 6 patient s (3 patient s with CLL/SLL and 3 patient s with MCL) are enrolled 
at all 4 planned dose levels, 24 patient s will be enrolled. If 2 additional dose 
levels are explored in 6  patient s/dose level (3 patient s with CLL/SLL and 3 
patient s with MCL), as many as 12  additional patient s could be enrolled, 
bringing the potential sample size to 36 patient s. To allow for the possibility 
that some patient s may not be fully evaluable, up to 48  patient s may be 
enrolled.  
  Part 2 (Cirmtuzumab + Ibr utinib)  
  It is planned that the RDR will be evaluated in up to 18 patient s with 
CLL/SLL. To allow for the possibility that some patient s may not be fully 
evaluable, up to [ADDRESS_664058] will be the same for 
CLL /SLL, MCL  and MZL . Up to 20 evaluable patients with MCL  and up to 
10 patients with R/R  MZL will be enrolled into Part 2; a clinical review will 
then be performed to determine if additional evaluable patient s are required  
to assess safety, efficacy, and exploratory biomarkers for further 
development . This review could lead to a further adjustmen t and increase in 
enrollment . 
  Part 3 (Cirmtuzumab + Ibrutinib vs Ibrutinib Alone)  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol:  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 18 of 115  Version 7 (15 April  2022) 
   Approximately 30 patients  will be enrolled and randomized 2:1 into Part 3 
(~20 patients will receive cirmtuzumab + ibrutinib and ~10 patients will 
receive ibrutinib alone).  
 Target Populations The target population comprises adult patient s with adequate performance 
status and organ function who have CLL/SLL, MCL  or  MZL  and are 
appropriate candidates for ibrutinib treatment.  
 
1.2. Schema  
Figure 1: Part 1 – Dose -Finding (Cirmtuzumab → Cirmtuzumab + Ibrutinib)  
 
Patients exhibiting a PR or CR may be eligible to continue combination treatment beyond Week 52 as part of an 
extended therapy program.  
 
Figure 2: Part 2 – Cohort Expansion (Cirmtuzumab + Ibrutinib)   
 
 
 Patients exhibiting a PR or CR may be eligible to continue combination treatment beyond Week 52 as part of an 
extended therapy program
. 
 
Figure 3: Part 3 – Efficacy Evaluation (Cirmtuzumab + Ibrutinib versus Ibrutinib)   
 
Patients exhibiting a PR or CR may be eligible to continue combination treatment beyond Week 52 as part of an 
extended therapy program.  
1.3. Schedule of Activities  
Tabular schedules of study activities are presented in Section 8.2 (Part 1), Section 8.3 (Part 2), 
and Section 8.4 (Part 3).  
 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 19 of 115  Version 7 ( 15 April  2022 ) 
 2. INTRODUCTION 
2.1. Lymphoid Cancers  
B-cell lymphoid malignancies arise from the accumulation of monoclonal, neoplastic B 
lymphocytes in lymph nodes and often in organs such as blood, bone marrow, spleen, and liver. 
Among the variants of B -cell lymphoid cancers  are chronic lymphocytic leukemia/small 
lymphocytic lymphoma (CLL/SLL) , mantle cell lymphoma (MCL) , and marginal zone 
lymphoma (MZL) . These disorders are characterized by [CONTACT_512935]; 
lymphadenopathy and organomegaly that can induce life -threatening organ dysfunction; and 
myelosuppression and immunocompromise that can result in susceptibility to infection and bleeding [ Zhang 2014b; Hallek 2015; Vose 2015; Cheah 2016].  Front -line use of multiagent 
chemoimmunotherapy is commonly successful in suppressing disease manifestations for prolonged periods [ NCCN 2016a ; NCCN 2016b]. However, these diseases are incurable, and 
patients require further therapy to maintain disease control.  
2.2. Inhibition of Bruton Tyrosine Kinase in Lymphoid Cancers  
Among the agents approved for the therapy of patients with relapsed or refractory CLL/SLL , 
MCL  or MZL  is the Bruton tyrosine kinase ( BTK) inhibitor, ibrutinib (PCI -[ZIP_CODE], 
Imbruvica™). Bruton tyrosine kinase (BTK) is a non- receptor enzyme in the TEC kinase family 
that is expressed among cells of hematopoietic origin, including B cells, myeloid cells, mast cells, and platelets, where it r egulates multiple cellular processes including proliferation, 
differentiation, apoptosis, and cell migration [ Khan 2001; Mohamed 2009; Bradshaw 2010]. 
Functional nul l mutations of BTK in humans cause the inherited disease, X -linked 
agammaglobulinemia, which is characterized by a lack of mature peripheral B cells [Vihinen 2000; Ponader 2014]. Conversely, BTK  activation is implicated in the pathogenesis of 
several B -cell malignancies [ Herman 2011; Buggy 2012; Herman 2014, Kil 2013; Woyach 
2014a ]. In addition, BTK -dependent activation of mast cells and other immunocytes in 
peritumoral inflammatory stroma has been shown to sustain the complex microenvironment needed for tumor maintenance and growth [ Ponader 2012; de  Rooij  2012].  
Based on this pharmacology, ibrutinib was developed by [CONTACT_14190], Inc (now a subsidiary of [COMPANY_013], Inc) and Janssen, Inc as an orally delivered, small -molecule, irreversible inhibitor of 
BTK for the treatment of B -cell malignancies. Studies in patients with heavily pretreated 
CLL/SLL have demonstrated that chronic ibrutinib therapy can provide lasting antitumor activity for the majority of patients [ Advani 2013; By[CONTACT_26752]  2013; By[CONTACT_26752]  2014; Farooqui 2015; O’Brien  2016; 
Winqvist  2016]. Similarly, in pa tients with substantial prior therapy for MCL  and MZL, chronic 
ibrutinib monotherapy has offered tumor regressions and durable tumor control [ Wang  2013; 
Dreyling 2016;  Maruyama 2016;  Noy 2017].  
Ibrutinib has been generally well tolerated. For patients with lymphoid cancers receiving ibrutinib, clinical adverse events (AEs) (of any causality) have included: atrial fibrillation or atrial flutter; bleeding (primarily bruising and petechiae); infections; neutropenia, 
thrombocytopenia, or anemia; diarrhea, and rash. Such events have generally been infrequent and typi[INVESTIGATOR_512909] 1 or 2 in intensity [ Pharmacyclics  2020 and  Ibrutinib I nvestigator 
Brochure  2021]. Across the tested ibrutinib dose range (through 1400 mg/day), no acute dose -
limiting toxicities (DLTs) were identified and the recommended P hase 2 doses (420 mg/day for 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 20 of 115  Version 7 ( 15 April  2022 ) 
 CLL/SLL and 560 mg/day for MCL  and MZL ) were established based on pharmacodynamic 
outcomes rather than safety limitations [ Advani 2013]. The drug has also proved safe when 
administered as oral cont inuous monotherapy for periods of several years [ By[CONTACT_26752]  2015a ; Wang 
2015]. Rates of discontinuations due to adverse events have consistently been <10% across 
studies in CLL/SLL , MCL  and MZL  although they may approach ~20% in clinical practice 
[Mato  2016]. Further, ibrutinib has been readily combined with therapeutic monoclonal 
antibodies and cytotoxic agents used to treat CLL/SLL , MCL  and MZL ; because of a lack of 
overlappi[INVESTIGATOR_512910], it has been possible to administer both ibrutinib and the other agents at the full recommended dose levels [ Burger 2014; Younes  2014; Brown 2015; 
Maddocks  2015a ; Chanan- Khan  2016; Wang  2016]. Whether given alone or in combination, 
instances of tumor lysis syndrome (TLS) at the initiation of ibrutinib have been rare [ Howard 
2016]. Based on its efficacy and safety in patients with previously treated disease, ibrutinib has been approved for the therapy of previously untreated and previously treated CLL/SLL and for the therapy of previously treated MCL  and MZL  in the [LOCATION_002] (US), the European Union 
(EU), and elsewhere [ de Claro 2015; Pharmacyclics  2020].  
While ibrutinib offers tumor regressions in the substantial majority of patients, the proportion of patients with CLL/SLL experiencing a complete response (CR) to ibrutinib monotherapy is consistently <5% within the first year of therapy [ By[CONTACT_26752]  2013; By[CONTACT_26752]  2014; Farooqui 2015; 
Burger  2015; O’Brien  2016] and rises to only 7% after several years of treatment [ By[CONTACT_26752]  2015a ]. 
In previously treated MCL, rates of CR have ranged from 12.5% to 23%, even with long- term 
therapy [ Wang  2013; Dreyling 2016;  Maruyama 2016; Wang  2015].  In relapsed/refractory  MZL 
treated with prior rituximab or rituximab -based chemoimmunotherapy, rate of CR to ibrutinib 
monotherapy was  3.2% and ORR  was 46%  after  19.4 months of follow -up [Pharmacyclics 
2020] . ORR rates increased  to 58%  after  a median follow -up of 33.1 months [ Noy 2020] . 
Progression- free survival (PFS) has been very long in most patients with CLL/SLL and has 
averaged 13 to 14.6 months in those with MCL [ Wang 2015; Dreyling 2016] . For MZL, median 
PFS was 14.2 and  15.7 months, after  a median follow -up of 19.4 and 33.1 months , respectively  
[Noy 2017;  Noy 2020]. However, resistance to ibrutinib eventually develops in many patients 
with CLL and most patients with MCL [ Chiron 2014; Furman  2014; Cheng 2015; Liu  2015; 
Burger  2016; Hamasy  2016]. Am ong those becoming resistant to ibrutinib, an aggressive natural 
history is common [ Cheah  2015; Jain  2015
; Maddocks  2015b; Stephens  2015; Martin  2016].  
Collectively, these data support development of a new agent that targets a complementary mechanism of action and can safely be combined with ibrutinib to enhance disease clearance and circumven t disease resistance.  
2.3. Receptor Tyrosine Kinase -like Orphan Receptor 1 (ROR1)  
ROR1 is a type 1 transmembrane protein that shares homology to other receptor tyrosine kinases and shows high evolutionary conservation [ Masiak owski  1992; Forrester 1999; Yoda  2003; 
Katoh  2005]. As shown in Figure  4, the extracellular portion contains immunoglobulin- like 
sequences, a cysteine -rich domain homologous to Frizzled receptors for various Wnt ligands, and 
a kringle domain. The cytoplasmic portion contains a tyrosine kinase -like domain followed by 
[CONTACT_96162]/threonine - and proline -rich motifs.  
 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol:  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 21 of 115  Version 7 (15 April  2022) 
 Figure 4. Structure of ROR1  
 
Abbreviations:  Ig=immunoglobulin, m/h ROR=mouse/human receptor tyrosine kinase -like orphan receptor 1, 
ser=serine, thr=threonine  
Based on studies in rodents, ROR1 is an embryonic factor that is physiologically expressed 
during early embryogenesis and plays a critical role in neural, skeletal, and vascular organogenesis [ Oishi  1999; Al -Shawi  2001; Matsuda 2001; Lyashenko 2010]. Functional studies 
in primary embryonic cells suggest that binding of the secreted glycoprotein ligand, Wnt5a, results in heterodimerization of ROR1 with ROR2 (the other member of the ROR family) and can stimulate neuronal synapse formation [ Paganoni 2010]. During fetal development, the 
expression of ROR1 decreases [ Masiakowski 1992; Al -Shawi  2001; Paganoni 2010]. With the 
exception of rare B -lymphocyte precursors known as hematogones (the non- neoplastic 
counterpart to precursor- B acute lymphoblastic leukemia (ALL) [ Broome 2011], normal adult 
tissues lack surface expression of the ROR1 protein [ Fukuda 2008; Hudecek  2010; Zhang 2012b; 
Liu 2015b].  
However, consistent with a role as an onco-embryonic factor, high levels of ROR1 protein expression have been found in multiple cancers, including both hematological malignancies [Daneshmanesh 2008; Baskar  2008; Hudecek  2010; Barna 2011; Uhrmacher  2011; 
Daneshmanesh  2013; Kotašková 2016] and solid tumors [ Zhang 2012b; Liu  2015b]. Among 
lymphoid cancers, these studies indicate near universal expression of ROR1 expression in CLL/SLL and MCL and document evidence of ROR1 expression in some patients with ALL [Bicocca 2012 ], marginal zone lymphoma (MZL), and diffuse large B -cell lymphoma (DLBCL) 
[Barna 2011]. ROR1 expression and activation appears to be correlated with features of tumor 
aggressiveness in models of CLL, breast cancer, lung cancer, gastric cancer, and melanoma [Li 2010; Daneshmanesh  2012; Zhang 2012a ; Daneshmanesh  2013; Gentile  2011; 
Yamaguchi  2012; Hojjat-Farsangi 2013a ; Hojjat-Farsangi 2013b; O’Connell 2013; Ida  2016; 
Janovska 2016]. Elevated levels of ROR1 expression in patients and cell lines are associated with genes involved in epi[INVESTIGATOR_018]- mesenchymal transition (EMT) [ Cui 2013]. In patients with 
CLL, high levels of ROR1 expression are associated with shorter treatment-free survival and overall survival (OS) [ Cui 2016]. Similarly, in patients with ovarian cancer, high ROR1 
expression is associated with poor clinical outcomes [ Zhang 2014a ].  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 22 of 115  Version 7 ( 15 April  2022 ) 
 The potential functional significance of ROR1 signaling has been evaluated. In a gene therapy 
experiment in which 6 patients with CLL received infusion of adenovirus -CD145- transduced 
autologous CLL cells, it was noted that 3  of the patients made endogenous IgG that was reactive 
with ROR1 [ Fukuda  2008]. In vitro studies indicated Wnt5a binding to ROR1 enhanced the 
survival of CLL cells in vitro, an effect that could be neutralized by [CONTACT_512936]-ROR1 -positive patients. These results were supported by [CONTACT_512937][INVESTIGATOR_84065] -ROR1 immune responses in patients with CLL were associated 
with a better prognosis [ Hojjat- Farsangi  2015]. In a mouse model, animals engineered to produce 
CLL- like B  cells that were positive for ROR1 showed high transcriptome expression of 
subnetworks implicated in embryonic and tumor -cell proliferation, and relatively low levels of 
transcripts involved in cell- cell adhesion or cell death [ Widhopf  2014]. These cells were also 
actively proliferating (as indicated by [CONTACT_15915] -67-positivity) and showed relatively little spontaneous 
apoptosis.  
Treatment of these mice with an anti -ROR 1 monoclonal antibody (D10) resulted in ROR1 
down- modulation, reduced down- stream signaling, and impaired engraftment of leukemia cells 
[Widhopf  2014]. Similarly, silencing of ROR1 with small interfering ribonucleic acid (siR NA) 
was observed to enhance apoptosis of human CLL cells [ Choudhury 2010]. In nonclinical 
models of breast cancer, treatment with anti- ROR1 antibodies or siRNA reduced tumor growth 
and metastatic potential [ Zhang 2012a ; Cui  2013]. Likewise, treatment of melanoma with 
anti-ROR1 monoclonal antibodies resulted in apoptosis in ROR1- positive but not 
ROR1 -negative cell lines [ Hojjat- Farsangi  2013a ]. 
Collectively, the accumulating data regarding its role in cancer and lack of expression in normal 
tissues indicate that ROR1 represents an attractive therapeutic target for cancer intervention.  
2.4. Cirmtuzumab  
2.4.1. Discovery  
Given its tumor -specific expression and potential functional significance in oncogenesis, 
investigators at the University of [LOCATION_004], San Diego (UCSD) initiated a drug discovery 
program to generate monoclonal antibodies for the treatment of  ROR1 -expressing hematological 
and solid tumors. Oncternal Inc (Oncternal) was formed to further develop the technology.  
At UCSD, hybridomas were screened for production of monoclonal antibodies mimicking the activity of anti- ROR1 autoantibodies observed i n patients vaccinated against transfected 
autologous leukemia cells [ Fukuda 2008 ] and were tested in vivo using the TCL1 x ROR1 CLL 
mouse model [ Widhopf  2014]. One murine monoclonal antibody, D10, was identified that could 
inhibit ROR1 -mediated signaling and engraftment of ROR1
+ leukemia cells in this model. When 
tested in an immune -deficient murine xenograft, the D10 antibody consistently demonstrated 
potent, dose -dependent activity against human CLL patient samples. Mappi[INVESTIGATOR_512911] D10 antibody allowed generation of monoclonal antibodies with substantially higher affinity for ROR1. Humanization of the variable regions allowed identification of an antibody 
that maintained high binding affinity while minimizing the potential for immunogenicity. This 
clinical development candidate was designated UC -961 or cirmtuzumab [ Choi 2015] . 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 23 of 115  Version 7 ( 15 April  2022 ) 
 2.4.2. Chemistry  
Cirmtuzumab is a recombinant humanized IgG1κ monoclonal antibody wi th specificity for an 
epi[INVESTIGATOR_512912]- like region of the extracellular domain of human ROR1 (see Figure 4 above ). 
The antibody has 1,320 amino acids and a molecular weight of ~148 kilodaltons  including N -
linked glycosylation. The antibody is humanized except for amino acids adjacent to the borders 
of the complementarity -determining region and one of the framework regions, both of which are 
immune protected sites.  
The protein is produced in Chinese hamster ovary (CHO) cells and is purified by a process that 
includes viral inactivation and removal steps. No animal sources are used in the production of the drug substance and culture media are serum -free and protein- free.  
2.4.3. Clinical Experience with Cirmtuzumab  
Clinical evaluation o f cirmtuzumab has comprised a Phase 1a, sequential, dose- escalation study 
[Choi 2017]. Patient s enrolled to the study have been adult men and women with relapsed or 
refractory CLL/SLL requiring treatment, Eastern Cooperative Gro up (ECOG) performance status 
≤2, and adequate organ function. Study patient s have received a total of 4  IV infusions of 
cirmtuzumab monotherapy, each to be administered every 2 weeks. Dose escalation has been performed with a 3+[ADDRESS_664059] been assessed.  
In summary, the Phase 1a results with cirmtuzumab admi nistration at dose levels of 0.015 to 
20 mg/kg show the drug to be very well tolerated, with no obvious drug- related toxicity 
(including no DLTs, no Grade 4 AEs, no SAEs and no discontinuations due to AEs). Pharmacokinetic and pharmacodynamic data indicate systemic drug exposure and provide 
preliminary clinical evidence of expected drug mechanism. Details are provided in the Investigator Brochure.  
2.4.4. Combination Studies of Cirmtuzumab and Ibrutinib  
Given that ibrutinib now represents a standard- of-drug in the therapy of CLL/SLL and MCL, 
studies were performed to evaluate the therapeutic potential of combining cirmtuzumab with ibrutinib in nonclinical models of these diseases [ Yu 2017; Yu 2018].  
To evaluate the in vitro effects of ibrutinib on the ROR1 pathway, circulating mononuclear cells from patients who were taking ibrutinib at the standard dose of 420 mg once per day ( QD) were 
evaluated [ Yu 2017] or fresh CLL cells were incubated with ibrutinib in culture. The cells were 
examined for Wnt5a -induced Rac1 activation with or without ibrutinib and/or cirmtuzumab. The 
data showed that cirmtuzumab, but not ibrutinib, could inhibit Wnt5a -induced Rac1 activation in 
CLL cells and that ibrutinib did not block the capacity of cirmtuzumab to inhibit Wnt5a -induced 
Rac1 activation. To assess the combined effects of cirmtuzumab and ibrutinib on CLL proliferation, leukemic cells were co -cultured with HeLa cells expressing CD154 and 
recombinant interleukin (IL) -4 and IL -10 [Yu 2017]. Treatment of the CLL cells with 
cirmtuzumab, but not ibrutinib, could block Wnt5a -enhanced proliferation. A cell -cycle analysis 
found that Wnt5a stimulation significantly enhanced the fraction of leukemia cells in S/G2/M and that the proportion of cells in S/G2/M could be decreased by [CONTACT_512938]. 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 24 of 115  Version 7 ( 15 April  2022 ) 
 Collectively, these data demonstrate that cirmtuzumab can block ROR1 -mediated leukemia- cell 
proliferation that is not a ffected by [CONTACT_9059].  
In vivo studies of the combination of cirmtuzumab and ibrutinib in several nonclinical models of 
CLL/SLL were performed [ Yu 2017]. To assess the activity of cirmtuzumab and/or ibrutinib in 
xenografts derived from patients with CLL, leukemic cells from such patients were transferred 
into the peritoneal cavities of immunodeficient Rag2−/−γc−/− mice. Following treatment with a 
single dose of cirmtuzumab or [ADDRESS_664060] than either drug administered alone. Similar combination effects were observed when R OR1 × TCL1 leukemia 
cell engraftment was evaluate in immunodeficient Rag2
−/−γc−/− mice or in immunocompetent 
human- ROR1 transgenic (ROR1- Tg) mice. Treatment with either single agent resulted in 
reductions in spleen size, and a lower mean proportion and num ber of leukemia cells in the 
spleen. However, treatment with both agents led to significantly greater antitumor effects than were observed with either monotherapy.  
To determine the influence of the ROR1 signaling pathway in MCL, primary cells from  patients 
with the disease were evaluated for evidence of ROR1 expression  [Yu 2018]. All of the tested 
patient samples showed intense surface staining for ROR1; the median (±SD) values for mean fluorescence intensity relative to control (ΔMFI) were higher in patients with MCL (N=8, 87.5±18.5) than in sample patients with CLL (N=167, 38.5±18.5), and substantially higher than those in normal lymphocytes (<1). It was also notable that immunoassay evaluation of plasma samples from patients with MCL all showed high Wnt5a concentrations, further supporting the potential importance of the Wnt5a -ROR1 pathway in the pathogenesis of MCL. 
As had be done with CLL cells, primary lymphoma cells from patients with MCL were examined for Wnt5a -induced, ROR1- dependent activation of the Rho- GTPase, Rac1 [ Yu 2018]. 
As noted in CLL cells, Wnt5a induced activation of primary MCL cells in a ROR1- dependent 
fashion. Cirmtuzumab, but not ibrutinib, could inhibit the capacity of W nt5a to induce Rac1 
activation. To evaluate cirmtuzumab effects on lymphoma proliferation, MCL cells were co -
cultured with HeLa cells expressing CD154, and recombinant IL -4 and IL -10 [Yu 2018]. The 
addition of exogenous Wnt5a to t hese co -cultures significantly enhanced the proportion of 
dividing MCL cells. Cell -cycle analysis showed that Wnt5a stimulation significantly increased 
the fraction of MCL cells in S/G2/M. The capacity of Wnt5a to enhance the proportion of 
primary MCL cell s in S/G2/M could be inhibited by [CONTACT_512939], but not with 
ibrutinib, as noted previously for CLL cells. 
These data demonstrate the functional importance of ROR1 signaling in both CLL and MCL and 
the ability of cirmtuzumab to inhibit ROR1 -mediated oncogenic activity in these disorders with a 
mechanism that complements BTK inhibition by [CONTACT_9059].  
2.5. Conclusions/Study Rationale  
The conduct of this Phase 1b- 2 study of the combination of cirmtuzumab and ibrutinib for 
patients with CLL/SLL , MCL  and R/R  MZL is founded on a current understanding of the natural 
history and current therapi[INVESTIGATOR_512913]; knowledge of the importance of ROR1 and BTK cellular pathways in the pathophysiology of these diseases; and 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 25 of 115  Version 7 ( 15 April  2022 ) 
 nonclinical an d clinical information regarding the efficacy and safety of the 2 study drugs. 
The collective data support the following conclusions:  
• Relapsed or refractory CLL/SLL , MCL  and MZL  represent serious, disabling, and 
life-threatening disorders. Existing BTK inhibitor therapy demonstrates activity but only 
infrequently induces complete tumor regression and loses effectiveness over time. 
The development of cirmtuzumab with ibrutinib offers a potential method for enhancing 
antitumor immunotherapeutic activity, ove rcoming disease resistance, and improving both 
short - and long- term outcomes for patients with CLL/SLL , MCL  and MZL . 
• Clinical evaluation of cirmtuzumab in combination with ibrutinib in patients with B -cell 
lymphoid cancers has sound scientific rationale founded on the known efficacy of BTK inhibition in lymphoid cancers, the frequent expression and oncogenic potential of  ROR1 in 
these malignancies, and the results of nonclinical pharmacology studies that demonstrate the therapeutic potential of the combination of cirmtuzumab and ibrutinib in lymphoid cancers.  
• Advancing the development of cirmtuzumab together with ibrutinib in this study is well supported by [CONTACT_512940], pharmacokinetics, and toxicology; by [CONTACT_7609]  1a safety, pharmacokinetic, and pharmacodynamic data obtained in 
patients with CLL/SLL receiving cirmtuzumab; and by [CONTACT_512941]. This collective information provides a basis for patient  enrollment 
criteria; starting dose selection and dose escalation; administration of an appropriate dosing regimen; and for safety, pharmacodynam ic, pharmacokinetic, and efficacy monitoring within 
this study.  
• Given the seriousness of previously treated, progressive CLL/SLL , MCL  and MZL  and the 
aggregate potential benefits considered in the context of potential risks, clinical development 
of cirmtuz umab with ibrutinib in patients with hematological cancers is justified.  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 26 of 115  Version 7 ( 15 April  2022 ) 
 3. OBJECTIVES AND ENDPOINTS  
3.1. Primary Objectives  
• Part 1 (cirmtuzumab →  cirmtuzumab + ibrutinib): To determine the RD R of 
cirmtuzumab when given alone and in combination with ibrutinib in patient s with 
CLL/SLL or MCL  
• Part 2 (cirmtuzumab + ibrutinib): To further characterize the safety , pharmacology, and 
clinical responses  of cirmtuzumab  + ibrutinib  when administered using the RDR in  
patients with CLL /SLL MCL  or R/R  MZL  
• Part 3 (cirmtuzumab + ibrutinib versus ibrutinib): To further evaluate the CR rate 
associated with cirmtuzumab  + ibrutinib  when administered using the RDR  in patients 
with CLL /SLL  
3.2. Secondary Objectives  
• To determine the drug administration, safety, and supportive care profiles of 
cirmtuzumab and the combination of cirmtuzumab  + ibrutinib  
• To evaluate the pharmacokinetic profile of cirmtuzumab alone and in combination with 
ibrutinib  
• To assess the effects of cirmtuzumab and cirmtuzumab  + ibrut inib on explorator y 
biomarker s/pharmacodynamic markers relating to drug mechanism, immune profile, and 
disease manifestations  
• To characterize the immunogenicity of cirmtuzumab  
• To characterize the antitumor activity of cirmtuzumab monotherapy and cirmtuzumab  + 
ibrutinib combination therapy  
3.3. Primary Study Endpoints  
• Part 1 (cirmtuzumab → cirmtuzumab + ibrutinib ): RDR within the tested dose range  
• Part 2 (cirmtuzumab + ibrutinib ): RDR with the cirmtuzumab  + ibrutinib  combination 
• Part 3 (cirmtuzumab + ibrutinib  versus ibrutinib): CR rate, defined as the proportion of 
patient s achieving a CR per pre -established CLL/SLL response criteria  
3.4. Secondary Study Endpoints  
3.4.1. Antitumor Activity and Survival  
Efficacy will be evaluated using consolidated response criteria for CLL /SLL [ Hallek 2018;  
Cheson 2012;  Hallek  2008] and for lymphoma [ Cheson 2014; Cheson 2007]. Efficacy will be 
evaluated as described in  Section  8.5, Appendix 12.5, and Appendix 12.6. Efficacy en dpoints 
will include: 
• Overall response (OR), defined as achievement of  complete response (CR), complete 
response with incomplete blood count recovery (CRi), partial response (PR), or partial 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 27 of 115  Version 7 ( 15 April  2022 ) 
 response with lymphocytosis (PR -L) for those with CLL/SLL; and the achievement of a 
CR or PR for those with MCL  or MZL 
• Complete respons e (CR), defined as achievement of CR or CRi for those with CLL/SLL; 
and the achievement of a CR for those with MCL  or MZL   
• Percent change in tumor dimensions, defined as the best (most negative) percent change 
from baseline in the sum of the products of the diameters (SPD) of index lesions  
• Time to response (TTR), defined as the interval from the start of study therapy to the first documentation of an objective response  
• Duration of response (DOR), defined as the interval from the first documentation of 
objec tive response to the earlier of the first documentation of disease progression or death 
from any cause  
• Progression- free survival (PFS), defined as the interval from the start of study therapy to 
the earlier of the first documentation of disease progression or death from any cause  
• Time to progression ( TTP), defined as the time from the start of study therapy until 
objective tumor progression; TTP does not include deaths  
• Time to treatment failure (TTF), defined as the interval from start of study therapy to the 
earliest of the first documentation of disease progression, the permanent cessation of study drug due to an AE, or death from any cause  
• Time to next treatment (TNT), defined as the interval from start of study therapy to the start of a new r egimen for CLL/SLL ,MCL  or MZL  due to study treatment failure  
• Overall survival (OS), defined as the interval from the start of study therapy to death 
from any cause  
3.4.2. Safety Profile  
• Type, frequency, severity, timing of onset, duration, and relationship to st udy drugs of 
any treatment -emergent adverse events (TEAEs); laboratory abnormalities; vital sign 
abnormalities; adverse electrocardiogram (ECG) findings; SAEs; or AEs leading to interruption, modification, or discontinuation of study treatment  
3.4.3. Pharmacokine tics 
• Cirmtuzumab serum concentrations (as measured using a validated immunoassay)  
• Derived pharmacokinetic parameters (including area under the serum concentration- time 
curve [AUC], maximum concentration [C
max], time of maximum concentration [T max], 
volume of distribution [V d], terminal elimination half -life [t 1/2], terminal elimination rate 
constant [λ z], and clearance [Cl]) (as determined using noncompartmental methods)  
3.4.4. Pharmacodynamics /Exploratory Biomarkers  
• Evaluate pre-  and post -regimen blood and bone marrow as well as any available 
CLL/SLL, MCL  or MZL  tumor biopsy samples for exploratory biomarkers that might be 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 28 of 115  Version 7 ( 15 April  2022 ) 
 predictive of tumor response and downstream effects of cirmtuzumab. Tests may include 
an examination of tumor receptor expression, gene activation, and blood cytokine levels. 
• Changes in ROR1 cell surface expression and receptor occupancy  
• Changes in ALC in peripheral blood (as assessed by [CONTACT_512942])  
• Changes in c ancer stem cell pa rameters  
• Changes in plasma concentrations of  cytokines  
3.4.5. Immunogenicity  
Changes in titers and neutralizing capacity of circulating cirmtuzumab -reactive antibodies (as 
assessed using immunoassay methods)  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 29 of 115  Version 7 ( 15 April  2022 ) 
 4. STUDY DESIGN  
This clinical trial is a Phase 1b -2 study of the safety, pharmacokinetics, pharmacodynamics, 
immunogenicity, and antitumor activity of the combination of cirmtuzumab and ibrutinib. The 
study will be conducted in 3 parts  (see schema, Section 1.2) . 
4.1. Part 1 – Dose -Finding (Cirmtuzumab → Cirmtuzumab + Ibrutinib)  
Part 1 comprises a Phase 1b, open- label, sequential allocation, dose -finding evaluation of the 
sequential administration of cirmtuzumab monotherapy followed by [CONTACT_512934]  + ibr utinib 
combination therapy in patient s with CLL/SLL or MCL. Patient s will be administered study 
therapy as follows:  
• Cirmtuzumab given by [CONTACT_33433] 2 weeks for 5 admi nistrations (Weeks 0, 2, 4, 6, 
8) and then every 4 weeks thereafter (Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52) at a dose of either 2, 4, 8, or 16 mg/kg. After establishment of safety at these dose levels, fixed doses of 300 and 600 mg IV  per dose will be examined  in patients with CLL/SLL.  
• Ibrutinib self -administered orally, QD, continuously starting in Week 4 at a dose of either 
420 mg/day (for patient s with CLL /SLL) or at a dose of 560 mg/day (for patient s with 
MCL).  
Allocation to cirmtuzuma b dose within each disease type (CLL/SLL or MCL) will be performed 
such that each successive patient  with that disease is assigned to 2, 4, 8, and then 16 mg/kg in a 
sequence that is repeated 3  times, resulting in enrollment of 3  patient s with CLL/SLL and 
[ADDRESS_664061] 3+3 design.  
Patients exhibiting a PR or CR may continue combination treatment beyond Week 52 until disease progression or unacceptable toxicity  as part of an extended therapy program.  Patients 
who remain in a PR or CR at the end of the 2 year treatment period, may be eligible for L ong-
term T herapy  and continue to receive cirmtuzumab and ibrutinib until they experience disease  
progression, unacceptable toxicity, or the study ends. Sites should discuss these cases with the sponsor in advance for approval. 
For CLL /SLL patients, long- term follow -up consisting of patient contact [INVESTIGATOR_135] 6 months and 
collection of disease, treatment , and  vital status  data, will continue following the E nd of 
Treatment  visit for up to 5 years . For MCL patients, long- term follow -up will occur every 3 
months and include collection of  disease, treatment, and vital status data for up to 5 years . 
Imaging reports may be requested by [CONTACT_512943]/SLL or MCL patients in long- term 
follow -up. Th ese data will be used to determine  progression free survival ( PFS), time to 
progression (TTP) , and t ime to next treatment.  Once a patient in long- term follow -up has 
progressed and received an alternate treatment for their disease, only vital status will be 
collected.  
At the conclusion of Part 1 of the study, a recommended dosing regimen (RDR) of cirmtuzumab will be selected based primarily on safety, pharmacokinetic, and pharmacodynamic  findings. 
This portion of the study has been completed and a [ADDRESS_664062] for both CLL /SLL and MCL . [Choi 2019a , Choi 2019b] .  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 30 of 115  Version 7 ( 15 April  2022 ) 
 4.2. Part 2 – Cohort Expansion (Cirmtuzumab + Ibrutinib)  
Part [ADDRESS_664063] derived from Part 1. Up to 18 evaluable patient s 
with CLL /SLL will be enrolled . Up to 20 evaluable patients with MCL  and up to 10 patients with 
MZL will be enrolled into Part 2; a clinical review will then be performed to determine if 
additional evaluable patient s are required  to complete any safety, effica cy, or biomarker 
analyses . This review could lead to a further adjustment or  increase in enrollment .  
Patient s will be administered study therapy as follows:  
• Cirmtuzumab given by [CONTACT_33433] 2 weeks for 3 administrations (Weeks 0, 2, 4) and then every 4 weeks thereafter (Weeks 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52) using the RDR  of cirmtuzumab (600 mg fixed dose IV) . 
• Ibrutinib self -administered orally QD, continuously starting concurrently with 
cirmtuzumab in Week  0 at a dose of either 420 mg/day (for patient s with CLL /SLL) or at 
a dose of 560 mg/day (for patient s with MCL  or MZL ). 
Patients exhibiting a PR or CR may continue combination treatment beyond Week 52 until disease progression or unacceptable toxicity as part of an extended therapy program.  Patients who remain in a PR or CR at the end of the 2 year treatment period, may be eligible for L ong-
term T herapy  and c ontinue to receive cirmtuzumab and ibrutinib until they experience disease 
progression, unacceptable toxicity, or the study ends. Sites should discuss these cases with the sponsor in advance for approval. 
For CLL/SLL patients, long- term follow -up consisting of patient contact [INVESTIGATOR_135] 6 months and 
collection of disease, treatment, and  vital status  data, will continue following the E nd of 
Treatment  visit for up to 5 years . For MCL  and MZL  patients, long- term follow -up will occur 
every 3 months and include collection of disease, treatment, and vital status data for up to 5 
years . Imaging reports may be requested by [CONTACT_512943]/SLL, MCL or MZL patients in 
long- term follow -up. These data will be used to determine progression free survival (PFS), time 
to progression (TTP), and time to next treatment. Once a patient in long -term follow -up has 
progressed and received an alternate treatment for their disease, only vital status will be 
collected.  
4.3. Part 3 – Efficacy Evaluation (Cirmtuzumab + Ibrutinib versus 
Ibrutinib)  
Part 3 comprises a Phase 2 open -label, randomized, controlled, 2- arm, parallel -group evaluation 
of the clinical activity and safety of cirmtuzumab  + ibr utinib versus ibrutinib a lone. Patient s with 
CLL/SLL will be randomized 2:[ADDRESS_664064]:  
o Arm A: cirmtuzumab  + ibrutinib 
o Arm B: ibrutinib alone  
Approximately 30 patients  will be enrolled and randomized into Part 3. 
Patients exhibiting a PR or CR may continue treatment beyond Week 52 until disease progression or unacceptable toxicity as part of an extended therapy program. P atients who  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 31 of 115  Version 7 ( 15 April  2022 ) 
 remain in a PR or CR at the end of the 2 year treatment period, may be eligible for  Long-term 
Therapy  and continue to receive cirmtuzumab and ibrutinib until they experience disease 
progression, unacceptable toxicity, or the study ends. Sites should discuss these cases with the 
sponsor in advance for approval. 
For CLL/SLL patients, long- term follow -up consisting of patient contact [INVESTIGATOR_135] 6 months and 
collection of disease, treatment, and  vital status  data, will continue following the E nd of 
Treatment  visit for up to 5 years . Imaging reports may be requested by [CONTACT_512943]/SLL 
patie nts in long- term follow -up. These data will be used to determine progression free survival 
(PFS), time to progression (TTP), and time to next treatment. Once a patient in long- term follow -
up has progressed and received an alternate treatment for their dise ase, only vital status will be 
collected.  
4.4. Rationale for Study Design  
The study has been designed to provide critical dosing, safety, pharmacokinetic, 
pharmacodynamic, and early efficacy data in support of future clinical development of cirmtuzumab and cirm tuzumab  + ibrutinib .  
In Part 1 of the study, the intra patient  comparison of sequential administration of cirmtuzumab 
monotherapy followed by [CONTACT_512934]  + ibr utinib combination therapy generates a rigorous 
evaluation of the pharmacology of cirmtuzumab at fixed repeated doses with and without ibrutinib. Such an evaluation is important for cirmtuzumab given knowledge that ibrutinib can increase pharmacokinetic exposure to therapeutic monoclonal antibodies (eg, rituximab) that have tumor cells as a major mediator of drug clearance [ Cramer 2016 ]. The intent is to obtain 
critical information regarding pharmacokinetic and pharmacodynamic dose -response and dose -
exposure relationships and any potential drug- drug interact ion to support selection of a RDR for 
use in Parts 2 and 3 of this study and in other trials of both single -agent and combination 
cirmtuzumab -based therapy. Introduction of ibrutinib within 4 weeks of starting the study 
ensures that study patient s transition rapi[INVESTIGATOR_512914]/SLL , MCL  or 
MZL.  
The planned rotating, sequential dose -assignment process in Part [ADDRESS_664065] ascending- dose 
design is not warranted given the substantial safety and lack of DLTs for either cirmtuzumab and ibrutinib within the tested dose range, the lack of overlappi[INVESTIGATOR_512915], and 
historical knowledge that ibrutinib can be combined with multiple types of intensive 
chemoimmunotherapy without the need for modification of either the ibrutinib or 
chemoimmunotherapy doses [ Burger 2014; Younes  2014; Brown 2015; Maddocks  2015a ; 
Chanan -Khan  2016; Wang  2016]. Randomized dose allocation is  not necessary because it would 
introduce complexity that would be disproportionate to the modest size and exploratory goals of 
Part 1 of the trial.  
Part 2 of the study provides a confirmatory characterization of the safety and pharmacology of 
the cirmtuzu mab + ibrutinib combination when administered using the provisional RDR defined 
from Part [ADDRESS_664066] 2 infusions in Part 1 and cohorts receiving ibrutinib together w ith cirmtuzumab 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 32 of 115  Version 7 ( 15 April  2022 ) 
 during the first 2 infusions in Part 2 will strengthen an understanding of the pharmacological 
consequences of adding ibrutinib to cirmtuzumab. 
Part 3 of the trial offers a Phase 2 assessment of cirmtuzumab  + ibrutinib activity that will be  
important as a basis for Phase 3 planning. The randomized, add- on design in Part 3 is customary 
in the comparative evaluation of new therapi[INVESTIGATOR_72911]; such a design documents the 
incremental benefit and safety of the investigational therapy (cirmtuzumab) in the context of a 
controlled clinical trial while ensuring that all participants receive potentially active treatment 
(ibrutinib). Randomization is an accepted means to reduce bias and allows for the highest standard of evidence in documenting a trea tment effect. Use of a 2:1 allocation enlarges the 
clinical experience with the investigational cirmtuzumab  + ibrutinib  combination. 
  
Involvement of a coordinating SRC  is considered appropriate to ensure safety and general study 
conduct oversight of this exploratory, open -label Phase 1b -2 trial; each study center may follow 
local standard operating procedures relating to institutional review of safety data at  that study 
center.  
4.5. Rationale for Study Drug Doses  
The cirmtuzumab starting dose levels to be evaluated in this study were selected based on data 
from a Phase 1a study showing that cirmtuzumab was very well tolerated in the range of 0.015 to 20 mg/kg and that dose levels of ≥2 mg/kg have the potential to induce pharmacodynamic inhibition of ROR1- mediated signaling [ Choi  2017]. The specific doses (2, 4, 8, and 16 mg/kg) 
to be evaluated in the current clinical trial were selected with the intent of defining the shape of the dose -response and exposure -response profiles and t o determine the minimal dose associated 
with maximal continuous ROR1 inhibition. The planned schedule of cirmtuzumab administration (2 infusions at 2- week intervals followed by [CONTACT_512944] 4- week intervals) builds on 
pharmacokinetics findings w ith the every -2-week schedule used in the Phase 1a study; the 
schedule in the current trial is intended to achieve early ROR1 inhibition with maintenance of target coverage during chronic therapy. The initial 90- minute cirmtuzumab infusion  time 
considered the lack of infusion toxicities observed in the Phase  1a cirmtuzumab experience and 
safety information developed with the therapeutic monoclonal antibody, rituximab, showing the feasibility of this approach [ Dakhil  2014, Genentech  2016] . Guidelines for the admini stration of 
cirmtuzuma b are detailed in the Pharmacy manual. In general, the first infusion will be given 
over 90 minutes. If no adverse reactions are observed, the infusion time may be shortened  with 
each subsequent administration as tolerated , following the guidelines in the Pharmacy M anual.  
The doses and schedule of ibrutinib (420 mg QD for patient s with CLL /SLL and 560 mg QD for 
patient s with MCL  or MZL ) and the dose modification provisions for ibrutinib are consistent 
with those recommended in product labeling [ Pharmacyclics  2020].  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 33 of 115  Version 7 ( 15 April  2022 ) 
 5. STUDY POPULATION: RECRUITMENT AND SELECTION OF 
STUDY PATIENT S 
5.1. Planned Number of Patient s 
5.1.1. Part 1 (Cirmtuzumab → Cirmtuzumab + Ibrutinib)  
If 6 patient s (3 patient s with CLL/SLL and 3 patient s with MCL) are enrolled at all 4 planned 
dose levels, 24 patient s will be enrolled. If 2 additional dose levels are explored in 
6 patient s/dose level (3 patient s with CLL/SLL and 3 patient s with MCL), as many as 
12 additional patient s could be enrolled, bringing the potential sample size to 36 patient s. To 
allow for the possibility that some patient s may not be fully evaluable, up to 48 patient s may be 
enrolled.  
5.1.2. Part 2 (Cirmtuzumab + Ibrutinib)  
The RDR derived from Part 1 will be evaluated in  up to 18 patient s with CLL/SLL . Up to 20 
evaluable patients with MCL and up to 10 evaluable patients with MZL will be enrolled into Part 
2; a clinical review will then be performed to determine if additional evaluable patient s are 
required. This review could lead to a further adjustment and an increase in enrollment.  
5.1.3. Part 3 (Cirmtuzumab + Ibrutinib versus Ibrutinib)  
Approximately 30 patients will be enrolled and randomized 2:1 into Part 3 ( ~20 patient s will 
receiv e cirmtuzumab + ibrutinib and  ~10 patients  will receiv e ibrutinib alone) . 
5.2. Enrollment of Study Patient s  
Inclusion and exclusion criteria will be reviewed for each potential patient  by [CONTACT_512945]. If the consented study candidate is considered eligible for study participation, 
the study center will transmit an enrollment request to Oncternal (or d esignee).  
Oncternal (or designee) will acknowledge receipt of the enrollment request and will assign the study part, the cirmtuzumab dose (Part 1), and the appropriate ibrutinib dose (for CLL/SLL , 
MCL  or MZL ). Once the study center has received this inform ation, the patient  can begin 
treatment.  
Study candidates who fail screening will be noted on a screening and enrollment log maintained by [CONTACT_6624]. Their data will not be entered into the EDC system (eCRF) . 
5.3. Patient  Selection Criteria  
This clinical trial can fulfill its objectives only if appropriate participants are enrolled. The protocol -specified eligibility criteria are designed to select patient s for whom study participation 
is considered appropriate. All relevant medical and non- medical conditions s hould be taken into 
consideration when deciding whether this protocol is suitable for a study candidate. Eligibility 
criteria may not be waived by [CONTACT_512946] a GCP or a regul atory authority audit. Any questions regarding a study 
candidate’s eligibility should be discussed with the medical monitor before enrollment.  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 34 of 115  Version 7 ( 15 April  2022 ) 
 5.3.1. Inclusion Criteria  
Study candidates must meet all of the following inclusion criteria to be eligible for particip ation 
in this study:  
1. Men and women of age ≥18 years.  
2. ECOG performance status of 0, 1, or 2 (see Appendix 12.1).  
3. Histological diagnosis of CLL/SLL , MCL  or MZL (including splenic,nodal and extranodal 
subtypes)  as documented in medical records  (pathology report s and slides or blocks should 
be available for review  or additional testing ).  
4. MCL has been previously treated and has relapsed after or progressed during prior therapy. 
CLL/SLL may have been previously treated or are treatment naïve but now require therapy. MZL has been previously treated and has relapsed after or progressed  during at least one 
prior ant i-CD20 - based therapy  
5. A medically appropriate candidate for ibrutinib treatment (based on the judgement of the clinical investigator).  
6. Patients who have received prior BTK inhibitor therapy are eligible, unless they 
demonstrated primary or acquired resistance to a BTK inhibitor or experienced a serious or severe adverse event attributed to BTK inhibitor therapy.  
7. Presence of radiographically measurable lymphadenopathy or extranodal lymphoid malign ancy (defined as the presence of ≥1 non -biopsied, non- irradiated lesion that measures 
>1.[ADDRESS_664067] dimension [LD] and ≥1.[ADDRESS_664068] perpendicular dimension 
[LPD] as assessed by [CONTACT_20420] [CT] or magnetic resonance imaging [MRI] ). 
8. Current medical need for therapy due to disease -related symptoms, lymphadenopathy, 
organomegaly, extranodal organ involvement, or progressive disease.  
9. Completion of all previous therapy (including any Bcl -2 or PI3K inhibitor therapy, surgery, 
radiotherapy, chemotherapy, immunotherapy, or investigational therapy) for the treatment of cancer  ≥1 week (or ≥3 half -lives of the previous drug) before the start of study therapy.  
10. All acute toxic effects of any prior antitumor therapy resolved to Grade ≤1 before the start of study therapy (with the exceptions of alopecia, or neurotoxicity [Grade 1 or 2 permitted], or selected laboratory parameters [Grade 1 or Grade  2 permitted with exceptions as noted 
below]).  
11. Adequate bone marrow function:  
a. Absolute neut rophil count (ANC) ≥1.0 × 10
9/L. 
b. Platelet count ≥50 × 109/L. 
c. Hemoglobin ≥8.0 g/dL maintained for ≥1 week from any prior transfusion.  
Note: Grade ≥3 neutropenia, thrombocytopenia, or anemia is permitted if the abnormality is related to bone marrow involveme nt with hematological malignancy (as documented by [CONTACT_512947]/aspi[INVESTIGATOR_512916]). 
12. Adequate hepatic profile:  
a. Serum alanine aminotransferase (ALT) ≤3 × upper limit of normal (ULN).  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 35 of 115  Version 7 ( 15 April  2022 ) 
 b. Serum aspartate aminotransferase (AST ) ≤3 × ULN. 
c. Serum bilirubin ≤1.5 × ULN unless elevated due to Gilbert syndrome.  
13. Adequate renal function:  
a. Estimated creatinine clearance (eCl CR) >30 mL/minute (with eCl CR to be calculated by 
[CONTACT_16424] -Gault formula [see Appendix 12.2]), or 
b. Measured creatinine clearance >30 mL/minute (as assessed with a 24 -hour urine 
collection).  
14. Adequate coagulation profile:  
a. Prothrombin time (PT) ≤1.5 × ULN.  
b. Activated partial thromboplastin time (aPTT) ≤1.5 × ULN.  
15. Negative viral serology:  
a. Negative human immunodeficiency virus (HIV) antibody. 
b. Negative hepatitis B surface antigen (HBsAg) and negative hepatitis B core (HBc) 
antibody or undetectable hepatitis B (HBV) deoxyribonucleic acid (DNA) by [CONTACT_121047] (PCR) testing.  
c. Negative hepatitis C virus (HCV) antibody or negative HCV RNA by [CONTACT_956].  
16. For female patient s of childbearing potential, a nega tive urine or serum pregnancy test prior 
to the start of study therapy. 
17. For female patient s of childbearing potential, willingness to use a  highly effective method of 
contraception from the start of the screening period until ≥[ADDRESS_664069] dose  of 
cirmtuzumab and ≥[ADDRESS_664070] dose of ibrutinib, whichever is later . Note:  A female 
patient  is considered to be of childbearing potential unless she has had a hysterectomy, 
bilateral tubal ligation, or bilateral oophorectomy; has medically documented ovarian 
failure (with serum estradiol and follicle -stimulating hormone [FSH] levels within the 
institutional laboratory postmenopausal range and a negative serum or urine beta human chorionic gonadotropin [βHCG]); or is menopausal (age ≥50 years w ith amenorrhea for 
≥6 months) .  
18. For male patient s who can father a child and are having intercourse with females of 
childbearing potential who are not using adequate contraception, willingness to use a n 
effective method of contraception from the start of s tudy therapy until ≥[ADDRESS_664071] dose of cirmtuzumab and ≥ [ADDRESS_664072] dose of ibrutinib, whichever is later  
and to refrain from sperm donation from the start of study therapy until ≥3 months after administration of the final dose of either of the study drugs. Note: A male patient is 
considered able to father a child unless he has had a bilateral vasectomy with documented 
aspermia or a bilateral orchiectomy . 
19. In the judgment of the investigator, participation in the protocol offers an acceptable benefit -
to-risk ratio when considering current disease status, medical condition, and the potential 
benefits and risks of alternative treatments for the patient ’s cancer.  
20. Willingness and ability of the patient  to comply with scheduled visits, drug administration 
plan, protocol -specified laboratory tests, other study procedures, and study restrictions. 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 36 of 115  Version 7 ( 15 April  2022 ) 
 21. Evidence of a personal ly signed informed consent indicating that the patient  is aware of the 
neoplastic nature of the disease and has been informed of the procedures to be followed, the 
experimental nature of the therapy, alternatives, potential risks and discomforts, potential  
benefits, and other pertinent aspects of study participation. 
5.3.2. Exclusion Criteria  
Study candidates who meet any of the following criteria will not be eligible for participation in 
this study:  
1. Known histological transformation to an aggressive lymphoma (ie, Richter transformation). 
Note: Biopsy documentation of the absence or presence of transformation is not required. 
2. Known central nervous system malignancy. Note: Central nervous system imaging is only required in patient s with suspected central nervous sys tem malignancy.  
3. Presence of another cancer with disease manifestations or therapy that could adversely  affect  
patient  safety or longevity, create the potential for drug- drug interactions, or compromise the 
interpretation of study results.  
4. Significant cardi ovascular disease (eg, myocardial infarction, arterial thromboembolism, 
cerebrovascular thromboembolism) within 3 months prior to start of study therapy; angina requiring therapy; symptomatic peripheral vascular disease; [LOCATION_001] Heart Association Class 3 or 4 congestive heart failure; or uncontrolled Grade ≥3 hypertension (diastolic blood pressure ≥100 mmHg or systolic blood pressure ≥160 mmHg) despi[INVESTIGATOR_6521].  
5. Significant screening ECG abnormalities, including unstable cardiac arrhythmia  requiring 
medication, atrial fibrillation/flutter, left bundle branch block, 2
nd-degree atrioventricular 
(AV) block type II, 3rd-degree AV block, or Grade ≥2 bradycardia.  
6. Gastrointestinal disease (eg, gastric or intestinal by[CONTACT_4897], pancreatic enzy me 
insufficiency, malabsorption syndrome, symptomatic inflammatory bowel disease, chronic diarrheal illness, bowel obstruction) that might interfere with drug absorption or with interpretation of gastrointestinal AEs.  
7. Contraindication for ibrutinib use bec ause of a bleeding diathesis . 
8. Evidence of an ongoing systemic bacterial, fungal, or viral infection (including upper respi[INVESTIGATOR_6014]) at the time of start of study therapy. Note: Patients with localized fungal infections of skin or nails are n ot precluded from participation.  
9. In patient s with prior hematopoietic progenitor cell transplantation, evidence of ongoing 
graft -versus -host disease (GVHD).  
10. Pregnancy or breastfeeding.  
11. Major surgery within 4 weeks before the start of study therapy.  
12. Prior solid organ transplantation. 
13. Prior anti -ROR1 therapy within 12 weeks prior to the start of study therapy.  
14. Use of a moderate or strong inhibitor or inducer of cytochrome P450 (CYP) 3A4 within 7 days prior to the expected start of ibrutinib  therapy (see Appendix 12.3).  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 37 of 115  Version 7 ( 15 April  2022 ) 
 15. Concurrent participation in another therapeutic or imaging clinical trial.  
16. Any illness, medical condition, or gan system dysfunction, or social situation, including 
mental illness or substance abuse, deemed by [CONTACT_493313] a 
patient ’s ability to provide informed consent, adversely affect the patient ’s ability to 
cooperate and par ticipate in the study, or compromise the interpretation of study results. 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 38 of 115  Version 7 ( 15 April  2022 ) 
 6. STUDY INTERVENTION  
6.1. Cirmtuzumab  
6.1.1. Known Potential Risks: Cirmtuzumab  (zilovertamab)  
 The safety profile (N = 31) of cirmtuzumab  in combination with ibrutinib in subjects with MCL 
was re cently presented (Lee, 2021). The overall safety profile of cirmtuzumab  plus ibrutinib was 
similar to the known safety profile of ibrutinib alone, with no dose reductions and no SAEs 
attributed to cirtuzumab . Most TEAEs were Grades 1 and 2. Few subjects ha d a Grade 3 or 
above AE.  
6.1.2. Known Potential B enefits : Cirmtuzumab  (zilovertamab)   
The efficacy data from 26 evaluable subjects with MCL enrolled in Study CIRM -0001 is 
summarized in Section 3.1 of the Cirmtuzumab Investigator Brochure , and was presented at 
ASH 2021 (Lee, 2021). The ORR of 80.8%, CR rate of 34.6%, and median PFS of 35.9 months (95% CI: 16.5 to 35.9 months) for evaluable subjects with MCL in Study CIRM -0001 compare 
favorably to the reported ORR of 66%, CR rate of 20%, and PFS of 12.8 months (95% CI: 8.5 to 16.6 months) for 370 subjects  with MCL in a merged analysis of 3 studies of single agent 
ibrutinib (Rule, 2017). 
The interim safety results from Study CIRM -[ADDRESS_664073] that myelosuppression associated with 
ibrutinib monotherapy, especially neutropenia, may occur less frequently when ibrutinib is 
administered in combination with cirmtuzumab therapy. TEAEs related to myelosuppression appeared to be slightly lower than expected for ibrutinib treatment, so quantitative analysis of complete blood count data for MCL was undertaken. Grade 3 or greater neutrophil decrease and platelets decreased of 9.7%, respectively, for cirmtuzumab plus ibrutinib appear to be qualitatively lower than the 29% Grade 3 or greater neutrophils decreased and 17% platelets decreased reported for the ibrutinib MCL r egistration study (Ibrutinib Investigator Brochure 
2021). This could be related to the observation that residual tumor cells during ibrutinib treatment express ROR1, which is activated by [CONTACT_512948]5a, leading to cross -activation of 
inflammatory pathwa ys including JAK/stat and secretion of inflammatory chemokines and 
cytokines including IL6 and IFN gamma. Cirmtuzumab has been shown to inhibit this inflammatory activity (Chen, 2019). These Grade [ADDRESS_664074] contributed to dose reductions, delays, or treatment discontinuation that may be associated with monotherapy BTK inhibitor therapy administration, potentially reducing optimal dosing and efficacy.  
6.1.3. Description  
Cirm tuzumab is manufactured under current Good Manufacturing Practices (cGMP) and is 
supplied in vials nominally containing 300 mg of drug substance  (40 mg/mL)  in 7.5 mL of 
formulation buffer  containing the excipi[INVESTIGATOR_512917], trehalose, polysorbate 80, and 
sodium -ethylenediaminetetraacetic acid  (Na-EDTA) . The drug product appears as a clear to 
slightly opalescent, colorless to slightly yellow liquid  and es sentially free  of visible particulates . 
The solution has a target pH of 5.2. The drug product is for IV administration.  A pharmacy 
manual outlining the preparation of the cirmtuzumab infusion bag will be provided to the site personnel.  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 39 of 115  Version 7 ( 15 April  2022 ) 
 6.1.4. Source 
Cirmtuzumab will be provided by [CONTACT_512949]. 
6.1.5. Packaging and Labelling 
Cirmtuzumab drug product is filled into steri le 10 -ml Type I, clear, borosilicate glass vials with 
butyl siliconized rubber stoppers and aluminum seals. 
Labels for cirmtuzumab vials meet all applicable requirements of the FDA, Annex  13 of cGMP 
(Manufacture of Investigational Medicinal Products, July 2003), and/or other local regulations, 
as applicable.  
6.1.6. Shippi[INVESTIGATOR_007], Storage, and Stability  
During shippi[INVESTIGATOR_353183], vials should remain refrigerated at temperatures of 2 to 8°C [35.6 
to 46.4°F]).  
After dilution and prior to use, cirmtuzumab should be maint ained at 2 to 8°C [35.6 to 46.4°F]) 
and is stable for at least 24  hours after dilution. However, cirmtuzumab contains no antimicrobial 
preservative and so should be administered as soon as possible after preparation. 
6.1.7. Cirmtuzumab Administration  
Cirmtuzumab will be given by [CONTACT_512950] s 
4.1-4.3. Intrapatient  dose escalation to dose levels above the dose level assigned to a patient  will 
not be permitted. 
A qualified person (eg, nurse or physician with experience in monitoring the administration of 
therapeutic agents used in patients with cancer) will be responsible for infusing cirmtuzumab. 
The initial cirmtuzumab infusion will be administered over a planned infusion time of ~90 minutes, with 20% of the total dose to be administered in the first ~30 minutes and the 
remaining 80% of the total protein dose to be administered in the subsequent ~60 minutes. For 
patient s who prove able to tolerate infusions without infusion- related toxicity, the infusion time 
may be shortened with each subsequent administration as tolerated following the guidelines in the Pharmacy M anual . Infusion times may be extended as necessary to accommodate individual 
patient  tolerance of treatment.  
[IP_ADDRESS]. Transient Lymphocytosis  
An asymptomatic lymphocytosis has been observed in patients with CLL/SLL treated with cirmtuzumab [ see Cirmtuzumab Investigator Brochure ; Choi 2017] . This effect may represent  a 
positive pharmacodynamic effect of cirmtuzumab  to redistribute malignant cells from sanctuary 
sites in lymph nodes and spleen and should not be considered a drug -related AE or sign of 
disease progression unless other evidence of disease progression is also present. 
[IP_ADDRESS]. Cirmtuzumab Infusion Reactions  
Cirmtuzumab administration has been well -tolerated and only rare G rade [ADDRESS_664075] been reported  in 3 patients ( considered at least possibly relate d in 2 patients , 
unrelated  in 1 patient ) [see Cirmtuzumab Investigator Brochure ]. However, other monoclonal 
antibodies used in the treatment of CLL /SLL, MCL  or MZL  (eg, rituximab, ofatum umab, 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 40 of 115  Version 7 ( 15 April  2022 ) 
 obinutuzumab) can cause severe infusion reactions with manifestations that may include 
dyspnea, bronchospasm, laryngeal edema, pulmonary edema, acute respi[INVESTIGATOR_1505], tachycardia, hypertension, hypotension, syncope, dizziness, cardiac ischemia/infarction, pyrexia, headache, chills, back pain, rigors, nausea, vomiting, abdominal 
pain, diarrhea, flushing, rash, urticaria, and angioedema. While infusion reactions are not 
expected with cirmtuzumab, the following guidelines for managing infus ion reactions are 
provided as a precaution:  
• If a Grade 1 -2 infusion reaction occurs, the infusion may be temporarily slowed or 
interrupted and then can be restarted at half of the previous rate when the patient ’s 
condition has stabilized. After resuming the infusion, the infusion rate may be increased 
consistent with patient  tolerance.  
• If an infusion reaction Grade  ≥[ADDRESS_664076] be interrupted. Medical 
management (eg, oxygen, epi[INVESTIGATOR_238], bronchodilators , corticosteroids ) may  be instituted 
as needed. After the severity of the reaction has decreased to Grade ≤2 the investigator 
may restart the infusion at a rate no higher than the initial rate for this cirmtuzumab dose. After resuming the infusion, the infusion rate may be increased consistent  with patient  
tolerance.  
[IP_ADDRESS]. Overdose Precautions  
An overdose is defined as a dose taken (accidentally or intentionally) exceeding the overdose limit. In the case of a discrepancy in drug accountability, an overdose will be established only when it is clear th at the patient  has received an excess dose, or the investigator has reason to 
suspect that the patient  has received an excess dose.  
There is no experience with overdose of cirmtuzumab. For this protocol, an overdose of 
cirmtuzumab is defined as administration of a dose that is ≥2- fold higher than that prescribed for 
the patient  or exceeds 20 mg/kg (whichever is smaller).  
In a patient  who experiences an overdose that is discovered during drug infusion, the 
cirmtuzumab infusion may  be interrupted or modified, as appropriate. Depending upon the 
degree of an overdose, it may be necessary to delay administration of subsequent cirmtuzumab infusions. Observation for any symptomatic side effects may  be instituted, and safety laboratory 
parameters may  be followed closely (consistent with the protocol or more frequently, as needed). 
Appropriate supportive management to mitigate adverse effects ma y be initiated , as needed .  
The medical monitor should be contact[CONTACT_35114] a study drug overdose occurs. The occurrence of an overdose does not preclude further protocol therapy if the patient  appears to be safely benefiting 
from treatment and the circumstances that led to the initial overdose are unlikely to recur.  
[IP_ADDRESS]. Inadvertent Exposure Precautions  
As noted in the cirmtuzumab investigator brochure, cirmtuzumab is not expected to be acutely toxic, irritating, or genotoxic at levels that are likely to result from inadvertent exposure. Personnel handling the drug should use reasonable precautions to avoid eye contact, skin contact, inhalation, ingestion, or injection of cirmtuzumab.  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 41 of 115  Version 7 ( 15 April  2022 ) 
 6.2. Ibrutinib  
6.2.1. Known potential risks : Ibrutinib  
In the Ibrutinib Investigator Brochure 2021, guidance regarding the following AEs associated 
with ibrutinib administration in patients with B -cell malignancies are conveyed:  
• Hemorrhage: Fatal bleeding events have occurred in patients who received ibrutinib. Use of either anticoagulant or antipl atelet agents concomitantly with ibrutinib 
increases the risk of major hemorrhage.  
• Infections: Fatal and non -fatal infections (including bacterial, viral, or fungal) have 
occurred with ibrutinib therapy. Consider prophylaxis according to standard of care i n 
patients who are at increased risk for opportunistic infections. 
• Cytopenias: In 645 patients with B -cell malignancies who received ibrutinib as a 
single agent, Grade 3 or 4 neutropenia occurred in 23% of patients, Grade 3 or 4 thrombocytopenia in 8% and Grade 3 or 4 anemia in 3%, based on laboratory measurements. Monitor complete blood counts monthly. 
• Cardiac Arrhythmias and Cardiac Failure: Fatal and serious cardiac arrhythmias and cardiac failure have occurred with ibrutinib. At baseline and then periodically, monitor patients clinically for cardiac arrhythmias and cardiac failure. Obtain an electrocardiogram (ECG) for subjects who develop arrhythmic symptoms (e.g., palpi[INVESTIGATOR_814], lightheadedness, syncope, chest pain) or new onset dyspnea.  
• Hypertens ion: Hypertension occurred in 19% of 1,[ADDRESS_664077] antihypertensive medication throughout treatment with ibrutinib as appropriate.  
• Second Primary Malignancies: Other malignancies (10%), including non- skin 
carcinomas (4%), occurred among the 1,476 patients who received ibrutinib in clinical trials.  
• Tumor Lysis Syndrome: Tumor lysis syndrome (TLS) has been infrequently reported with ibr utinib. Assess the baseline risk (e.g., high tumor burden) and take appropriate 
precautions. Monitor patients closely and treat as appropriate.  
• Embryo- Fetal Toxicity: Based on findings in animals, ibrutinib can cause fetal harm 
when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with ibrutinib and for [ADDRESS_664078] dose.  
Ibrutinib is primarily metabolized by [CONTACT_097]3A4, so some patients treated with moderate or strong CYP3A4 in hibitors or inducers are not eligible for ibrutinib therapy unless these drugs are 
discontinued > [ADDRESS_664079] dose of ibrutinib (See Section 6.4.[ADDRESS_664080] of potent inhibitors and inducers of CYP3A4).  
Lymphocytosis has been observed after the administration of ibrutinib, and patients with MCL who develop lymphocytosis greater than 400,000/mcL have developed intracranial hemorrha ge, 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 42 of 115  Version 7 ( 15 April  2022 ) 
 lethargy, gait instability, and headache. However, some of these cases were in the setting of 
disease progression (Ibrutinib Investigator Brochure 2021).  
Serious (Grade ≥ 3) hematologic effects (neutropenia, anemia, thrombocytopenia), pneumonia, and lymphocytosis are associated with the use of all approved BTK inhibitor therapi[INVESTIGATOR_512918], including ibrutinib. 
6.2.2. Description  
Ibrutinib is manufactured and formulated under cGMP. The drug product for investigational use 
is suppli ed as gray  opaque Size 0, gelatin capsules that contain 140 mg ibrutinib as the active 
ingredient. Inactive compendial ingredients include: croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. The capsule shell contains gelatin, titanium dioxide and black iron oxide.  
Further information regarding Imbruvica
® (ibrutinib)  as supplied for commercial use can be 
obtained in product labelling [ Pharmacyclics  2020  and Ibrutinib Investigator Brochure  2021 ]. In 
addition, a pharmacy manual will be provided to site personnel with additional information. 
6.2.3. Source 
It is intended that sufficient investigational ibrutinib for a planned duration of study treatment in 
each patient  will be supplied by [CONTACT_59919] (Pharmacyclics, LLC) and distributed by 
[CONTACT_512949].  
6.2.4. Packaging and Labelling 
Ibrutinib capsules are supplied in high- density polyethylene (HDPE) bottles, each of which is 
closed with an induction seal and a child- resistant, plastic screw cap. Each bottle contains either 
92 or 120 capsules per bottle (as indicated on the label).  
6.2.5. Shippi[INVESTIGATOR_007], Storage, and Stability  
Bottles of ibrutinib should be stored at 15 to 25°C (59 to 77°F). Excursions are permitted to 30°C 
(86°F). It is recommended that the capsules be retained in the original package until ingestion. 
Stability information will be provided to study center personnel.  
6.2.6. Dispensing   
For the investigational product, a  pharmacist or  other qualified staff member will dispense 
bottles containing ibrutinib capsules. Sufficient bottles will be dispensed to the patient  to provide 
an adequate drug supply (with a modest overage) until the patient ’s next planned clinic visit.  
For ibrutinib doses that are taken in the study center, patient s will take the dose from the drug 
dispensed to them for that specific dispensing interval. All other ibrutinib doses will be taken at 
home. 
6.2.7. Return and Compliance Assessment  
At the completion o f each dispensing interval, empty, partially used, or full bottles of ibrutinib 
should be retrieved from the patient . The quantities of unused ibrutinib and the date when these 
study supplies are returned by [CONTACT_512951]: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 43 of 115  Version 7 ( 15 April  2022 ) 
 records.  Appropriate site personnel should confirm the number of capsules taken through an 
interview with the patient . Returned bottles of investigational product may be redispensed to the 
same patient  but not to another patient . Returned c apsules bottles may be destroyed according to 
the site’s standard operating procedures (see Section  10.11).  
Interruptions in treatment, for any re ason, that result in  missed doses  of >7 days (sequential days 
or total  days , for example 3 days and 4 days) during a 28 day period should be reported to the 
Sponsor as soon as possible.  
6.2.8. Ibrutinib Administration 
As described in Section s 4.1- 4.3, ibrutinib will be started at a dose of 420 mg (for patient s with 
CLL/SLL) or at a dose of 560 mg (for patient s with MCL  or MZL ) on Day 28 (Study Part 1) or 
on Day 0 (Study Parts 2 and  3) with the first dose of ibrutinib administered ~30 minutes prior to 
the start of the cirmtuzumab infusion on that day. Thereafter, patient  should self -administer 
ibrutinib at approximately the same time each day, ideally at ~24 -hour intervals (eg, ~7 AM 
every day). While it is realized that variations in dosing schedule may occur in the outpatient 
setting, the prescribed regimen should be followed as closely as possible.  
At each dose administration, the required number of 140- mg capsules should be removed from 
the storage bottle and swallowed whole . Patient s should be instructed not to bite or chew on the 
capsules. In case of breakage of the capsules in the oral cavity, additional wate r should be taken 
as a rinse.  
Ibrutinib may be given without regard to food, however ingestion of the drug following a meal may be desirable to enhance drug exposure [ de Jong 2015; Marostica 2015 ]. 
Patient s who have a delay in administration of a dose of ibrutinib of <[ADDRESS_664081] 
a delay in administration of ibrutinib of ≥12 hours, the dose should not be taken. The planned timing of subsequent ibrutinib dosing should not be altered.  
For patient s who vomit shortly after taking ibrutinib, the vomited dose should not be replaced. 
The planned timing of subsequent ibrutinib dosing should not  be altered.  
[IP_ADDRESS]. Overdose Precautions  
There are limited data on the effects of ibrutinib overdose. No MTD was reached in a Phase  1 
study in which patient s received up to 12.5 mg/kg/day (1400 mg/day) [ Advani  2013]. O ne 
healthy patient  who received a dose of [ADDRESS_664082] [ Pharmacyclics  2020, Ibrutinib Investigator Brochure  2021].  
For this protocol, an overdose of ibrutinib is defined as administration of a daily dose ≥700 mg. 
In a patient  who experiences an overdose, consideration should be given as to whether ibrutinib 
administration should be temporarily interrupted. If the overdose  is recent and substantial, and if 
there are no medical contraindications, use of gastric lavage or induction of emesis may be considered. Observation for any symptomatic side effects may  be instituted, and safety 
laboratory parameters may  be followed clos ely (consistent with the protocol or more frequently, 
as needed). Appropriate supportive management should be instituted if needed to mitigate adverse effects. There is no specific antidote for ibrutinib. 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 44 of 115  Version 7 ( 15 April  2022 ) 
 The medical monitor should be contact[CONTACT_35114] a study drug overdose occurs. The occurrence of an 
overdose does not preclude further protocol therapy if the patient  appears to be safely benefiting 
from treatment and the circumstances that led to the initial overdose are unlikely to recur.  
[IP_ADDRESS]. Inadvertent Exposure Precautions  
Based on available data, ibrutinib is not expected to be acutely toxic, irritating, or genotoxic at 
levels that are likely to result from inadvertent exposure. However, personnel handling the drug 
should use reasonable precautions to avoid eye contact, skin contact, inhalation, or ingestion of 
ibrutinib. Patient s should be instructed to keep the drug secured such that it is out of the reach of 
children and is not inadvertently taken by [CONTACT_2312].  
6.3. Dose Modifications  
Recommendations for modifications of the dosing regimens for each of the study drugs are based 
on current knowledge regarding the safety profiles of these agents. Recommendations comprise only guidelines; variations from these recommendations may be warranted based on an investigator’s i ndividual judgment in considering potential risks, benefits, and therapeutic 
alternatives available to each patient .  
6.3.1. Dose adjustments for Cirmtuzumab   
The Investigator is encouraged to discuss modifications in the dosing regimen with the Medical Monitor. For an AE that is attributed primarily to cirmtuzumab and requires a dose modification, the dose of cirmtuzumab should be reduced by 1 dose level  to 300 mg per dose . Successive 
adjustments to progressively lower dose levels (ie, 150→100 mg fixed dose ) can be made. If the 
patient  cannot tolerate cirmtuzumab at a dose of 100 mg per dose, then the patient  should be 
discontinued from cirmtuzumab therapy and from the study overall  unless continued treatment is 
permitted by [CONTACT_7195].  
After the cirmtuzumab or ibrutinib dose is reduced, the dose can be maintained at that dose level, 
even if there is minimal or no toxicity with the reduced dose. However, if the patient tolerates the drug at a reduced dose for ≥4 weeks, then the dose may be re -escalated to the next higher dose 
level at the discretion of the investigator (particularly if the AE comprised TLS or if further evaluation reveals that the AE that led to the dose reduction was primarily related to the underlying malignancy, an intercurrent il lness, a comorbid condition, or a concomitant 
medication). Successive adjustments to progressively higher dose levels can be made at intervals of ≥4 weeks with the condition that the escalated dose level of either cirmtuzumab or ibrutinib cannot exceed the  starting dose level for that patient.  
6.3.2. Treatment interruptions for Cirmtuzumab  
During the course of the study, treatment may be interrupted due to unforeseen causes  including 
the COVID -19 pandemic . If the interruption was not due to a safety event and the  PI [INVESTIGATOR_512919], the patient may be able to continue as long as the missed treatment interval is ≤ 60 days. If the patient's missed treatment interval is >60 
days and due to extenuating circumstances, the patient may only be allowed to continue after discussion with the sponsor and written approval.  
If a patient misses cirmtuzumab doses, treatment may resume following the guidelines below.  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 45 of 115  Version 7 ( 15 April  2022 ) 
 • Resuming therapy: If one dose of cirmtuzumab is missed AND the interval between last 
dose administered and planned next dose is <45 days:  
o Administer 1 dose as soon as possible  
o Continue with scheduled administrations after that  
• Reloading doses to reach optimal drug levels quickly: If one dose of cirmtuzumab is missed 
AND the interval between last dose administered and planned next dose is 45- 60 days OR 
if two sequential doses of cirmtuzumab are missed: 
o Administer [ADDRESS_664083] as possible  
• If the missed treatment interval is >60 days, the reloading procedure will be determined 
by [CONTACT_512952].  
Continue with scheduled doses after the patient has been reloaded. These guidelines may not cover 
all potential scenarios or circumstances. Please discuss with Oncternal all cases where such interruption in treatment is anticipated.  Please refer to the Pharmacy manual for details.  
6.3.3. Dose modifications for Ibrutinib  
Recommendations for modifications of the dosing regimens for ibrutinib are based on current knowledge regarding its safety profile  and in alignment with guidance in marketing authorization 
document s and the Ibrutinib Investigator Brochure 2021 for ibrutinib as a second- line or 
subsequent treatment of patients with CLL/SLL, MCL  and MZL. 
[IP_ADDRESS]. Dosage modifications for Adverse Reactions  
Ibrutinib therapy should be interrupted for any Grade 3 or 4 non- hematological toxicities, 
Grade 3 or 4 neutropenia with infection or fever, or Grade 4 hematological toxicities. Once the 
adverse reaction has improved to Grade 1 or baseline (recovery), ibrutinib may be reinitiated at 
the current  dose. If the adverse reaction reoccurs ( Table 1 ), the dose should be reduced by 
[ADDRESS_664084] or recur  following two dose reductions, ibrutinib should 
be discontinued. 
  
 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 46 of 115  Version 7 ( 15 April  2022 ) 
 Table 1:  Dose Adjustments for Ibrutinib  
Toxicity Occurrence  Dose Modification for MCL  and 
MZL After Recovery  
Starting Dose = 560 mg Dose  Dose Modification for CL L 
After Recovery  
Starting Dose = [ADDRESS_664085] 
tolerates the drug at a reduced dose without toxicity for ≥  8 weeks, then the dose may be re -
escalated to the next higher dose at the discretion of the Investigator (if the AE comprised TLS, 
as defined by [INVESTIGATOR_86223], 2011 or if further evaluati on reveals that the AE that led to the dose 
reduction was primarily related to the underlying malignancy, an intercurrent illness, a comorbid 
condition, or a concomitant medication). Dose re -escalation to progressively higher doses can be 
made at intervals  of ≥  [ADDRESS_664086]/caregiver about the change in dose.  
6.4. Concomitant Therapy  
If considered necessar y for the patient ’s well -being, drugs for concomitant medical conditions or 
for symptom management may be given at the discretion of the investigator. The investigator’s 
decision to authorize the use of any drug other than study drug will take into account  patient  
safety, the medical need, the potential for drug interactions, the possibility for masking symptoms of a more significant underlying event, and whether use of the drug will compromise the outcome or integrity of the study. 
Patient s will be instruc ted about the importance of the need to inform the clinic staff of the use of 
any drugs or remedies (whether prescribed, over -the-counter, or illicit) before and during the 
study.  
6.4.1. Cirmtuzumab Infusion- Reaction Prophylaxis  
Based on the available experience, clinically significant infusion reactions are not expected in 
patient s receiving cirmtuzumab. Thus, premedication for infusion- reaction prophylaxis should be 
avoided on Day 0 (and on Day 28 in Part  1 of the study) unless infusion reactions become a 
safet y concern during the study.  
Patient s who develop infusion- related toxicities may be premedicated before subsequent 
cirmtuzumab infusions with an antipyretic and an antihistamine to reduce the incidence and severity of infusion reactions , for example  an or al or IV antipyretic (acetaminophen 650 to 
1,000 mg or equivalent) and an oral or IV antihistamine (cetirizine, 10 mg or equivalent) both given 30 to 60 minutes prior to each cirmtuzumab infusion. 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol:  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 47 of 115  Version 7 (15 April  2022) 
 6.4.2. Tumor Lysis Syndrome (TLS) Prophylaxis 
Based on the available experience in CLL /SLL, cirmtuzumab does not specifically pose a risk of 
TLS and ibrutinib monotherapy in patients with CLL /SLL, MCL  or MZL  is only rarely 
associated with TLS [ Howard 2016]. However, patient s who are at intermediate to high risk of 
TLS can be considered for medical prophylaxis of TLS depending upon physician judgement or 
if evidence of TLS is observed during the study. The general risk for TLS can be characterized according to the following criteria, considering established algorithms [ Cairo  2010, 
MDACC  2016, Roberts 2016]: 
• Low-risk: Serum lactate dehydrogenase (LDH) ≤ULN, all measurable lymph nodes <5 
cm, and ALC <25 × 109/L. 
• I ntermediate risk : Serum LDH >1 to ≤2 × ULN, ≥1 measurable lymph node with an LD 
of ≥5 but <10 cm, or ALC ≥25 × 109/L. 
• H igh risk: Serum LDH >2 × ULN, ≥1 measurable lymph node with a LD of ≥10 cm, or 
both ≥1 measurable lymph node with an LD of ≥5 but <10 cm  and ALC ≥25 × 109/L. 
• An institutional TLS prophylaxis regimen may be used, or the following prophylaxis 
regimens may be considered: 
• Intermediate Risk of TLS : These patient s may receive allopurinol, 100 to 300 mg orally 
daily starting ≥24 to 48 hours befor e the initial administration of ibrutinib; in addition, 
patient s who develop hyperuricemia may receive rasburicase, 3 to 4.5 mg by [CONTACT_16228]. 
• H igh Risk of TLS : These patient s may receive allopurinol, 100 to 300 mg orally daily 
starting ≥24 to 48 hours be fore the initial administration of ibrutinib; in addition, high -
risk patient s may receive rasburicase, [ADDRESS_664087] dose of ibrutinib. 
6.4.3. TLS Management  
Information regarding TLS prophylaxis is provided in Section  6.4.2. 
Patient s who develop TLS may experience hyperkalemia, hypocalcemia, hyperuricemia, 
hyperphosphatemia, cardiac dysrhythmias, and acute renal failure; thus, close monitoring of 
electrolytes is  important after initial therapy.  
Patient s with TLS should receive IV hydration, rapid reversal of hyperkalemia, 
antihyperuricemic agents, and appropriate cardiac and renal support, including dialysis as indicated. Upon recovery to baseline functioning and as medically appropriate, such patient s 
should continue with protocol therapy to maintain tumor control. 
6.4.4. Anticancer Therapi[INVESTIGATOR_512920] (including chemotherapy, antibody therapy, hormonal therapy, 
immunotherapy, or other experimental therapi[INVESTIGATOR_014]) for the patient’s cancer are permitted while the patient  is receiving study treatment. Patient s are not allowed to participate concurrently in any 
other therapeutic clinical or imaging study. 
The use of palliative r adiotherapy should be minimized given the potential of such treatment to 
confuse assessments of cirmtuzumab  + ibrutinib  safety or therapeutic effect. However, in a 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 48 of 115  Version 7 ( 15 April  2022 ) 
 patient  participating in Part [ADDRESS_664088] occurred in patients trea ted with ibrutinib . Grade 3 or higher bleeding 
events (intracranial hemorrhage [including subdural hematoma], gastrointestinal bleeding, hematuria, 
and post procedural hemorrhage) have occurred in up to 6% of patients. Bleeding events of any grade, includi ng bruising and petechiae, occurred in approximately half of patients treated with 
ibrutinib  [Pharmacyclics  2020, I brutinib I nvestigator Brochure  2021 ]. The mechanism for the 
bleeding events is not well understood, although ibrutinib may impair platelet function.  
Ibrutinib may increase the risk of hemorrhage in patients receiving antiplatelet or anticoagulant 
therapi[INVESTIGATOR_014]. Such agents should be administered with caution, and patient s should be monitored for 
signs of bleeding. However, for patient s who develop atrial fibrillation, it has been suggested that 
additional anticoagulation not be administered unless they are at substantial risk of 
thromboembolism ba sed on the presence of comorbid conditions [ Vrontikis  2016].  
6.4.6. Drugs with Potential for Drug -Drug Interactions with Ibrutinib  
Ibrutinib is primarily metabolized by [CONTACT_097]3A4. In healthy subjects, coadministration of a strong CYP 3A4 inhibitor , increased ibrutinib plasma exposure by >20- fold ibrutinib and 
coadministration of a strong CYP3A4 inducer decreased ibrutinib exposures by ≥10- fold 
[Pharmacyclics  2020, Ibrutinib Investigator Brochure  2021]. Based on these findings, protocol 
candidates who require therapy with the moderate or strong CYP3A4 inhibitors or inducers listed in Appendix 12.[ADDRESS_664089] this enzyme can be substituted >[ADDRESS_664090] dose of  ibrutinib .  
During study participation, coadministration of ibrutinib with moderate or strong CYP3A4 inhibitors or inducers listed in Appendix 12.3 should be avoided, if possible. However, a patient  
who develops a condition that may require use of such drugs is not required to discontinue ibrutinib if the patient  is experiencing clinical benefit and other options for treating the patient ’s 
cancer are limited. If medically appropriate, investigators may wish to use a therapeutic alternative that would not be expected to affect these enzymes. For patient s who require 
temporary use of a drug that does affect these enzymes (eg, treatment with a systemic antifungal agent), ibrutinib therapy may be temporarily interrupted and then resumed after completion of 
the other drug. For patient s who require initiation of chronic therapy with a moderate or strong 
inhibitor of CYP3A4, the dose of ibrutinib should be re duced to 140 mg QD and the patient  
should be monitored closely for signs of ibrutinib toxicity. 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 49 of 115  Version 7 ( 15 April  2022 ) 
 6.4.7. Drugs Known to Prolong the QT Interval  
To satisfy regulatory requirements , the clinical potential of cirmtuzumab to prolong the QT 
interval was  assessed in CLL Parts 1 and 2 and MCL Part 1 of this study. Protocol candidates 
who were taking drugs at screening known to prolong the QT interval were  not enrolled into 
those parts of the  study. As of Amendment 6, MCL or MZL patients in Part 2 , and for CLL/SLL 
patients  in Part 3, the exclusion criteria restricting the enrollment of patients with QTc 
abnormalities or taking  drugs known to prolong the QT  interval  is removed .  
6.4.8. Procedures/Surgery  
The extent to which cirmtuzumab may affect wound healing, enhance the risk of infection, or 
increase the risk of bleeding is unknown. Ibrutinib causes inhibition of platelet function (see Section  6.4.5) . Considering parameters such as ANC, platelet count, and PT/aPTT, investigators 
may use clinical discretion in deciding whether to interrupt cirmtuzumab therapy before and after surgery or other invasive procedures. Depending upon the type of procedure or surgery and the risk of bleeding, investigators may wish to withhold ibrutinib for [ADDRESS_664091] discontinue nursing during protocol therapy 
and for ≥  [ADDRESS_664092] dose of cirmtuzumab and for ≥  [ADDRESS_664093] agree to use a highly effective method of 
contraception during heterosexual intercourse from the start of the screening period until ≥[ADDRESS_664094] dose of cirmtuzumab and ≥[ADDRESS_664095] dose of ibrutinib, whichever is later.  
In the context of this protocol, a female patient  is considered to be of childbearing potential 
unless she has had a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy; has medically documented ovarian failure (with serum estradiol and FSH levels within the institutional laboratory postmenopausal range and a negative serum or urine beta βHCG); or is menopausal (age ≥50 years with amenorrhea for ≥6 months).  
Sexually active male patient s who can father a child and are having intercourse with females of 
childbearing potential who are not using adequate contraception must agree to use a n effective 
method of contraception from the start of study therapy until ≥[ADDRESS_664096] dose of 
cirmtuzumab and ≥ [ADDRESS_664097] dose of ibrutinib, whichever is later. Male patient s 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 50 of 115  Version 7 ( 15 April  2022 ) 
 should also refrain from sperm donation from the start of study therapy until ≥3 months after 
administration of the final dose of either of the study drugs. 
In the context of this protocol, a male patient  is considered able to father a child unless he has 
had a bilateral vasectomy with documented aspermia or a bilateral orchiectomy.  
6.5.3. Diet 
Because ibrutinib is a sensitive substrate of CYP3A4, patient s should be advised to avoid 
ingestion of grapefruit, grapefruit juice, or Seville oranges (which contains a potent  CYP3A4 
inhibitor) and should not use St. John’s wort, which is a potent CYP3A4 inducer. No other 
specific dietary restrictions are required.  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 51 of 115  Version 7 ( 15 April  2022 ) 
 7. STUDY INTERVENTION DISCONTINUATION AND 
PARTICIPANT DISCONTINUATION/ WITHDRAWAL  
7.1. Duration of Study Drug Administration and Study Participation  
Patients exhibiting a PR or CR may continue combination treatment beyond W eek 52 until 
disease progression or unacceptable toxicity as part of an extended therapy program .  
Patients who  remain in a PR or CR at the end of the 2 yea r treatment period, may be eligible for 
Long-term T herapy  and continue to receive cirmtuzumab and/or  ibrutinib until disease 
progression, unacceptable toxicity, or the study ends. Sites should discuss these cases with the 
sponsor in advance for approval. 
For CLL /SLL patients, long- term follow -up consisting of patient contact [INVESTIGATOR_135] 3- 6 months and 
collection of disease, treatment , and vital status  data will continue  following the E nd of 
Treatment  visit for up to five years . For MCL  or MZL  patients, long- term follow -up will occur 
every 3 months and include collection of disease , treatment, and vital status data for up to five 
years . Imaging reports may be requested by [CONTACT_456]. Th ese data will be used to establish 
PFS, TTP , and time to n ext treatment.  Once a patient in long- term follow -up has progressed and 
received an alternate treatment for their disease, only vital status will be collected.  
For patients actively receiving study drug therapy, the occurrence of any of the following event s 
requires treatment discontinuation:  
• Patients who withdraw from either ibrutinib or cirmtuzumab treatment will be withdrawn 
from the study. 
• Documented objective evidence of cancer progression while receiving combination study 
treatment  
• Intolerable toxicity despi[INVESTIGATOR_493275]/or dose modification 
• The development of intercurrent illness or other substantial change in the patient ’s 
condition or circumstances that would place the patient  at unacceptable risk as 
determined by [CONTACT_512953]  
• Initiation of treatment for the patient ’s cancer with an off -study therapeutic regimen  
• Pregnancy or breastfeeding  
• Substantial noncompliance with study drug administration, study procedures, or study 
requirements in circumstances that increase risk or substantially compromise the interpretation of study results  
• Discontinuation of the study by [CONTACT_5243], Oncternal, relevant regulatory agencies, 
or the IRB 
Patient s in Part 1 who experience disease  progression while receiving cirmtuzumab monotherapy 
should not be discontinued from study therapy solely for that reason; if otherwise medically 
appropriate, they should continue on study to receive combination cirmtuzumab + ibrutinib  
treatment.  
Unless th ey withdraw consent, patient s will e nter long- term follow -up. Patients who discontinue 
study therapy will be followed for acquisition of safety information through ≥30 days  after the 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 52 of 115  Version 7 ( 15 April  2022 ) 
 last dose of study treatment, and for up to five years for further collec tion of information 
regarding subsequent anti -cancer therapi[INVESTIGATOR_512921] . 
7.2. Patient  Replacement  
Patient s who do not have the necessary baseline and on- study measurements to provide 
interpretable results for safety, pharmacodynamic, pharmacokinetics, or efficacy parameters may 
be replaced at the discretion of the sponsor. In general, this will mean that patient s who do not 
complete study drug administration and protocol evaluation through Week 16 of therapy in Part 1 or through Week 12 of therapy in Parts  2 or 3 of the study will be considered for 
replacement. The replacement patient  will be assigned to the same treatment cohort as the 
original patient . Accrual of additional patient s to a treatment cohort may also be considered at 
the discretion of the SRC. A replacement patient  or an additional patient  may be accrued if there 
is agreement that treatment of such a pati ent is unlikely to constitute an unacceptable safety risk. 
7.3. Study Discontinuation  
Both the investigator and Oncternal reserve the right to terminate the study at any time. Should this be necessary, both parties will arrange discontinuation procedures. The i nvestigator will be 
responsible for notifying the relevant study center IRB. Oncternal will be responsible for 
notifying the appropriate regulatory authorities. In terminating the study, the investigator and Oncternal will assure that adequate consideratio n is given to the protection of the patient s’ 
interests.  As directed by [CONTACT_512949], all study materials must be collected and all eCRFs 
completed to the greatest extent possible.  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal  Therapeutics, Inc.  
CONFIDENTIAL  Page 53 of 115  Version 7 ( 15 April  2022 ) 
 8. STUDY ASSESSMENTS AND PROCEDURES  
8.1. Study Activities  
The specific study procedur es and time of activities to be conducted for each patient  enrolled in 
the study are presented in tabular form in Section 8.2 (Part 1 ), Section 8.3 (Part 2), and  Section 
8.4 (Part 3) below.  
To provide necessary medical care to the patient  while on study, additional types of clinical 
evaluations and laboratory studies or more frequent assessments may be performed if clinically 
indicated, even if not specified in the protocol. Physical examinations may be performed consistent with appropriate medical care for the patient , but physical examination data 
considered not clinically significant or an AE will not be routin ely collected  in the eCRF .  
To optimize scheduling convenience for the patient  and for the study center staff, screening 
procedures may be performed over as many days as necessary provided that screening is completed within [ADDRESS_664098] -dose, the acceptable margin for actual 
time is the specified time ±15 minutes. If multiple procedures are  to be done at the same time 
point, the preferred order is vital signs, blood sampling, and then ECG, with blood sampling 
(particularly for pharmacokinetics) occurring as close as possible to the specified time. 
Missed procedures or evaluations should be performed as close to the originally scheduled 
date/time as possible. Based on the investigator’s judgment, an exception can be made when rescheduling becomes medically unnecessary because it is too close in time to the next scheduled procedure or evaluatio n. In that case, the missed evaluation may be omitted. 
If necessary, remote/telemedicine visits and local laboratories are allowed to ensure continued safety monitoring.  
 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol:  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 54 of 115  Version 7 (15 April  2022) 8.2. Schedule of Activities – Part 1 MCL and CLL/SLL  (Cirmtuzumab → Cirmtuzumab + Ibrutinib)  
Period  Screen  Treatment  End of  
Tx  Follow -up 
Visit  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20+ 22+  Safety 
FU Long -
term  Week  -4 0 0 2 4 4 6 8 12 16 20 24 28 32 36 40 44 48 52 56+ 64+ 104 
Study Day  Within  
28 Days  0 1 14 28 29 42 56 84 112 140 168 196 224 252 280 308 336 364 Q 4 
weeks  
[bb] Q 12 
weeks  
[bb] 728 
[bb] Within 
+30 
days  To ≤5  
years  
Visit Window, days     ±2 ±2 ±2 ±2 ±2 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +7  
General Eligibility/Safety Assessments                          
Written informed consent [b]  X                        
Height [c]  X                        
Weight/Vital signs [d]  X X* X X* X* X X X X X X X X X X X X X X X X X X  
Performance status [e]  X X X X X X X X X X X X X X X X X X X X X X X  
Medical history [f]  X                        
Adverse Event (AE) assessment [g]   X X X X X X X X X X X X X X X X X X X X X X  
Concomitant medications [h]  X X X X X X X X X X X X X X X X X X X X X X   
12-lead ECG [i]  X X* X X*                  X X  
Drug Administration/Dispensing/Return                          
TLS prophylaxis [j]      X                    
Ibrutinib administration in the clinic [ k]     X                    
Cirmtuzumab administration [ l]  X  X X  X X X X X X X X X X X X X X X    
Dispensing of ibrutinib [m]      X   X X X X X X X X X X X  X X    
Ibrutinib compliance check [m]         X X X X X X X X X X X X X X X   
Laboratory Assessments  ##                         
Serum virology [ n] X                        
Serum chemistry [ o] X X(a) X X X X X X X X X X X X X X X X X X X X X  
Hematology [ p] X X(a) X X X X X X X X X X X X X X X X X X X X X  
Urinalysis [ q] X X(a) X X X X  X  X   X   X   X  X X X  
Coagulation [ r] X X(a)   X X  X  X   X   X   X  X  X  
Serum or urine pregnancy test [ s] X X(a)   X     X   X   X   X  X    
Serum for cirmtuzumab pharmacokinetics [ t]  X* X X* X*(k) X  X  X   X   X   X   Xt Xt  
Blood for ROR1 [ u]  X* X X* X*(k) X  X  X   X   X   X      
MCL ONLY: Blood for exploratory 
biomarkers [v]  X X X X(k) X  X  X   X   X   X      
Serum for cirmtuzumab -reactive antibodies 
[w]  X           X      X  X  X  
Disease Assessments                          
Radiology examination [ x] X    X     X   X   X   X  X XX   
Blood and Bone marrow biopsy/aspi[INVESTIGATOR_337] [ y]  X        ------------  If required to document complete response ----------     
Posttherapy Follow -up                         
Posttherapy safety assessment [ z]                       X  
Long -term follow -up [aa]                        X 
 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 55 of 115  Version 7 ( 15 April  2022 ) Footnotes  – Part 1  
Note:   For procedures to be performed at a specified time postdose, the acceptable margin for actual time is the specified time ±15 minutes. If multiple procedures are to be 
done at the same time point, the preferred order is vital signs, blood sampling, and then ECG, with blood sampling occurring as close as possible to the specified time.  
## General safety lab assays will be done utilizing your CLIA approved local lab. Other required labs will utilize  a central laboratory, so samples will need to be prepared and 
shipped according to the study lab manual.  
a. If obtained within 7 days prior to the start of therapy, urinalysis and serum pregnancy, serum chemistry, hematology, and coagulation studies coll ected during Screening need 
not be repeated on Day 0.  
b. Written informed consent will be obtained before any study procedures are p erformed that are not part of routine medical care.  
c. Height (in centimeters) will be obtained at Screening only.  
d. Weight (in kilograms) and v ital signs (blood pressure, pulse,  and temperature)  will be assessed prior to the cirmtuzumab infusion , and at any  time if no infusion that day .  
* -  on Days 0, 14, and 28 vital signs will also be assessed  immediately  after the end of the cirmtuzumab infusion . 
e. Performance status will be assessed using ECOG scale (see Appendix 12.1). 
f. Medical history to include recording of cancer history, previous therapy for cancer, clinically significant past and ongoing medical conditions, review of systems, and relevant 
social history and will be obtained at Screening only.  
g. Description of all AEs using concise medical terminology, including whether the AE is se rious, the date of onset, the date of resolution, the severity based on the CTCAE, 
Version 4.03, a description of the potential relatedness to study drug or to a study procedure, the action taken, and the out come (see Section 8.6). 
h. Concomitant medication assessments should include information regarding all prescription, nonprescription, illicit, and alter native medications.  
i. 12-lead ECGs will be obtained with the patient  resting in a supi[INVESTIGATOR_2547].  
* -  on Days 0 and 14 ECGs will also be assessed one hour after the end of the cirmtuzumab infusion.  
j. Based on the risk of TLS (low, intermediate, or high), patient s at intermedi ate or high risk should be considered for TLS prophylaxis (see Section 6.4.2 ).  
k. The first dose of ibrutinib will be administered to the patient  in the study center  after collection of the predose blood samples and  ~30 minutes prior to the start of the 
cirmtuzumab inf usion (with recording of the date and actual clock time of the ibrutinib administration).  
l. Cirmtuzumab will be infused as indicated in Section 6.1.[ADDRESS_664099] any cirmtuzumab 
infusion reaction as an adverse event (s) in the eCRF, and record any supportive care provided. If infusion prophylaxis is required for subsequent infusions, see Section 6.4.1.  
m. A supply of ibrutinib will be dispensed to the patient  with instructions for self -administration at home. At subseq uent visits, empty, partially used, or full bottles of ibrutinib 
will be retrieved from the patient and drug compliance will be assessed.  
n. Virology evaluation to include serum HIV antibody, HBsAg antibody, HBc antibody, HCV antibody. Patient s with a positive antibody evaluation for HBc or HCV should 
undergo evaluation for HBV DNA and for HCV RNA to determine if the antibody test may be falsely positive.  
o. Serum chemistry  to include sodium, potassium, chloride, bicarbonate, BUN, creatinine, glucose, calcium, phosphorus, magnesium  (screening only) , total protein, albumin, 
ALT, AST, ALP, LDH, and total bilirubin.  
p. Hematology  to include hematocrit, hemoglobin, erythrocyte count; absolute counts of leukocytes, neutrophils, lymphocytes , monocytes, eosinophils, basophils; platelet count.  
q. Urinalysis to include specific gravity, pH, protein, glucose, ketones, bilirubin, urobilinogen, blood, nitrite, leukocyte est erase as assessed by [CONTACT_5230] , and microscopic 
urinalysis evaluating white bl ood cells, red blood cells, epi[INVESTIGATOR_1663], bacteria, cast and crystals.  
r. Coagulation studies to include PT and aPTT.  
s. Serum or urine pregnancy testing will be performed in women of childbearing potential only. See Section 8.6.6  for reporting requirements in the event of a pregnancy.  
t. Serum for cirmtuzumab pharmacokinetics will be collected on the indicated days prior to the cirmtuzumab infusion , and at any time if no infusion that day .  
* -  on Days 0, [ADDRESS_664100] sites:  on the day of the last infusion, [ADDRESS_664101]  
infusion should be collected and, if possible, 1 additional s ample every 28 days x4 (post  last infusion).  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 56 of 115  Version 7 ( 15 April  2022 ) u. Blood for ROR1 cell surface expression and receptor occupancy will be collected on the indicated days prior to the cirmtuzuma b infusion, and at any time if no infusion that 
day.  
* -  on Days 0, 14 and 28, blood for ROR1 cell surface expression and receptor occupancy will also be collected one hour after the end of the cirmtuzuma b infusion.   
v. MCL Patients Only: Blood for  exploratory biomarkers , such as cytokines and stem cell gene profile,  will be collected on the indicated days prior to the cirmtuzumab infusion. 
On Day [ADDRESS_664102] be collected prior to ibrutinib administration.  (The samples collected for each Part of the study will be described in the lab manual .) Tumor 
samples (unstained slides, tissu e/cells or blocks) obtained pre -treatment or post -treatment, if available, may be requested for biomarker testing . 
w. Serum for cirmtuzumab -reactive antibodies will be collected on the indicated days prior to the cirmtuzumab infusion.  
x. Radiology examination to include contrast -enhanced CT or MRI imaging of neck, chest, abdomen, and pelvis and may include FDG -PET/CT  for MCL . The same method of 
assessment (CT, MRI, FDG -PET/CT) and the same technique should be used, whene ver possible, to characterize each identified and reported lesion at Screening and while 
on study. Evaluations may be performed within the [ADDRESS_664103] performed > 8 weeks before the E nd 
of Treatment  visit, then they should be performed as part of this visit. For patients ending treatment due to radiographic confirmation of disease progression following 
cirmtuzumab + ibrutinib combined therapy, the E nd of Treatment  visit should occur ≤ 4 weeks after the documentation of progression and the ima ging studies do not need to 
be performed.  
y. A bone marrow aspi[INVESTIGATOR_337], biopsy and peripheral blood sample should be obtained prior to Day 0 and before  the cirmtuzumab infusion for exploratory bio markers , with a 
biopsy for disease assessment if no biopsy results are available in the preceding 45 days . Subsequent bone marrow aspi[INVESTIGATOR_512922], 
including samples for exploratory biomarkers, will only be obtained as needed to confirm a clinical/radiologic complete response. A bli nded bone marrow sample may be 
sent for central review/confirmation.  
z. The End of Treatment  visit will be performed after permanent cessation of study therapy. The Safety Follow -up visit will occur either [ADDRESS_664104] dose of study 
treatment or u pon resolution/stabilization of any ongoing drug-related AEs and/or SAEs , whichever occurs later . AE/SAE follow -up may be obtained in person, by [CONTACT_756], 
or by e -mail contact.  
aa. Long -term follow -up information will be obtained for up to [ADDRESS_664105]-study cancer therapi[INVESTIGATOR_014] (including ibrutinib) will be collected. Once a patient has progressed and received a subsequent cancer therapy, only vital status will be collected . 
Reports of imaging studies performed during lo ng-term follow -up may be requested by [CONTACT_512954].  
bb. For patients continuing beyond Week 52, the combination treatment will continue at the same dose and schedule as year 1. Assessments will continue to be perf ormed with  
visits and infusions every 4 weeks and scans and other additional assessments  every 12 weeks , as indicated in the SOA .  
Abbreviations:  AE=adverse event, ALP=alkaline phosphatase, ALT=alanine aminotransferase, aPTT=activated partial thromboplastin time, AST=asp artate aminotransferase, 
BUN=blood urea nitrogen, CLL/SLL=chronic lymphocytic leukemia/small lymphocytic lymphoma, CR=complete res ponse, CT=computed tomography, DNA=deoxyribonucleic 
acid, ECG=electrocardiogram, ECOG=Eastern Cooperative Oncology Group, FDG=fluorodeoxyglucose, HBc antibody=anti -hepatitis B core antibody, HBsAg=hepatitis B surface 
antigen, HBV=hepatitis B virus, HCV=hepatitis C virus, HIV=human immunodeficiency virus, LDH=lactate dehydrogenase, MCL=mantle cell lymphoma, MRD=minimal 
residual disease, MRI=magnetic resonance imaging, OS=overall survival, PD=progressive disease, PET=positron emission tomography, PT=partial t hromboplastin time, 
RNA=ribonucleic acid, ROR1= receptor tyrosine kinase -like orphan receptor 1, SAE=serious adverse event, TLS=tumor lysis syndrome , Tx=treatment . 
 
 
 
 
  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol:  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 57 of 115  Version 7 (15 April  2022) 8.3. Schedule of Activities – Part 2 MCL , MZL  and CLL/SLL (Cirmtuzumab + Ibrutinib)  
Period  Screen  Treatment  End of 
Tx Follow -up 
Visit  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18+ 19+  Safety 
FU Long -term  Week  -4 0 0 2 4 8 12 16 20 24 28 32 36 40 44 48 52 56+ 60+ 104 
Study Day  Within  
28 
Days  0 1 14 28 56 84 112 140 168 196 224 252 280 308 336 364 Q 4  
weeks  
[bb] Q 12  
weeks  
[bb]  
728 
[bb] Within 
+30 
days  To 
≤5 years  
Visit Win dow, days     ±2 ±2 ±2 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +7  
General Eligibility/Safety Assessments                        
Written informed consent [b]  X                      
Height [c]  X                      
Weight/Vital signs [d]  X X* X X* X* X X X X X X X X X X X X X X X X  
Performance status [e]  X X X X X X X X X X X X X X X X X X X X X  
Medical history [f]  X                      
Adverse Event (AE) assessment [g]   X X X X X X X X X X X X X X X X X X X X  
Concomitant medications [h]  X X X X X X X X X X X X X X X X X X X X   
12-lead ECG [i]  X                   X   
Drug Administration/Dispensing/Return                        
TLS prophylaxis [j]   X                     
Ibrutinib administration in the clinic [ k]  X                     
Cirmtuzumab administration [ l]  X  X X X X X X X X X X X X X X X X    
Dispensing of ibrutinib [m]   X   X X X X X X X X X X X Xcc X X X    
Ibrutinib compliance check [m]      X X X X X X X X X X X X X X X X   
Laboratory Assessmen ts ##                       
Serum virology [ n] X                      
Serum chemistry [ o] X X(a) X X X X X X X X X X X X X X X X X X X  
Hematology [ p] X X(a) X X X X X X X X X X X X X X X X X X X  
Urinalysis [ q X X(a) X X X  X   X   X   X   X X X  
Coagulation [ r] X X(a)   X  X   X   X   X   X X X  
Serum or urine pregnancy test [ s] X X(a)   X  X   X   X   X   X    
Serum  for cirmtuzumab pharmacokinetics [ t]  X*(k)  X X     X*   X   X    Xt Xt   
Blood for ROR1 [ u]  X(k)  X X     X   X   X    X   
Blood for exploratory biomarkers  [v]  X(k)   X     X   X   X   X X   
Serum for cirmtuzumab -reactive antibodies 
[w]  X(k)        X      X   X  X  
Disease Assessments                        
Radiology examination [ x] X      X   X   X   X   X XX   
Blood and Bone marrow biopsy/aspi[INVESTIGATOR_337] [ y]  X     ------------  If required to document complete response ----------     
Posttherapy Follow -up                       
Posttherapy safety assessment [ z]                     X  
Long -term follow -up [aa]                      X  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 58 of 115  Version 7 ( 15 April  2022 ) Footnotes  – Part 2   
Note:   For procedures to be performed at a specified time postdose, the acceptable margin for actual time is the specified time ±15 minutes. If multiple procedures are to be 
done at the same time point, the preferred order is vital signs, blood sampling, and then ECG, with blood sampling occurring as close as possible to the specified time.  
## General safety lab assays will be done utilizing your CLIA approved local lab. Other required labs will utilize  a central laboratory, s o samples will need to be prepared and 
shipped according to the study lab manual.  
a. If obtained within 7 days prior to the start of therapy, urinalysis and serum pregnancy, serum chemistry, hematology, and coagulation studies coll ected during Screening 
need not be repeated on Day 0.  
b. Written informed consent will be obtained before any study procedures are p erformed that are not part of routine medical care.  
c. Height will be obtained once at Screening.  
d. Weight (in kilograms) and vital signs (blood pressure, pulse, and temperature) will be assessed prior to the cirmtuzumab infusion , and at any time if no infusi on that day .  
* -  on Days 0, 14, and [ADDRESS_664106] infusion.  
e. Performance status will be assessed using ECOG scale (see Appendix 12.1) once on each designated day.  
f. Medical history to include recording of cancer history, previous therapy for cancer, clinically significant past and ongoing medical conditions, review of syste ms, and 
relevant social history and will be obtained at Screening only.  
g. Description of all AEs using concise medical terminology, including whether the AE is serious, the date of onset, the date of  resolution, the severity based on the CTCAE, 
Version 4.03 , a description of the potential relatedness to study drug or to a study procedure, the action taken, and the outcome  (see Section 8.6). 
h. Concomitant medication assessments should include information regarding all prescription, nonprescription, illicit, and alter native medications .  
i. 12-lead ECGs will be obtained with the patient  resting in a supi[INVESTIGATOR_2547].  If ECG abnormalities such as QT prolongation are observed compared to baseline following 
study treatment, the test result should be confirmed and ECG repeated at the Safety Follow -up visit (post the End of Treatment visit ). 
j. Based on the risk of TLS (low, intermediate, or high), patient s at intermediate or high risk should be considered for TLS prophylaxis (see Section 6.4.2 ).  
k. The first dose of ibrutinib will be administered to the patient  in the study center  after collection of the predose blood samples and  ~30 minutes prior to the start of the 
cirmtuzumab infusion (with recording of the date and actual clock time of the ibruti nib administration).   
l. Cirmtuzumab will be infused as indicated in Section 6.1.[ADDRESS_664107] any cirmtuzumab 
infusion reaction as an adverse event(s) in the eCRF, and record any supportive care provided. If infusion prophylaxis is req uired for subsequent infusions, see Section 6.4.[ADDRESS_664108] may be falsel y positive.  
o. Serum chemistry to include sodium, potassium, chloride, bicarbonate, BUN, creatinine, glucose, calcium, phosphorus, magnesium  (screening only) , total protein, albumin, 
ALT, AST, ALP, LDH,  and total bilirubin . 
p. Hematology to include hematocrit, hemoglobin, erythrocyte count; absolute counts of leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, b asophils; platelet 
count.  
q. Urinalysis to include specific gravity, pH, protein, glucose, ketones, bilirubin, urobilinogen, blood, n itrite, leukocyte esterase as assessed by [CONTACT_5230], and microscopic 
urinalysis evaluating white blood cells, red blood cells, epi[INVESTIGATOR_1663], bacteria, cast and crystals.  
r. Coagulation studies to include PT and aPTT.  
s. Serum or urine pregnancy testing wil l be performed in women of childbearing potential only. See Section 8.6.6  for reporting requirements in the event of a pregnancy.  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 59 of 115  Version 7 ( 15 April  2022 ) t. Serum for cirmtu zumab pharmacokinetics will be collected on the indicated days prior to the cirmtuzumab infusion . 
* -  In addition,  on Day [ADDRESS_664109] sites : on the day of the last 
infusion, [ADDRESS_664110] infusion should be collected and, if possible, 1 additional sample every 28 days x4 (post last infusion).  
u. Blood for ROR1 cell surface expression and receptor occupancy will be collected on the indicated days p rior to the cirmtuzumab infusion, and at any time if no infusion that 
day. Additional timepoints may be requested, should it be needed to complete the dataset.  
v. Blood for exploratory biomarkers will be collected on the indicated days prior to the cirmtuzu mab infusion.  Additional timepoints may be requested, should it be needed to 
complete the dataset.  Tumor samples (unstained slides, tissue/cells or blocks) obtained pre -treatment or post -treatment, if available, may be requested for biomarker testing .  
w. Serum for cirmtuzumab -reactive antibodies will be collected on the indicated days prior to the cirmtuzumab infusion.  
x. Radiology examination to include contrast -enhanced CT (preferred) or MRI imaging of neck, chest, abdomen, and pelvis ( for MCL  and MZL  FDG -PET/CT, i s preferred ). 
The same method of assessment (CT, MRI, FDG -PET/CT) and the same technique should be used, whenever possible, to characterize each identified and reported lesion at 
Screening and while on study. Evaluations may be performe d within the [ADDRESS_664111] performed 
> 8 weeks before the E nd of Treatment  visit, then they should be performed as part of this visit. For patients ending treatment due to radiographic confirmation of  disease 
progression following cirmtuzumab + ibrutinib combined therapy, the E nd of Treatment  visit should occur ≤ [ADDRESS_664112] e, 
including samples for exploratory biomarkers, will only be obtained as needed to confirm a clinical/radi ologic complete response. As the data for exploratory biomarkers 
develops, additional samples may be requested to better analyze and confirm the resu lts of these tests. A blinded bone marrow sample may be sent for central 
review/confirmation.  
z. The End of Treatment  visit will be performed after permanent cessation of study therapy. The Safety Follow -Up visit will occur the later of either [ADDRESS_664113] dose 
of study treatment or until resolution/stabilization of any ongoing drug-related AEs and/or SAEs. AE/SAE follow-up may be obtained in person, by [CONTACT_756], or by e -mail 
contact.  
aa. Long -term follow -up information will be obtained for up to [ADDRESS_664114]-study cancer therapi[INVESTIGATOR_014] (including ibrutinib) will be collected. Once a patient has progressed and received a subsequent cancer therapy, only vital status  
will be collected.  Reports of imaging studies performed during long -term follow -up may be requested by [CONTACT_512954] .  
bb. For patients continuing beyond Week 52, the combination treatment will continue at the same dose and schedule as year 1. Assessments will continue to be perf ormed with 
visits and infusions every 4 weeks and scans and other additional assessments every 12 weeks , as indicated in the SOA . 
cc. Ibrutinib can be dispensed if documented intention is for patient to extend and scans are planned or pending.  
Abbreviations:  ALP=alkaline phosphatase, ALT=alanine aminotransferase, aPTT=activated partial thromboplastin time, AST=aspartate aminotransf erase , BUN=blood urea 
nitrogen, CLL/SLL=chronic lymphocytic leukemia/small lymphocytic lymphoma, CR=complete response, CT=computed tomography, DNA=deoxyribonucleic acid, 
ECG=electrocardiogram, ECOG=Eastern Cooperative Oncology Group, FDG=fluorodeoxyglucose, HBc  antibody=anti -hepatitis B core antibody, HBsAg=hepatitis B surface 
antigen, HBV=hepatitis B virus, HCV=hepatitis C virus, HIV=human immunodeficiency virus, LDH=lactate dehydrogenase, MCL=mantl e cell lymphoma, MRD=minimal 
residual disease, MRI=magnetic res onance imaging, MZL = Marginal Zone Lymphoma,  OS=overall survival, PD=progressive disease, PET=positron emission tomography, 
PT=partial thromboplastin time, RNA=ribonucleic acid, ROR1= receptor tyrosine kinase-like orphan receptor 1, SAE=serious adverse even t, SOA=schedule of activities, 
TLS=tumor lysis syndrome , Tx=treatment.  
  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol:  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 60 of 115  Version 7 (15 April  2022) 8.4. Schedule of Activities – Part 3 CLL/SLL (Cirmtuzumab + Ibrutinib versus Ibrutinib)  
Period  Screen  Treatment  End of 
Tx Follow -up 
Visit  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17+ 18+  Safety 
FU Long -
term  Week  -4 0 2 4 8 12 16 20 24 28 32 36 40 44 48 52 56+ 60+ 104 
Study Day  Within  
28 Days  0 14 28 56 84 112 140 168 196 224 252 280 308 336 364 Q 4  
weeks  
[z] Q 12 
weeks  
[z] 728 
[z] Within 
+30 days  To ≤5 
years  
Visit Window, days    ±2 ±2 ±2 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +7  
General Eligibility/Safety Assessments                       
Written informed consent [b]  X                     
Height [c]  X                     
Weight/Vital signs [d]  X X X X X X X X X X X X X X X X X X X X  
Performance status [e]  X X X X X X X X X X X X X X X X X X X X  
Medical history [f]  X                     
Adverse Event (AE) assessment [g]   X X X X X X X X X X X X X X X X X X X  
Concomitant medications [h]  X X X X X X X X X X X X X X X X X X X   
12-lead ECG [i]  X                  X   
Drug Administration/Dispensing/Return                       
TLS prophylaxis [j]   X                    
Ibrutinib administration in the clinic [ k]  X                    
Cirmtuzumab administration (Arm A) [ l]  X X X X X X X X X X X X X X X X X    
Dispensing of ibrutinib [m]   X  X X X X X X X X X X X Xaa X X X    
Ibrutinib compliance check [m]     X X X X X X X X X X X X X X X X   
Laboratory Assessments                       
Serum virology [ n] X                     
Serum chemistry [ o] X X(a) X X X X X X X X X X X X X X X X X X  
Hematology [ p] X X(a) X X X X X X X X X X X X X X X X X X  
Urinalysis [ q] X X(a) X X  X   X   X   X   X X X  
Coagulation [ r] X X(a)    X   X   X   X   X X X  
Serum or urine pregnancy test [ s] X X(a)    X   X   X   X   X    
Serum for cirmtuzumab -reactive antibodies 
and cytokines , and blood for exploratory 
biomarkers [t]  X          X   X   X X X  
Disease Assessments                       
Rai stage [ u] X                     
Radiology examination [ v] X     X   X   X   X   X XV   
Bone marrow biopsy/aspi[INVESTIGATOR_337] [ w]  X    ------------  If required to document complete response -------     
Posttherapy Follow -up                      
Posttherapy safety assessment [ x]                    X  
Long -term follow -up [y]                     X 
 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 61 of 115  Version 7 ( 15 April  2022 ) Footnotes  – Part 3  
Note:   For procedures to be performed at a specified time postdose, the acceptable margin for actual time is the specified time ±15 minutes. If multiple procedures are to be 
done at the same time point, the preferred order is vital signs, blood sampling, and then ECG, with blood sampling occurring as close as possible to the specified time.  
a. If obtained within 7 days prior to the start of therapy, urinalysis and serum pregnanc y, serum chemistry, hematology, and coagulation studies collected during Screening 
need not be repeated on Day 0.  
b. Written informed consent will be obtained before any study procedures are performed that are not part of routine medical care . 
c. Height will be measured once during Screening.  
d. Weight (in kilograms) and vital signs (blood pressure, pulse, temperature) will be assessed at Screening and on each subseque nt study day prior to cirmtuzumab treatment , 
and at any time if no infusion that day.  
e. Performance status will be assessed using ECOG scale (see Appendix 12.1) once on each designated day . 
f. Medical history to include recording of cancer history, previous therapy for cancer, clinically significant past and ongoing medical conditions, review of systems, a nd 
relevant social history and will be obtained at Screening only.  
g. Description of all AEs using concise medical terminology, inclu ding whether the AE is serious, the date of onset, the date of resolution, the severity based on the CTCAE, 
Version 4.03, a description of the potential relatedness to study drug or to a study procedure, the action taken, and the out come (see Section 8.6). 
h. Concomitant medication assessments should include information regarding all prescription, nonprescription, illicit, and alter native medications.  
i. 12-lead ECGs will be obtained with the patient resting in a supi[INVESTIGATOR_2547]. ECGs will be collected at Screening and at End of Treatment  visits.  If ECG abnormalities such 
as QT prolongation are observed compared to baseline following study treatment, the test result should be confirmed and ECG re peated at the Safety Follow -up visit (post 
the End of Treatment visit ). 
j. Based on the risk of TLS (low, intermediate, or high), patient s at intermediate or high risk should be considered for TLS prophylaxis (see Section 6.4.2 ).  
k. The first dose of ibrutinib will be administered to the patient  in the study center ~30 minutes prior to the start of the cirmtuzumab infusion (with recording of the date and 
actual clock time of the ibrutinib administration).  
l. Cirmtuzumab will be infused as indicated in Section 6.1.[ADDRESS_664115] any cirmtuzumab 
infusion reaction as an adverse event(s) in the eCRF, and record any s upportive care provided. If infusion prophylaxis is required for subsequent infusions, see Section 6.4.[ADDRESS_664116] may be falsely positive.  
o. Serum chemistry to include sodium, potassium, chloride, bicarbonate, BUN, creatinine, glucose, calcium, phosphorus, magnesium  (screening only) , total protein, albumin, 
ALT, AST, ALP, LDH  (screening only) , and total bilirubin.  
p. Hematology to include hematocrit, hemoglobin, erythrocyte count; absolute counts of leukocytes, neutrophils, lymphocytes, mon ocytes, eosinophils, basophils; platelet 
count.  
q. Urinalysis to include specific gravity, pH, protein, glucose, ketones, bilirubin, urobilinogen, blood, nitrite, leukocyte est erase as assessed by [CONTACT_5230], and microscopic 
urinalysis evaluating white blood cells, red blood cells, epi[INVESTIGATOR_1663], bacteria , cast and crystals.  
r. Coagulation studies to include PT and aPTT.  
s. Serum or urine pregnancy testing will be performed in women of childbearing potential only. See Section 8.6.6  for reporting requirements in the event of a pregnancy.  
t. Serum for cirmtuzumab -reactive antibodies  and cytokines , and blood for exploratory biomarkers  will be collected on the indicated days prior to the cirmtuzumab infusion.  
Tumor samples (unstained slides, tissue/cells or blocks) obtained pre -treatment or post -treatment, if available, may be requested for biomarker testing.  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 62 of 115  Version 7 ( 15 April  2022 ) u. For patient s with CLL/SLL,  Rai stage will be calculated (see Appendix  12.4).  
v. Radiology examination to include contrast -enhanced CT (preferred) or MRI imaging of neck, chest, abdomen, and pelvis (and may include FDG -PET/CT, if relevant). The 
same method of assessment (CT, MRI, FDG -PET/CT) and the same technique should be used, whene ver possible, to characterize each identified and reported lesion at 
Screening and while on study. Evaluations may be performed within the [ADDRESS_664117] performed 
> 8 weeks before the E nd of Treatment  visit, th en they should be performed as part of this visit. For patients ending treatment due to radiographic confirmation of disease 
progression following cirmtuzumab + ibrutinib combined therapy, the E nd of Treatment  visit should occur ≤ 4 weeks after the document ation of progression and the imaging 
studies do not need to be performed.  
w. A bone marrow  aspi[INVESTIGATOR_337],  biopsy and peripheral blood sample should be obtained prior to Day 0 and before the cirmtuzumab infusion for exploratory biom arkers, with a 
biopsy for disease assessment if no biopsy results are available in the preceding 45 days. Subsequent bone marrow as pi[INVESTIGATOR_512922], 
including samples for exploratory biomarkers, will only be obtained as needed to confirm a clinical/radiologic complete respo nse. A blinded bone marrow sample may be 
sent for central review/confirmation.  
x. The End of Treatment  visit will be performed after permanent cessation of study therapy. The Safety Follow -up visit will occur  either [ADDRESS_664118] dose of study 
treatment or upon  resolution/stabilization of any ongoing drug-related AEs and/or SAE s, whichever occurs later . AE/SAE follow -up may be obtained in person, by 
[CONTACT_756], or by e -mail contact.  
y. Long -term follow -up information will be obtained for up to [ADDRESS_664119]-study cancer therapi[INVESTIGATOR_014]  (including ibrutinib)  will be collected. Once a patient has progressed and 
received a subsequent cancer therapy, only vital status will be collected .  Reports of imaging studies performed during long-term follow -up may be requested by [CONTACT_512955].   
z. For CLL/SLL patients continuing beyond Week 52, they will continue with the assigned  treatment at the same dose and the same assessments will be performed with visits 
and infusions every 4 weeks  and scans and other additional assessments every 12 weeks . 
aa. Ibrutinib can be dispensed if documented intention is for patient to extend and scans are planned or pending.  
Abbreviations:  AE=adverse event, ALP=alkaline phosphatase, ALT=alanine aminotransferase, aPTT=activated partial thromboplastin time, AST=asp artate aminotransferase, 
BUN=blood urea nitrogen, CLL/SLL=chronic lymphocytic leukemia/small lymphocytic lymphoma, CT= computed tomography, DNA=deoxyribonucleic acid, 
ECG=electrocardiogram, ECOG=Eastern Cooperative Oncology Group, FDG=fluorodeoxyglucose, HBc antibody=anti -hepatitis B core antibody, HBsAg=hepatitis B surface 
antigen, HBV=hepatitis B virus, HCV=hepatitis C v irus, HIV=human immunodeficiency virus, LDH=lactate dehydrogenase, MCL=mantle cell lymphoma, MRD=minimal 
residual disease, MRI=magnetic resonance imaging, OS=overall survival, PD=progressive disease, PET=positron emission tomography, PT=partial thromboplas tin time, 
RNA=ribonucleic acid, SAE=serious adverse event, TLS=tumor lysis syndrome  
 
 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 63 of 115  Version 7 ( 15 April  2022 ) 8.5. Efficacy Assessments 
8.5.1. Overview  
Tumor response and progression will be assessed using standard criteria appropriate for each 
hematological malignancy. During the course of the study, investigators will periodically determine general disease status based on radiographic and laboratory eva luations (supplemented 
by [CONTACT_5292], as appropriate). Treatment decisions by [CONTACT_512956], in part, on these assessments. The investigator assessment of tumor control endpoints will be used  for the primary analyse s in all Parts of the study.  
8.5.2. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma  
[IP_ADDRESS]. Tumor Assessment Criteria  
The determination of CLL/SLL response and progression will be based on standardized criteria iwCLL [ Hallek 2008], as recently updated [ Hallek 2018;  Cheson 2012]. A d etailed description of 
response assessment for this study is presented in Appendix 12.5. 
[IP_ADDRESS]. Method of Assessment  
Imaging -based evaluation will be used in this study in all patient s enrolled. CT scan is the 
preferred method for radiographic tumor assessment. MRI scanning may be used at the 
investigator’s discretion in patient s for whom this may be a preferred alternat ive to CT scanning; 
however, if MRI is performed, a non- contrast CT of the chest should be performed. Contrast -
enhanced scanning is preferred, but iodine -containing or gadolinium contrast material may be 
omitted in patient s for whom use of a contrast agent  would be medically contraindicated. Chest 
x-ray, ultrasound, endoscopy, laparoscopy, PET, radionuclide scans, or tumor markers will not 
be considered for response assessment.  
For radiographic evaluations, the same method of assessment and the same technique (eg, scan type, scanner, patient  position, dose of contrast, injection/scan interval) should be used, 
whenever possible, to characterize each identified and reported lesion at screening and during study treatment and follow -up. However, if a patient  is imaged without contrast at screening, 
subsequent assessments should be performed with contrast, unless the patient  cannot tolerate the 
contrast.  
All relevant radiographic and clinical information required to make each tumor status assessment 
must be made available for source verification a nd review . 
[IP_ADDRESS]. Timing of Assessments  
During screening, imaging- based and laboratory assessments should be performed within the 
specified screening period. On- study tumor assessments should be scheduled as indicated in 
Section  8. For patients having an E nd of Treatment  visit and evaluations, if radiology imaging 
studies were last performed > 8 weeks before the E nd of Treatment  visit, then they should be 
performed as part of this visit. For patients ending treatment due to radiographic confirmation of disease progression following cirmtuzumab + ibrutinib combined therapy, the E nd of Treatment  
visit should occur ≤4 weeks after the documentat ion of progression and the imaging studies do 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 64 of 115  Version 7 ( 15 April  2022 ) not need to be performed. If a patient  permanently discontinues study drug prior to objective 
documentation of CLL/SLL progression, investigators should attempt to obtain further follow -up 
at ~12 -week intervals  until CLL/SLL progression is documented or until the initiation of a new 
post-study therapy for the patient ’s CLL/SLL.  
8.5.3. Lymphoma  
[IP_ADDRESS]. Tumor Assessment Criteria  
The determination of response and progression for MCL  and MZL  will be based on standardized 
criteria  [Cheson 2007] as recently updated [ Cheson 2014]. A detailed description of response 
assessment for this study is presented in Appendix 12.6. 
[IP_ADDRESS]. Method of Assessment  
Imaging -based evaluation will be us ed in this study as the primary basis of lymphoma 
assessment. Preferred methods for radiographic tumor assessment are diagnostic CT (with 
contrast enhancement) or PET/CT. If CT is performed, contrast -enhanced scanning is preferred, 
but contrast material ma y be omitted in patient s for whom use of a contrast agent becomes 
medically contraindicated or if the CT is obtained in conjunction with PET scanning. If available, PET scan data will be considered in response and progression assessment; however, PET scann ing will not be a required component of assessment in this study. As required by [CONTACT_512957], bone marrow aspi[INVESTIGATOR_337]/biopsy (eg, for confirmation of CR) or cytological/histological evaluation of lymph nodes, effusions, ascites, or other organ abnormalities) will be also be considered. Clinical palpation, chest x- ray, ultrasound, endoscopy, 
laparoscopy, radionuclide scan, or tumor markers will not be considered for response assessment. MRI scanning is not advised but may be used at t he investigator’s discretion in 
patient s for whom this becomes a necessary alternative to CT scanning.  
For radiographic assessments, the same method of assessment and the same technique (eg, scan type, scanner, patient  position, dose of contrast, injection/scan interval) should be used, 
whenever possible, to characterize each identified and reported lesion at screening and during study treatment and follow -up. CT of the neck, chest, abdomen, and pelvis should be performed 
with cuts of ≤ 0.[ADDRESS_664120] be made available for source verification  and review.   
[IP_ADDRESS]. Timing of Assessments  
During screening, imaging- based and laboratory assessments should be performed within the 
specified screening period. On- study tumor assessments should be scheduled as indicated in 
Section 8. For patients having an E nd of Treatment  visit and evaluations, if radiology imaging 
studies were last performed > 8 weeks before the E nd of Treatment  visit, then they should be 
performed as part of this visit. For patients ending treatment due to radiographic confirmation of disease progression following cirmtuzumab + ibrutinib combined therapy, the E nd of Treatment  
visit should occur ≤4 weeks after the documentation of progression and the imaging studies do not need to be performed. If a patient  permanently discontinues treatment prior to objec tive 
documentation of lymphoma progression, investigators should continue further follow -up of 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 65 of 115  Version 7 ( 15 April  2022 ) tumor status with assessments at ~[ADDRESS_664121] -study therapy for the patient ’s lymphoma. 
8.6. Safety Assessments  
8.6.1. Definitions  
[IP_ADDRESS]. Adverse Event  
An AE can be any unfavorable and unintended sign or symptom, or disease temporally 
associated with the use of a study drug, whether or not related to the study drug. An AE can  
therefore be any unfavor able and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.  
In this study, any of the following events will be considered an AE:  
• Any preexisting condition that increases in severity or changes in nature during or as a consequence of study drug administration. Worsening manifestations of the underlying cancer (eg, increase in pain, tumor flare reaction, TLS) may be considered AEs in this study but should be reported as disease progression.  
• Any injury or accident. If a medical condition is known to have caused the injury or accident (eg, a fall secondary to dizziness), the medical condition (dizziness) and the accident (fall) should be reported as 2 separate AEs.  
• Any abnormality in physiological testing or a physical examination finding that 
requires clinical intervention or further investigation (beyond ordering a repeat 
[confirmatory] test).  
• Any laboratory (eg, clinical chemistry, hematology, urinalysis) or investigational 
abnormality (eg, ECG, X -ray) independent of the underlying medical condition that 
requires clinical intervention, results in further investigation (beyond ordering a 
repeat [confirmatory] test), or leads to investigational medicinal product interruption 
or discontinuation unless it is associated with an already reported clinical event. If the 
laboratory abnormality is part of a syndrome, the syndrome or diagnosis (eg, anemia)  
not the laboratory result (eg, decreased hemoglobin) should be recorded.  
• A complication related to pregnancy or termination of a pregnancy (see Section  8.6.6 
for additional information). 
• However, none of the following events is considered an AE:  
• Asymptomatic lymphocytosis  
• Cancer progression without worsening disease manifestations. In cases of SAEs, cancer progression may be reported if there is no alternative term that can be satisfactorily substituted. In such cases, the AE description should match the SAE description. 
• Laboratory abnormalities not requiring clinical intervention or further investigation. Such abnormalities will be captured as part  of laboratory monitoring. 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol:  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 66 of 115  Version 7 (15 April  2022) • A diagnostic, medical or surgical procedure (eg, surgery, endoscopy, tooth extraction, 
transfusion). However, the medical condition for which the procedure was performed should be reported if it meets the definition of an AE. For example, an acute 
appendicitis that begins during the AE reporting period should be reported as the AE and the resulting appendectomy should be recorded in the source documents.  
• A preexisting disease or condition or laboratory abnormality present or dete cted 
before the initial s creening visit and that does not worsen. 
• An intervention not associated with an untoward medical occurrence (eg, hospi[INVESTIGATOR_283633]/or convenience reasons). 
• An overdose without clinical sequelae. 
[IP_ADDRESS]. Serious Adverse Event  
An SAE is defined as an untoward medical occurrence that results in any of the following outcomes: 
• Death  (ie, all deaths occurring from the time of  the first drug administration  to within 
[ADDRESS_664122] study drug administration), including deaths due to cancer progression if no other event more satisfactorily explains the reason for death. Deaths that occur as a result of an AE that started during the study period should be reported. Death is not an SAE term; the reported AE should be the event that caused the death. Death is the outcome of this SAE. 
• L
ife -threatening situation  (ie, with an immediate risk of death from the event as it 
occurred but not including an event that, had it occurred in a more serious form, might have caused death). 
• In-pa
tient hospi[INVESTIGATOR_1081]. Of note, an 
untoward medical occurrence that occurs during hospi[INVESTIGATOR_493277] a complication that prolongs hospi[INVESTIGATOR_61375]. In patient  hospi[INVESTIGATOR_512923] a hospi[INVESTIGATOR_113979], for any length of time, whether or not hospi[INVESTIGATOR_283636]. However, hospi[INVESTIGATOR_512924], diagnostic observations or procedures, logistical issues (eg, lengthy travel), or the convenience of the patient or clinical personnel are not considered serious.  
• P
ersistent or significant disability/incapacity . 
• Congenital anomaly/birth defect in the offspring of a patient  who received the 
investigational medicinal product. 
• O ther medically significant event. Such events may not be immediately life-
threatening or result in death or hospi[INVESTIGATOR_059], but based upon appropriate medical and scientific judgment, may jeopardize the patient or may require medical or surgical intervention to prevent one of the outcomes listed above. Examples of such events might include: 
o Allergic bronchospasm requiring intensive treatment in an emergency room or at home 
o New cancers or blood dyscrasias 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 67 of 115  Version 7 ( 15 April  2022 ) o Convulsions that do not result in hospi[INVESTIGATOR_059]  
o Development of drug dependency or drug abuse  
[IP_ADDRESS]. Unexpected Adverse Event  
An unexpected AE is defined as an event that has a nature, severity, or specificity that is not 
consistent with the applicable investigator brochure, or that is symptomatically and 
pathophysiologically related to a known toxicity but differs because of greater severity or 
specificity. For example, under this definition, hepatic necrosis would be unexpected (by [CONTACT_36092]) if the investigator brochure only referred to elevated hepatic enzymes or hepatitis. Similarly, cerebral thromboembolism and cerebral vasculitis would be unexpected (by [CONTACT_14214]) if the investigator brochure only listed cerebral vascular accidents. “Unexpected,” as used in this definition, refers to an adverse drug experience that has not been previously observed and reported rather than an experience that has not been anticipated based on the pharmacological properties of the study drug. 
[IP_ADDRESS]. Treatment -Emergent Adverse Event  
A TEAE is defined as an AE that occurs or worsens in the period from the first dose of study 
drug administration to 30 days after the final dos e of study drug administration. 
[IP_ADDRESS]. Adverse Events of Special Interest  
The AEs of special interest in this protocol will be: 
• Grade ≥3 infusion reactions  
• TLS 
• Major hemorrhage (defined as any of hemorrhagic TEAEs of Grade ≥3, treatment -
emergent hemorrhagic SAEs of any grade, or treatment -emergent central nervous 
system hemorrhage of any grade).  
• Covid- 19 infection (in addition, if the patient withdraws due to fear of contracting 
Covid- 19 at the treatment site, due to travel, or other causes associated with trial, 
please note this as a reason for discontinuation.)  
In addition to description in listings and tables, these types of events will be characterized in narratives.  
8.6.2. Grading of the Severity of an Adverse Event  
The severity of AEs will be graded using the CTCAE, Version 4.03 [ NCI 2010]. For each 
epi[INVESTIGATOR_1865], the highest severity grade attained should be reported.  
If a CTCAE criterion does not exist, the investigator should use the grade or adjectives: Grade  1 
(mild), Grade  2 (moderate), Gr ade 3 (severe), Grade  4 (life -threatening), or Grade  5 (fatal) to 
describe the maximum intensity of the AE. For purposes of consistency with the CTCAE, these intensity grades are defined in Table 2.  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 68 of 115  Version 7 ( 15 April  2022 ) Table 2: Grading of Adverse Event Severity  
Grade  Adjective  Description  
Grade  [ADDRESS_664123] on the patient’s overall health and 
well- being, does not interfere with the patient’s usual function, and is 
not likely to require medical atten tion. 
Grade  2 Moderate  Sign or symptom causes interference with usual activity or affects 
clinical status, and may require medical intervention.  
Grade  3 Severe  Sign or symptom is incapacitating or significantly affects clinical status 
and likely requires medical intervention and/or close follow -up. 
Grade  4 Life-threatening  Sign or symptom results in a potential threat to life.  
Grade  5 Fatal  Sign or symptom results in death.  
The distinction between the seriousness and the severity of an AE shoul d be noted. Severe is a 
measure of intensity; thus, a severe reaction is not necessarily a serious reaction. For example, a 
headache may be severe in intensity, but would not be classified as serious unless it met one of the criteria for serious events (as  listed in Section  [IP_ADDRESS]).  
8.6.3. Describing Adverse Event Relationship to Study Drug  
The investigator will evaluate the causal relationship of each AE to a study drug and record that 
relationship on the appropriate CRFs. Causality will be assessed considering whether the AE is reasonably related to the study drug or whether the AE is not r easonably related to the study drug 
considering the definitions in Table 3. 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol:  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 69 of 115  Version 7 (15 April  2022) Table  3: Relationship of Study Drug to Adverse Event  
Relationship  Description  
Definite  A clinical event in which a relationship to the use of the study drug seems definite because 
of such factors as consistency with known effects of the drug; a clear temporal association 
with the use of the drug; lack of alternative explanations for the event; improvement upon 
withdrawal of the drug (de -challenge); and recurrence upon resumption of the drug 
(rechallenge).  
Probable  A clinical event in which a relationship to the study drug seems probable because of such 
factors as consistency with known effe cts of the drug; a reasonable temporal association 
with the use of the drug; lack of alternative explanations for the event; and improvement 
upon withdrawal of the drug (de -challenge).  
Possible  A clinical event with a reasonable temporal association with administration of the study 
drug, and that is not likely to be explained by [CONTACT_113395]. Information on drug withdrawal may be lacking.  
Unlikely  A clinical event with a temporal relationship to study drug administration that makes a 
causal relationship improbable and for which other factors suggesting an alternative etiology 
exist. Such factors might include a known relationship of the clinical event to a concomitant drug, past medical history of a similar event, the patient ’s disease state, intercurrent illness, 
or environmental factors.  
Unrelated  A clinical event in which a relationship to the study drug seems improbable because of 
factors such as inconsistency with known effects of the study drug; lack of a temporal association with study drug administration; lack of association of the event with study drug withdrawal or rechallenge; and/or presence of alternative explanations for the event. Alternative explanations might include a known relationship of the clinical event to a concomitant drug, past medical history of a similar event, the patient’s  disease state, 
intercurrent illness, or environmental factors.  
8.6.4. Adverse Event Reporting Period  
The start of the AE reporting for a study patient  will coincide with study day  0, upon the start of 
dosing. After the first administration of study drug, all AEs (serious and nonserious, related and 
unrelated) should be reported. Unless a patient  withdraws consent for follow-up, each patient  
must be followed until the end of the AE reporting period at 30 days after the final cirmtuzumab administration or when any ongoing drug-related AEs and/or SAEs have resolved or become stable. The investigator should use appropriate judgment in ordering additional tests as necessary to monitor the resolution of events. The medical monitor or Oncternal may request that certain AEs be followed longer.  
Investigators are not obligated to actively seek information regarding the occurrence of new 
SAEs beginning after the 30-day post-cirmtuzumab period. However, if the investigator learns of such an SAE and that event is deemed relevant to the use of cirmtuzumab, he/she should promptly document and report the event. A longer reporting period applies in the case of pregnancy (see Section  8.6.6).  
8.6.5. Adverse Event Reporting Requirements  
Whether completing a paper SAE form or entering the SAE through the EDC system, SAEs must be reported to the sponsor or designee within [ADDRESS_664124] also submit written safety reports as req uired by [CONTACT_512958]. The study site should retain documentation of the submission of expedited safety reports to the IRB, and their receipt.  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol:  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 70 of 115  Version 7 (15 April  2022) The following minimum information is required when reporting the SAE to the sponsor or 
designee:  
• Patient  identification (ie, patient  number, sex, age) 
• Description of the SAE (diagnosis preferred, symptoms, etc. ) 
• Study drug and causal relationship of the SAE to the study drugs 
• Investigator name 
[CONTACT_512992]-up forms must be kept on file at the study site. An SAE is 
followed until it is considered resolved, it returns to baseline, is chronically ongoing, or 
explained otherwise by [CONTACT_458].  
Contact [CONTACT_512959] (or designee) is provided in Table 4. 
Table  4: Contact [CONTACT_512960]  E-mail: [EMAIL_9746]  
8.6.6. Pregnancy and Reporting  
Each female patient  should be instructed to inform the investigator immediately if she becomes 
pregnant at any time between the start of study screening until [ADDRESS_664125] 
administration of study drug.  
The investigator should counsel t he patient  regarding the possible effects of study drug exposure 
on the fetus and the need to inform the study center, the medical monitor, and Oncternal (or 
designee) of the outcome of the pregnancy. 
Neither the pregnancy itself nor an induced elective abortion to terminate the pregnancy without 
medical reasons is considered an AE; such occurrences should be reported on the appropriate pregnancy report forms. However, if the outcome of the pregnancy meets the criteria for classification as an SAE (ie, spon taneous abortion, induced abortion due to complications, 
stillbirth, neonatal death, or congenital anomaly [including that in an aborted fetus]), the investigator should follow the procedures for reporting SAEs (ie, report the event to Oncternal [or designee] and follow up by [CONTACT_493322] (see Section  8.6.5).  
Information regarding any pregnancy in a study patient  or the female partner of a male patient  
must be documented on a pregnancy report form and forwarded to Oncternal (or designee) within 24 hours of becoming aware of the pregnancy. Monitoring of the pregnancy in both female study patients and female partners of male stu dy patient s should continue until the 
conclusion of the pregnancy. For female partners of male study patient s, such monitoring applies 
if they  became pregnant in the period from the patient ’s start of study drug until 30 days after the 
patient ’s last dose of study drug. The outcome of the pregnancy should be reported on the 
pregnancy outcome report form within 5 days of the conclusion of the pregnancy. If the end of the pregnancy occurs after the study has been completed, the outcome should be reported to Oncternal (or designee). 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 71 of 115  Version 7 ( 15 April  2022 ) Contact [CONTACT_102084] a  pregnancy to Oncternal (or designee) is provided in Table 4.  
8.6.7. Sponsor Reporting Requirements  
Each SAE or special situation report received from the investigator will be evaluated by 
[CONTACT_512949] (or designee). Oncternal (or designee) will assess the seriousness of the event the expectedness of the event, and the relationship to participation in the s tudy. Oncternal (or 
designee) will also indicate whether there is concurrence with the details of the report provided 
by [CONTACT_093].  
Oncternal (or designee) will provide information for reporting of suspected, unexpected, serious 
adverse reactions ( S[LOCATION_003]Rs) to the FDA per US FDA CFR. S[LOCATION_003]RS will be reported to within 
[ADDRESS_664126] notification of the event from the reporting investigator to Oncternal (or designee), which represents the start of the regulatory clock (Day 0). .  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 72 of 115  Version 7 ( 15 April  2022 ) 9. STATISTICAL CONSIDERATIONS  
9.1. Analysis Plan  
Details of the statistical analyses will be fully described in a statistical analysis plan to be 
finalized prior to the analyses.  
9.1.1. Pharmacokinetics  
Pharmacokinetic parameters will be calculated using non -compartmental methods. Only serum 
concentrations greater than or equal to the validated lower limit of quantitation (LLQ) will be used in the pharmacokinetic analyses. Per -protoc ol times will be used to calculate mean serum 
concentrations for graphical displays. Actual blood sampling times will be used in all pharmacokinetic analyses.  
9.1.2. Pharmacodynamics  
For each pharmacodynamic variable, the value at each assessment will be describ ed. Changes 
from baseline to each assessment and the most extreme changes from baseline during the study will be summarized using tabular and graphical methods. The data may also be described by [CONTACT_283678], age, weight, body- mass index, and disease type (CLL/SLL , MCL  
or MZL ). 
As appropriate, changes in the pharmacodynamic parameters will be assessed using paired t -tests 
or analysis of covariance (ANCOVA) with baseline values as covariates; in these analyses, both changes from baseline to  each subsequent time point and most extreme on study changes will be 
evaluated.  
9.1.3. Efficacy Analyses  
Tumor control will be documented at each assessment by [CONTACT_115188] (eg, CR, PR, PR -L, 
SD, PD, or NE), as defined for each response parameter, the SPDs , percentage change in the 
SPDs from the pre -cirmtuzumab and pre -ibrutinib baselines (Part 1), or pretreatment baseline 
(Parts 2 and 3); percentage change in the SPDs from the nadir, date that response is first documented, date that response is confirmed, and date of tumor progression. Evaluable patients for efficacy are those who have completed treatment and have had the planned [ADDRESS_664127] cirmtuzumab + ibrutinib combination therapy imaging studies or had documented or clinical PD following 28 days of therapy. These analyses will be further described in the Statistical Analysis Plan.  
9.1.4. Other Analyses  
Using appropriate regression techniques, possible relationships between patient  characteristics 
(eg, sex, race, age, weight, tumor characteristics, dose) and outcome measures (eg, pharmacodynamic and pharmacokinetic parameters) may be assessed. Similarly, 
associations between outcome measures (eg, relationships between pharmacokinetic and pharmacodynamic parameters) may be evaluated.  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 73 of 115  Version 7 ( 15 April  2022 ) 9.2. Timing of Analyses  
9.2.1. Interim A nalyses  
During Parts 1 and 2, conference calls among the members of the SRC will be conducted 
periodically to discuss study progress, exchange study information, and review safety events, determine whether additional dose levels should be evaluated, and di scuss potential amendments 
to the protocol. It is expected that these discussions will be scheduled at intervals of ~ [ADDRESS_664128] of the study. 
During Part 2 of the study, interim futility analyses are planned that will evaluate whe ther there 
is sufficient antitumor activity to warrant further development of the cirmtuzumab  + ibrutinib  
combination in the selected disease types (CLL/SLL and MCL). The interim analysis will be 
performed when: ≥9 evaluable patient s with either  disease ty pe from Part 1 and Part 2 of the 
study (eg, ≥6 from Part 1 and ≥3 from Part 2) have: a) received treatment using a dose of cirmtuzumab that is at or below  the RDR for the combination, and, b) have ≥24 weeks of 
evaluable efficacy data on combination treatme nt.  
In patients with CLL/SLL, the target CR rate of interest with cirmtuzumab  + ibrutinib is an 
increment of ≥25% over that expected with ibrutinib alone. Thus, for CLL/SLL a CR rate of ≥30% is targeted with the combination based on knowledge of an antici pated CR rate of ≤5% 
with ibrutinib monotherapy [ By[CONTACT_26752]  2013; By[CONTACT_26752]  2014; Farooqui 2015; Burger  2015, 
O’Brien  2016].  Futility will be tested using a [ADDRESS_664129] binomial CI upper bound of 90% 
considering all evaluable patient s meeting the criteria (a and b) described above. Assuming the 
minimum futility sample for CLL /SLL, if 0/9 evaluable patient s experience a CR, then a 
population CR rate of ≥30% can be ruled out with >90% certainty (1- sided exact binomial 90% 
CI upper bound=22.5%). The interim analysis of this study presented at ASCO 2020 showed that the CLL/SLL data did not  satisfy the hypothesis that cirmtuzumab + ibrutinib would produce a 
CR rate 25% greater than that for ibrutinib alone [ Lee 2020] . Therefore, the number of patients 
to be enrolled and randomized into Part 3 was  reduced to inc lude approximately 30 patients. 
For MCL, a CR rate of  ≥50% is targeted with the combination based on knowledge of an 
anticipated CR rate of ≤ 23 to 27% with ibrutinib monotherapy [ Wang  2013; Dreyli ng 2016, 
Maruyama 2016; Wang  2015, Rule 2019]. Pooled analyses of large single agent ibrutinib studies 
in MCL indicate an overall CR rate of 27% with a 23% CR rate in those previously receiving 2 or more prior treatments [Rule 2019] . The interim analysis of this study presented at ASCO 2020 
[Lee 2020]  indicates that a complete response rate of 58% was achieved in heavily pre -treated 
patients with MCL.  Because of the promising clinical results from this interim analysis, the 
sample size of the MCL expansion study was  increased.  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 74 of 115  Version 7 ( 15 April  2022 ) 9.2.2. Final Analyses  
[IP_ADDRESS]. Part 1  (Cirmtuzumab → Cirmtuzumab + Ibrutinib) and 
Part  2 (Cirmtuzumab  + Ibrutinib))  
Parts [ADDRESS_664130] been followed for ≥ 30 days  thereafter.  
[IP_ADDRESS]. Part 3 (Cirmtuzuma b + Ibrutinib versus Ibrutinib)  
Final study reporting for Part [ADDRESS_664131] 
discontinued study treatment or ≥72 weeks after accrual of the final patient  (whichever occurs 
earlier).  
9.3. Basis for the Planned Sample Sizes  
9.3.1. Part 1 (Cirmtuzumab → Cirmtuzumab + Ibrutinib) and 
Part  2 (Cirmtuzumab  + Ibrutinib)  
Sample sizes for Part 1 and Part 2 of the study are not based on formal statistical hypotheses but on experience from similar types of Phase 1b dose -ranging studies  and Phase  2 expansion 
cohorts of patients treated with the same regimen.  
9.3.2. Part 3 (Cirmtuzumab + Ibrutinib versus Ib rutinib)  
In patients with CLL/SLL receiving ibrutinib, rates of CR have been ≤5% [ By[CONTACT_26752]  2013; 
By[CONTACT_26752]  2014; Farooqui 2015; Burger  2015, O’Brien  2016]. Based on these data, it is assumed that 
in Part  3 of this trial, the CR rate in patient s with CLL/SLL receiving ibrutinib monotherapy will 
be ≤5%. A ≥25% absolute improvement in CR rate (to ≥30%) is targeted for patie nts with 
CLL/SLL treated with cirmtuzumab  + ibrutinib , with testing of this hypothesis using Fisher’s 
exact test with a 1 -sided significance level of ≤0.05. 
The interim analysis performed for ASCO 2020 showed that the CLL /SLL data did not satisfy 
the hypot hesis that cirmtuzumab + ibrutinib would produce a CR rate 25% greater than that for 
ibrutinib alone  [Lee 2020 ]. Therefore , the number of patients to be enrolled and randomized into 
Part 3 was  reduced to include approximately 30 patients.  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 75 of 115  Version 7 ( 15 April  2022 ) 10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  
10.1. Study Conduct  
Oncternal  will serve as  the regulatory sponsor for the study and will maintain the investigational  
new drug (IND) applications with the FDA. The current and future protocol  amendments  will be 
submitted to Oncternal’s  IND (IND# 133131) for cirmtuzumab and the trial design has been and 
will be subject to review by [CONTACT_1622].  
Onct ernal will serve as the operational coordinator  for all aspects  of the study and will oversee 
conduct of the study at participating study centers and through contract research organization 
(CROs). The CROs will perform activities relating to pharmacovigila nce, site monitoring, data 
collection, data management and study reporting, sample handling, centralized performance of pharmacokinetic and pharmacodynamic assays, and centralized assessments of drug efficacy  
(Part 3  only) . 
10.2. Study Committees  
During Parts 1, 2, and [ADDRESS_664132] will be performed 
by a safety review committee (SRC) comprising the investigators, the medical monitor, and the 
Oncternal study director. AEs and SAEs will be reviewed on an ongoing basis to identify any 
safety concerns. Conference calls among the members of the SRC will be conducted periodically to discuss study progress, exchange study information, and review safety events (in particular, SAEs and AEs leading to dose interruption, dose reduction, or therapy discontinuation), determine whether the dose range should be restricted or whether additional dose levels should be evaluated based on emerging safety data, and discuss potential amendments to the protocol.  
10.3. Protocol Compliance  
The investigator is re sponsible for ensuring the study is conducted in accordance with the 
procedures and evaluations described in this protocol. 
10.4. Institutional Review Board ( IRB) 
This protocol and any accompanying material to be provided to the patient  (such as 
advertisements, patient  information sheets, or descriptions of the study used to obtain informed 
consent) will be submitted by [CONTACT_124541] . Approval from the IRB must be 
obtained before starting the study and should be documented in a letter from the IRB  to the 
investigator specifying the protocol number, protocol version, protocol date, documents reviewed, and date on which the committee met and granted the approval.  
Any modifications or amendments made to the protocol or informed consent document after receipt of the initial IRB  approval  must also be submitted to the IRB  for approval before 
implementation. Only changes necessary to eliminate apparent immediate hazards to the patient s 
may be initiated prior to IRB  approval. In that event, the investigator m ust notify the IRB , the 
medical monitor, and Oncternal in writing within [ADDRESS_664133] increases the risk to the patient  or changes the scope of the 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 76 of 115  Version 7 ( 15 April  2022 ) study, then written documentation of IRB appr oval must be received by [CONTACT_512961].  
10.5. Informed Consent  
The investigator, or designee (designee must be listed on the Study Personnel 
Responsibility/Signature [CONTACT_94618]), must explain to each patient  the purpose and nature of t he study, 
the study procedures, the possible adverse effects, and all other elements of consent as defined in [ADDRESS_664134] remain in each patient ’s study file and be available for verification by 
[CONTACT_9534]. 
10.6. Confidentiality  
Every effort will be made to maintain the anonymity and confidentiality of all patient s during 
this clinical study. However, because of the experimental nature of this study drug, the investigator agrees to allow the IRB, representatives of Oncternal and i ts designated agents, and 
authorized employees of appropriate regulatory agencies to inspect the facilities used in this study and, for purposes of verification, allow direct access to the study center records of all patient s enrolled into this study. This  includes providing by [CONTACT_6791], email, or regular mail 
de-identified copi[INVESTIGATOR_493294], laboratory, ECG, radiology, pathology, and/or other test results 
when requested by [CONTACT_512949]. A statement to this effect will be included in the informed consent and a per mission form authorizing the use of protected health information will also be included. 
In accordance with local and national patient  privacy regulations, the investigator or designee 
must explain to each patient  that in order to evaluate study results, the patient ’s protected health 
information obtained during the study may be shared with IRBs, Oncternal and its designees, and 
regulatory agencies. It is the investigator’s or designee’s responsibility to obtain written permission to use protected health inf ormation from each patient . If a patient  withdraws 
permission to use protected health information, it is the investigator’s responsibility to obtain the withdrawal request in writing from the patient  and to ensure that no further data will be collected 
from the patient . Any data collected on the patient  before withdrawal will be used in the analysis 
of study results. Oncternal will only use or disclose the patient ’s protected health information as 
defined in the informed consent document. 
The investigator m ust assure that each patient ’s anonymity will be strictly maintained,  and that 
each patient ’s identity is protected from unauthorized parties. Only patient  initials, date of birth, 
and an identification code (but no patient  names) should be recorded on any form or biological 
sample submitted to the IRB , to Oncternal or its designees (eg, laboratories), or to regulatory 
authorities. However, sufficient information must be retained at the study center to permit 
sample data and data in the database to be connected with the unique patient  number assigned to 
each study participant.  
The investigator agrees that all information received from Oncternal, including but not limited to 
the study drug, the investigator brochure, this protocol, the eCRFs, and any other st udy 
information remain the sole and exclusive property of Oncternal during the conduct of the study and thereafter. This information is not to be disclosed to any third party (except employees or agents directly involved in the conduct of the study or as r equired by [CONTACT_2371]) without prior written 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 77 of 115  Version 7 ( 15 April  2022 ) consent from Oncternal. The investigator further agrees to take all reasonable precautions to 
prevent the disclosure by [CONTACT_145447]. 
10.7. Sample Shippi[INVESTIGATOR_007], Storage, and Retention  
Routine clinical safety samples (for serum virology, serum pregnancy test, serum chemistry, hematology, and coagulation) will be analyzed at the CLIA certified clinical laboratory at the study center and will not be shipped.  
Other samples (serum for pharmacokinetics, blood, bone marrow, and plasma for pharmacodynamics, serum for immunogenicity, and blood and bone marrow for disease characterization , exploratory biomarkers , and MRD assessment)  will be prepared following the 
instructions outlined in the clinical study laboratory manual.  
These samples will be shipped to Oncternal, UCSD or the contract analytical laboratories using a shippi[INVESTIGATOR_512925] O ncternal and as specified in the study laboratory manual. For the 
duration of the sample analysis campaign, samples will be stored at these contract laboratory facilities or sent for long -term storage at a storage facility designated by [CONTACT_512949].  
10.8. Study F iles and Retention of Records and Biological Samples  
The investigator must maintain adequate and accurate records to enable the conduct of the study to be fully documented and the study data to be subsequently verified by [CONTACT_1201], representatives 
of Oncter nal and its designated agents, and authorized employees of appropriate regulatory 
agencies. These documents should be classified into at least the following 2 categories: (1) investigator’s study file, and (2) patient  clinical source documents.  
The invest igator’s study file will contain the protocol/amendments, eCRF and query forms, the 
IRB and governmental approval with correspondence, signed informed consent documents, drug 
accountability records, staff curriculum vitae and authorization forms (eg, Form FDA 1572), and other appropriate documents and correspondence pertaining to the conduct of the study.  
The required source data referenced in the monitoring plan for the study should include 
sequential notes containing at least the following information for each patient:  
• Patient  identification (name, date of birth, gender)  
• Documentation that the patient  meets eligibility criteria, eg, history, physical 
examination, and confirmation of diagnosis (to support inclusion and exclusion criteria)  
• Participation in trial (including trial number)  
• Trial discussed and date of informed consent  
• Dates of all visits  
• Documentation that protocol -specific procedures were performed  
• Results of efficacy parameters, as required by [CONTACT_760]  
• Start and end date (including dose re gimen) of study drug (including relevant drug 
dispensing information)  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 78 of 115  Version 7 ( 15 April  2022 ) • Record of all AEs and other safety parameters (including start and end date, causality and 
intensity)  
• Concomitant medications (including start and end date and dose if relevant dose changes occur)  
• Date of trial completion and reason for discontinuation, if applicable  
All clinical study documents must be retained by [CONTACT_12415] [ADDRESS_664135] approval of a marketing application in an ICH region (ie, the United S tates, Europe, or 
Japan) and until there are no pending or contemplated marketing applications in an ICH region; or, if no application is filed or if the application is not approved for such indication, until [ADDRESS_664136] be 
obtained before changes can be implemented.  
10.10.  Case Report Forms  
Authorized study center personnel will submit all required information into a central electronic case report form (eCRF ) designed for this study and maintained by [CONTACT_512949]’s CRO, according 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 79 of 115  Version 7 ( 15 April  2022 ) to the completion guidelines that will be provided. A n eCRF is required and must be completed 
for each enrolled patient , with all required study data accurately recorded such that the 
information matches the data contained in medical records (eg, physicians’ notes, nurses’ notes, 
study center charts, or othe r study- specific source documents). The investigator will ensure that 
the eCRFs are accurate, complete, legible, and completed in a timely fashion after each patient ’s 
visit. If a patient  withdraws from the study, the reason must be noted on the eCRF and t horough 
efforts should be made to clearly document outcome.  
The eCRFs for this study will exist within a web -based electronic data capture (EDC) system.  
10.11.  Study Drug Accountability  
The disposition of all investigational cirmtuzumab and ibrutinib should be  documented from the 
time of receipt at the study center through patient  administration. An investigational drug 
accountability log must be maintained for drug accountability. It is acceptable to use a protocol -
specific form or a study center form that cap tures the relevant information. Within the drug 
accountability log, the responsible study center personnel must maintain accurate records of the 
receipt of all cirmtuzumab and ibrutinib shipped by [CONTACT_512949] (or its designee), including, but not limited to,  the date received, lot number, amount received, pertinent details about the 
condition of the study drug upon receipt based on visual inspection, and the disposition of the drug (eg, to storage). If a cirmtuzumab or ibrutinib drug shipment arrives damaged, or if there are any other complaints relating specifically to the drug, a product complaint should be emailed to the sponsor or the sponsor’s representative. Cirmtuzumab and ibrutinib accountability records must also be maintained that include the patient  number to whom the study drug was 
administered and the date, quantity and lot number of the cirmtuzumab administered. 
Study personnel must ensure that cirmtuzumab and ibrutinib are kept in a secure locked area 
with access limited to authorized personnel. The study drugs must not be used outside the context of this protocol. Under no circumstances should the investigator or study center personnel supply cirmtuzumab or ibrutinib designated for this study to other investigators, patient s, or clinics, or allow  the study drugs to be used other than as directed by [CONTACT_512962].  
Depending upon the decision of Oncternal, remaining unused cirmtuzumab and ibrutinib supplies will be returned to Oncternal or its designee  after the study is completed or will be 
discarded or destroyed at the study center. After investigational product accountability has been performed, cirmtuzumab and ibrutinib may be returned or destroyed on an ongoing basis during the study if appropriate . If the study drug is discarded or destroyed at the study center, standard 
institutional policy should be followed. At study initiation, the monitor will evaluate the study center’s standard operating procedure for study drug disposal/destruction in order  to ensure that 
it complies with Oncternal requirements. At the end of the study, following final drug inventory reconciliation by [CONTACT_2037], the study center will dispose of and/or destroy all unused study drug supplies, including empty containers, according to these procedures. If the study center cannot meet Oncternal requirements for disposal, arrangements will be made between the study center and Oncternal or its representative for destruction or return of unused study drug supplies. 
All study drug s upplies and associated documentation will be periodically reviewed and verified 
by [CONTACT_5276]. Study drug accountability records must be 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 80 of 115  Version 7 ( 15 April  2022 ) readily available for inspection by [CONTACT_512963] O ncternal or by 
[CONTACT_12721].  
10.12.  Monitoring  
Representatives of Oncternal or its designee will monitor this study until completion at 
appropriate intervals. Clinical site monitoring is conducted to ensure that the rights and well -
being of trial parti cipants are protected, that the reported trial data are accurate, complete and 
verifiable and the conduct of the trial is in compliance with the currently approved protocol/amendment(s), and within ICH guidelines and the CFR.  
In accordance with GCP, the st udy monitor must have direct access to the investigator’s source 
documentation in order to verify the data recorded in the eCRFs for consistency. Because of constraints caused by [CONTACT_25963] -[ADDRESS_664137] within a web -based electronic data capture (EDC) system.  
During the data collection process, automated quality assurance programs will be used to identify missing data, out -of-range data, and other data inconsistencies. Requests f or data clarification or 
correction will be forwarded to the investigative study center for resolution. 
Quality assurance and quality control systems will be implemented and maintained according to 
written standard operating procedures to ensure that the data are generated, recorded, and reported in compliance with the protocol, GCP, and applicable regulatory requirements. Data collection and storage systems will provide audit trail, security mechanisms, and electronic signature [CONTACT_512993] r equirements of FDA Title 21 of CFR Part 11 regarding 
electronic records and electronic signatures.   
10.15.  Communications with Regulatory Authorities  
Oncternal (or its designee) will have responsibility for interactions with the FDA and any other relevant regulat ory authorities. Oncternal will maintain their IND for the development of 
cirmtuzumab in support of the study in the US. In fulfilling these responsibilities, Oncternal (or a 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 81 of 115  Version 7 ( 15 April  2022 ) designee) will collect and assemble all required regulatory documents (eg, Form F DA 1572, 
investigator financial disclosure forms, protocol and protocol amendments, investigator 
brochures, informed consent documents, annual reports) as required by [CONTACT_5151]. Oncternal  (or 
a designee) will assume primary responsibility for AE reporting to regulatory authorities (as 
described in Section  8.6.7).  
10.16.  Public Notification of Study Conduct  
Consistent with Se ction [ADDRESS_664138] of 1997 (FDAMA) and to 
ensure meeting the requirement of the International Committee of Medical Journal Editors (ICMJE) as a condition of consideration for publication of study results, Oncternal will regist er 
this protocol at the ClinicalTrials.gov website (or equivalent). Oncternal will appropriately update the information at the website relating to study design and conduct during the course of the study. In order to facilitate this process, investigators w ill need to supply Oncternal with 
appropriate contact [CONTACT_493344].  
10.17.  Study Reporting and Publication  
Oncternal may make information obtained during this study available in order to further the scientific or business needs of the company or as required by [CONTACT_6617]. In this regard, Oncternal may provide study information to private or public organizations (eg, business partners, collaborators, consultants, CROs, investors, other physicians who are conducting similar studies, funding organizations, regulatory authorities, or other government authorities). The results may also be used for papers, abstracts, posters or other material presented at scientific meetings or published in professional journals or as part of an academic thesis.  
Oncternal will prepare a clinical study report for submission to relevant regulatory agencies. Oncternal will ensure that the report meets the standards set out in the ICH Guideline for Structure and Content of Clinical Study Reports (ICH E3). An abbreviated report may be prepared in certain cases, as appropriate.  
Oncternal intends that the data from this study will be presented and published. Because the study will ultimately part of a multicenter clinical trial, data from all study centers will b e pooled 
and analyzed for a primary publication of the study results. Oncternal will coordinate and prepare this primary publication. The investigator agrees that the primary publication, which will be coordinated by [CONTACT_512949], will be the first publication to present the pooled study results. Other ancillary publications or presentations relating to the pooled data from this study may be suggested by [CONTACT_512964] s; such ancillary publications will also be coordinated by [CONTACT_512949].  
After the primary publication, or if the primary publication is not published within [ADDRESS_664139] matter and/or any inadvertent disclosure of its confidential information, which must be redac ted from any final publication or presentation. If necessary, to 
permit the preparation and filing of patent applications, Oncternal may elect an additional review 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 82 of 115  Version 7 ( 15 April  2022 ) period. The durations of the review periods will be specified in a contractual agreement bet ween 
each study center and Oncternal.  
In most cases, the principal investigators at the study centers with the highest accruals of eligible 
patient s and/or who have provided significant intellectual input into the study design, shall be 
listed as lead or s enior authors on publications and presentations of study results. Oncternal 
clinical personnel, lead statistician, scientific personnel, or other staff members meeting the 
requirements for authorship may also be included in the list of authors. This custom  can be 
adjusted upon mutual agreement of the authors and Oncternal.  
 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 83 of 115  Version 7 ( 15 April  2022 ) 11. BIBLIOGRAPHY  
Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, 
Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, Hamdy A, Hedrick E, Fowler NH. Bruton tyrosine kinase inhibitor ibrutinib (PCI -[ZIP_CODE]) has significant activity in patients with 
relapsed/refractory B -cell malignancies. J Clin Oncol. 2013 Jan 1;31(1):88- 94. PMID: 23045577.  
Al-Shawi R, Ashton SV, Underwood C, Simons JP. Expression of the Ror1 and Ror2 receptor 
tyrosine kinase genes during mouse development. Dev Genes Evol. 2001 Apr;211(4):161- 71. 
PMID: 11455430.  
Asghar A, Naaz S, Agrawal D, Sharma P. Morphometric study of spleen in north Indian adult population: CT scan image based study. Journal  of Clinical and Diagnostic Research. [ADDRESS_664140]; 
5(5):974- 7. 
Atkinson BT, Ellmeier W, Watson SP. Tec regulates platelet activation by [CONTACT_512965]. Blood 2003;102:3592- 3599. PMID: 12842985.  
Barna G, Mihalik R, Timár B, Tömböl J, Csende Z, Sebestyén A, Bödör C, Csernus B, Reiniger L, Peták I, Matolcsy A. ROR1 expression is not a unique marker of CLL. Hematol Oncol. 2011 Mar;29(1):17- 21. PMID: 20597086.  
Baskar S, Kwong KY, Hofer T, Levy JM, Kennedy MG, Lee E, Staudt LM, Wilson WH, Wiestner A, R ader C. Unique cell surface expression of receptor tyrosine kinase ROR1 in human 
B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2008 Jan 15;14(2):396- 404. PMID: 
18223214.  
Bezerra AS, D'Ippolito G, Faintuch S, Szejnfeld J, Ahmed M. Determination of splenomegaly by 
[CONTACT_4654]: is there a place for a single measurement? AJR Am J Roentgenol. 2005 May;184(5):1510- 3. 
PMID: 15855107.  
Bicocca VT, Chang BH, Masouleh BK, Muschen M, Loriaux MM, Druker BJ, Tyner JW. 
Crosstalk between ROR1 and the Pre -B cell receptor pr omotes survival of t(1;19) acute 
lymphoblastic leukemia. Cancer Cell. 2012 Nov 13;22(5):656- 67. PMID: 23153538.  
Bradshaw JM. The  Src, Syk, and Tec family kinases: distinct types of molecular switches. Cell 
Signal 2010;22:1175- 84. PMID: 20206686.  
Broome HE , Rassenti LZ, Wang HY, Meyer LM, Kipps TJ. ROR1 is expressed on hematogones 
(non- neoplastic human B -lymphocyte precursors) and a minority of precursor -B acute 
lymphoblastic leukemia. Leuk Res. [ADDRESS_664141];35(10):1390- 4. PMID: 21813176.  
Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, Clow F, James DF, Graef T, Friedberg JW, Rai K, O'Brien S. The Bruton tyrosine kinase inhibitor ibrutinib with 
chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood. 2015 May 
7;125(19):2915- 22. PM ID: 25755291.  
Buggy JJ, Elias L. Bruton tyrosine kinase (BTK) and its role in B -cell malignancy. Int Rev 
Immunol. 2012 Apr;31(2):119- 32. Erratum in: Int Rev Immunol. [ADDRESS_664142];31(5):428. PMID: 
22449073. 
Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, de Weerdt I, 
Jeyakumar G, Ferrajoli A, Cardenas -Turanzas M, Lerner S, Jorgensen JL, Nogueras -González 
GM, Zacharian G, Huang X, Kantarjian H, Garg N, Rosenwald A, O'Brien S. Safety and activity 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 84 of 115  Version 7 ( 15 April  2022 ) of ibrutinib plus rituximab for patients w ith high- risk chronic lymphocytic leukaemia: a single -
arm, phase 2 study. Lancet Oncol. 2014 Sep;15(10):1090- 9. PMID: 25150798.  
Burger JA, Landau DA, Taylor -Weiner A, Bozic I, Zhang H, Sarosiek K, Wang L, Stewart C, 
Fan J, Hoellenriegel J, Sivina M, Dubuc  AM, Fraser C, Han Y, Li S, Livak KJ, Zou L, Wan Y, 
Konoplev S, Sougnez C, Brown JR, Abruzzo LV, Carter SL, Keating MJ, Davids MS, Wierda 
WG, Cibulskis K, Zenz T, Werner L, Dal Cin P, Kharchencko P, Neuberg D, Kantarjian H, Lander E, Gabriel S, O'Brien S, Letai A, Weitz DA, Nowak MA, Getz G, Wu CJ. Clonal evolution in patients with chronic lymphocytic leukaemia developi[INVESTIGATOR_512926]. Nat Commun. 2016 May 20;7:[ZIP_CODE]. PMID: 27199251.  
Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ; RESONATE -2 
Investigators. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015 Dec 17;373(25):2425- 37. PMID: 26639149. 
Bye AP, Unsworth AJ, Vaiyapuri S, Stainer AR, Fry MJ, Gibbins  JM. Ibrutinib inhibits platelet 
integrin αIIbβ3 outside -in signaling and thrombus stability but not adhesion to collagen. 
Arterioscler Thromb Vasc Biol. 2015 Nov;35(11):2326- 35. PMID: 26359510.  
By[CONTACT_9063], Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy N M, Coutre S, Tam CS, Mulligan 
SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris -Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, 
Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P; RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014 Jul 17;371(3):213- 23. PMID: 24881631.  
By[CONTACT_9063], Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Shaw Y, Bilotti E, Zhou C, James DF, O'Brien S. Three -
year follow -up of treatment -naïve and previously treated patients with CLL and SLL receiving 
single -agent ibrutinib. Blood. 2015a Apr 16;125(16):2497- 506. PMID: 25700432.  
By[CONTACT_9063], Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O 'Brien S. Targeting BTK with ibrutinib in 
relapsed chronic lymphocytic leukemia. N Engl J Med. 2013 Jul 4;369(1):32- 42. Erratum in: N 
Engl J Med. 2014 Feb 20;370(8):786. PMID: 23782158. 
By[CONTACT_9063], Hillmen P, James DF. Response: Additional data needed for a better understanding of 
the potential relationship between atrial fibrillation and ibrutinib. Blood. 2015b Mar 5;125(10):1673. PMID: 25745185. 
Cairo MS, Coiffier B, Reiter A, Younes A; TLS Expert Panel. Recommendations for the 
evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010 May;149(4):578- 86. 
PMID: 20331465  
Chanan -Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, 
Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Mato A, Pavlovsky MA, Karlsson C, Mahler M, Salman 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 85 of 115  Version 7 ( 15 April  2022 ) M, Sun S, Phelps C, Balasubramanian S, Howes A, Hallek M; HELIOS investigators.. Ibrutinib 
combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double -blind, phase 3 study. La ncet Oncol. 2016 Feb;17(2):200 -11. 
PMID: 26655421.  
Chang BY, [LOCATION_009]sco M, De Rooij MF, Magadala P, Steggerda SM, Huang MM, Kuil A, Herman SE, Chang S, Pals ST, Wilson W, Wiestner A, Spaargaren M, Buggy JJ, Elias L. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood. [ADDRESS_664143] 3;122(14):2412- 24. 
PMID: 23940282.  
Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Hagemeister FB, Champlin RE, Wang ML. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015 Jun;26(6):1175- 9. PMID: 
25712454.  
Cheah CY, Seymour JF, Wang ML. Mantle cell lymphoma. J Clin Oncol. 2016 Apr 
10;34(11):1256- 69. PMID: 26755518. 
Cheng S, Guo A, Lu P, Ma J, Coleman M, Wang YL. Functional characterization of 
BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase 
inhibitors. Leukemia. 2015 Apr;29(4):895- 900. P MID: 25189416.  
Cheson BD, By[CONTACT_9063], Rai KR, Kay NE, O'Brien SM, Flinn IW, Wiestner A, Kipps TJ. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol. 2012 Aug 10;30(23):2820- 2. PMID: 22778323.  
Ches on BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, 
Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisati on for Research; Treatment of Cancer/Dutch Hemato -Oncology Group; Grupo 
Español de Médula Ósea; German High- Grade Lymphoma Study Group; German Hodgkin's 
Study Group; Japanese Lymphoma Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nor dic Lymphoma Study Group; Southwest Oncology Group; [LOCATION_008] 
National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non- Hodgkin lymphoma: the Lugano classification. J Clin 
Oncol. 2014 Sep 20;32(27):3059- 68. PMID: 25113753. 
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007 Feb 10;25(5):579- 86. PMID: 17242396. 
Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P, Mathew S, Vijay P, Eng K, Ali S, Johnson A, Chang B, Ely S, Elemento O, Mason CE, Leonard JP, Chen- Kiang S. 
Cell-cycle reprogramming for PI3K inhibition overrides a relapse -specific C481S BTK mutation 
revealed by [CONTACT_132218]. Cancer Discov. 2014 Sep;4(9):1022- 35. PMID: 25082755. 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 86 of 115  Version 7 ( 15 April  2022 ) Choi  MY, Ghia  EM, Siddiqi  T, Wierda WG , Lee HJ, Barrientos  JC, Lamanna  N, Goldenberg A , 
Tzachanis  D, Reid  EG, Weihe EK , Rassenti  LZ, Isufi  I, Bieler  S, Ianopulos  X, Breitmeyer  JB, 
Jamieson  C, Kipps  TJ. Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its 
Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial 
for CLL and MCL. Blood 2019a ; 134 (Supplement_1): 1755 (abstract).  
Choi M, Widhopf GF 2nd, Yu J, Chen L, Hasan K, Rassenti LZ, Pi[INVESTIGATOR_2289] E, Messer K, Gutierrez 
C, Kidwell RL, Prussak CE, Castro JE, Jamieson C, Kipps TJ. Durable and specific inhibition of ROR1 signaling associates with prolonged progression free survival in patients with chronic lymphocytic leukemia treated with cirmtuzumab. Blood 2017 Dec 11;130(Suppl1):829 
(abstract).  
Choi MY, Widhopf GF 2nd, Ghia EM, Kidwell RL, Hasan MK, Yu J, Rassenti LZ, Chen L, Chen Y, Pi[INVESTIGATOR_2289] E, Pu M, Messer K, Prussak CE, Castro JE, Jamieson C, Kipps TJ. Ph ase I 
Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. Cell Stem Cell. 2018 Jun 1;22(6):951- 959.e3. PMID: 29859176. 
Choi MY, Widhopf GF 2nd, Wu CC, Cui B, Lao F, Sadarangani A, Cavagnaro J, P russak C, 
Carson DA, Jamieson C, Kipps TJ. P re-clinical specificity and safety of UC -961, a first -in-class 
monoclonal antibody targeting ROR1. Clin Lymphoma Myeloma Leuk. 2015 Jun;[ADDRESS_664144]:S167- 9. PMID: 26297272.  
Choi MY, Wierda WG, Lee HJ, Tzachanis D, I anopulos X, Jezior D, Breitmeyer  JB, Jamieson  
CHM , Kipps  TJ. Phase 1/2 trial of cirmtuzumab and ibrutinib: Planned analysis of phase 1 CLL 
cohorts. J Clin Oncol . 2019b; 37([ADDRESS_664145]): 7527 (abstract) . 
Choudhury A, Derkow K, Daneshmanesh AH, Mikaelsson E, Ki aii S, Kokhaei P, Osterborg A, 
Mellstedt H. Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells. Br J Haematol. 2010 Nov;151(4):327- 35. PMID: 20813009. 
Cramer P, Demirkan F, Fraser G, Pristupa A, Bartlett NL, Dilhuydy M -S, Loscertales J , Avigdor 
A, Rule SA, Samoilova O, Goy A, Ganguly S, Poggesi I, Lavezzi SM, De Nicolao G, de Jong J, Neyens M, Salman M, Howes A, Mahler M. Systemic exposure of rituximab increased by [CONTACT_9059]: pharmacokinetic results from the Helios trial. Blood 2016 Dec  2;128(22):4403 
(abstract).  
Cui B, Ghia EM, Chen L, Rassenti LZ, DeBoever C, Widhopf GF 2nd, Yu J, Neuberg DS, Wierda WG, Rai KR, Kay NE, Brown JR, Jones JA, Gribben JG, Frazer KA, Kipps TJ. High-level ROR1 associates with accelerated disease- progression i n chronic lymphocytic leukemia. 
Blood. 2016 Nov 4. [Epub ahead of print] PMID: 27815263.  
Cui B, Zhang S, Chen L, Yu J, Widhopf GF 2nd, Fecteau JF, Rassenti LZ, Kipps TJ. Targeting 
ROR1 inhibits epi[INVESTIGATOR_018]- mesenchymal transition and metastasis. Cancer Res.  2013 Jun 
15;73(12):3649- 60. PMID: 23771907. 
Dakhil S, Hermann R, Schreeder MT, Gregory SA, Monte M, Windsor KS, Hurst D, Chai A, Brewster M, Richards P. Phase III safety study of rituximab administered as a 90- minute 
infusion in patients with previously untreated diffuse large B -cell and follicular lymphoma. Leuk 
Lymphoma. [ADDRESS_664146];55(10):2335- 40. PMID: 24471908. 
Daneshmanesh AH, Hojjat -Farsangi M, Khan AS, Jeddi -Tehrani M, Akhondi MM, Bayat AA, 
Ghods R, Mahmoudi AR, Hadavi R, Österborg A, Shokri F, Rabbani H, Mellstedt H. 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 87 of 115  Version 7 ( 15 April  2022 ) Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) 
cells. Leukemia. 2012 Jun;26(6):1348- 55. PMID: 22289919.  
Daneshmanesh AH, Mikaelsson E, Jeddi -Tehrani M, Bayat AA, Ghods R, Ostadkarampour M, 
Akhondi M, Lagercrantz S, Larsson C, Osterborg A, Shokri F, Mellstedt H, Rabbani H. Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. Int J Cancer. 2008 Sep 1;123(5):1190- 5. PMID: 18546292.  
Daneshmanesh AH, Porwit A, Hojjat -Farsangi M, Jeddi -Tehrani M, Tamm KP, Grandér D, 
Lehmann S, Norin S, Shokri F, Rabbani H, Mellstedt H, Österborg A. Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies. Leuk Lymphoma. 2013 Apr;54(4):843-50. PMID: 22988987.  
de Claro RA, McGinn KM, Verdun N, Lee SL, Chiu HJ, Saber H, Brower ME, Chang CJ, Pfuma E, Habtemariam B, Bullock J, Wang Y, Nie L, Chen XH, Lu DR, Al -Hakim A, Kane RC, 
Kaminskas E, Justice R, Farrell AT, Pazdur  R. FDA approval: ibrutinib for patients with 
previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia. Clin Cancer Res. 2015 Aug 15;21(16):3586- 90. PMID: 26275952.  
de Jong J, Sukbuntherng J, Skee D, Murphy J, O'Brien S, By[CONTACT_9063], James D, Hellemans P, Loury DJ, Jiao J, Chauhan V, Mannaert E. The effect of food on the pharmacokinetics of oral ibrutinib 
in healthy participants and patients with chronic lymphocytic leukemia. Cancer Chemother 
Pharmacol. 2015 May;75(5):907- 16. PMID: 25724156.  
de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ, Pals ST, Spaargaren M. The clinically active BTK inhibitor PCI -[ZIP_CODE] targets B -cell receptor - and chemokine -controlled 
adhesion and migration in chronic lymphocytic leukemia. Blood. 2012 Mar 15;119(11):2590- 4. 
PMID: 22279054.  
Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens -Harig M, Hess G, Bence -Bruckler I, Cho SG, Bothos J, Goldberg JD, Enny C, 
Traina S, Balasubramanian S, Bandyopadhyay N, Sun S, Vermeulen J, Rizo A, Rule S. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle -cell lymphoma: an 
international, randomised, open- label, phase 3 study. Lancet. 2016 Feb 20;387([ZIP_CODE]):770- 8. 
Erratum in: L ancet. 2016 Feb 20;387([ZIP_CODE]):750. PMID: 26673811.  
Erturk SM, Mortelé KJ, Binkert CA, Glickman JN, Oliva MR, Ros PR, Silverman SG. CT features of hepatic venoocclusive disease and hepatic graft -versus -host disease in patients after 
hematopoietic stem cell transplantation. AJR Am J Roentgenol. 2006 Jun;186(6):1497- 501. 
PMID: 16714636.  
Farooqui MZ, Valdez J, Martyr S, Aue G, Saba N, Niemann CU, Herman SE, Tian X, Marti G, Soto S, Hughes TE, Jones J, Lipsky A, Pi[INVESTIGATOR_61818] S, Stetler -Stevenson M, Yuan C, Lee YS, 
Pedersen LB, Geisler CH, Calvo KR, Arthur DC, Maric I, Childs R, Young NS, Wiestner A. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single -arm trial. L ancet Oncol. 2015 Feb;16(2):169- 76. PMID: 
25555420. 
Food and Drug Administration. Drug development and drug interactions: table of substrates, 
inhibitors and inducers. [ADDRESS_664147] 27. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#4 (accessed 2016 Dec 27).  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 88 of 115  Version 7 ( 15 April  2022 ) Forrester WC, Dell M, Perens E, Garriga G. A  C. elegans Ror receptor tyrosine kinase regulates 
cell motility and asymmetric cell division. Nature. 1999 Aug 26;400(6747):881- 5. PMID: 
10476968.  
Fukuda T, Chen L, Endo T, Tang L, Lu D, Castro JE, Widhopf GF 2nd, Rassenti LZ, Cantwell 
MJ, Prussak CE, Ca rson DA, Kipps TJ. Antisera induced by [CONTACT_512966]- CD154-
leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3047- 52. PMID: 18287027.  
Furman RR, Cheng S, Lu P, Setty M, Perez AR, Guo A, Racchumi J, Xu G, Wu H, Ma J, Steggerda SM, Coleman M, Leslie C, Wang YL. Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med. 2014 Jun 12;370(24):2352- 4. PMID: 24869597.  
Genentech. Rituxan® (rituximab) prescribing informat ion. 2016 April. Available at: 
https://www.gene.com/download/pdf/rituxan_prescribing.pdf  (accessed 2016 Dec 26).  
Gentile A, Lazzari L, Benvenuti S, Trusolino L, Comoglio PM. ROR1 is a pseudokinase that is crucial for Met -driven tumorigenesis. Cancer Res. 2011 Apr 15;71(8):3132 -41. PMID: 
21487037.  
Hallek M, Cheson BD, Catovsky D, Caligaris -Cappio F, Dighiero G, Döhner H, Hillmen P, 
Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, By[CONTACT_9063], Eichhorst B, O'Brien 
S, Robak T, Seymour JF, Kipps TJ. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 Jun 21;131(25):2745-2760. PMID: 29540348  
Hallek M, Cheson BD, Catovsky D, Caligaris -Cappio F, Dighiero G, Döhner H, Hillmen P, 
Keating MJ, Montserrat E, Rai KR, Kipps TJ; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report 
from the International Workshop on Chronic Lymphocytic Leukemia updating the National 
Cancer Institute -Working Group 1996 guidelines. Blood. 2008 Jun 15;111(12):5446- 56. Erratum 
in: Blood. 2008 Dec 15;112(13):5259. PMID: 18216293. 
Hallek M. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and 
treatment. Am J Hematol. 2015 May;90(5):446- 60. PMID: 25908509.  
Hamasy A, Wang Q, Blomberg KEM, Mohammad DK, Yu L, Vihinen M, Berglöf A, Cmith CIE. Substitution scanning identifies a novel, c atalytically active ibrutinib -resistant BTK 
cysteine 481 to threonine (C481T) variant. Leukemia 2016 June 10; online publication. PMID: 27282255. 
Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, 
Blum KA, Buggy JJ, Hamdy A, Johnson AJ, By[CONTACT_9063]. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by [CONTACT_9090] -[ZIP_CODE]. Blood. 2011 Jun 9;117(23):6287- 96. PMID: 21422473. 
Herman SE, Niemann CU, Far ooqui M, Jones J, Mustafa RZ, Lipsky A, Saba N, Martyr S, Soto 
S, Valdez J, Gyamfi JA, Maric I, Calvo KR, Pedersen LB, Geisler CH, Liu D, Marti GE, Aue G, Wiestner A. Ibrutinib- induced lymphocytosis in patients with chronic lymphocytic leukemia: 
correlativ e analyses from a phase II study. Leukemia. 2014 Nov;28(11):2188- 96. PMID: 
24699307.  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 89 of 115  Version 7 ( 15 April  2022 ) Herson J. Predictive probability early termination plans for phase II clinical trials. Biometrics. 
1979 Dec;35(4):775 -83. PMID: 526523.  
Hojjat- Farsangi M, Ghaemimanesh F, Daneshmanesh AH, Bayat AA, Mahmoudian J, Jeddi -
Tehrani M, Rabbani H, Mellstedt H. Inhibition of the receptor tyrosine kinase ROR1 by [CONTACT_14181] -
ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells. PLoS One. 2013a Apr 8;8(4):e [ZIP_CODE]. PMID: 23593420.  
Hojjat- Farsangi M, Jeddi -Tehrani M, Daneshmanesh AH, Mozaffari F, Moshfegh A, Hansson L, 
Razavi SM, Sharifian RA, Rabbani H, Österborg A, Mellstedt H, Shokri F. spontaneous immunity against the receptor tyrosine kinase ROR1 in patients with chronic lymphocytic leukemia. PLoS One. 2015 Nov 12;10(11):e0142310. PMID: 26562161.  
Hojjat- Farsangi M, Khan AS, Daneshmanesh AH, Moshfegh A, Sandin A, Mansouri L, Palma 
M, Lundin J, Österborg A, Mellstedt H. The tyrosine kinase receptor ROR1 is c onstitutively 
phosphorylated in chronic lymphocytic leukemia (CLL) cells. PLoS One. 2013b Oct 24;8(10):e78339. PMID: 24205204.  
Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin- Nelemans HC, 
Pfreundschuh M, Reiser M, Metzner B, Einsele H, Peter N, Jung W, Wörmann B, Ludwig WD, 
Dührsen U, Eimermacher H, Wandt H, Hasford J, Hiddemann W, Unterhalt M; German Low 
Grade Lymphoma Study Group (GLSG).; European Mantle Cell Lymphoma Network..A new 
prognostic index (MIPI) for patients with advanced- stage mantle cell lymphoma. Blood. 2008 
Jan 15;111(2):558- 65. Erratum in: Blood. 2008 Jun 15;111(12):5761. PMID: 17962512. 
Hoster E, Klapper W, Hermine O, Kluin- Nelemans HC, Walewski J, van Hoof A, Trneny M, 
Geisler CH, Di Raimondo F, Szymczyk M, Stilgenbaue r S, Thieblemont C, Hallek M, 
Forstpointner R, Pott C, Ribrag V, Doorduijn J, Hiddemann W, Dreyling MH, Unterhalt M. Confirmation of the mantle -cell lymphoma International Prognostic Index in randomized trials of 
the European Mantle -Cell Lymphoma Network. J Clin Oncol. 2014 May 1;32(13):1338- 46. 
PMID: 24687837.  
Howard SC, Trifilio S, Gregory TK, Baxter N, McBride A. Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review. Ann Hematol. 2016 Mar;95(4):563- 73. PMID: 26758269.  
Hudecek M, Schmitt TM, Baskar S, Lupo- Stanghellini MT, Nishida T, Yamamoto TN, Bleakley 
M, Turtle CJ, Chang WC, Greisman HA, Wood B, Maloney DG, Jensen MC, Rader C, Riddell SR. The B -cell tumor -associated antigen ROR1 can  be targeted with T cells modified to express 
a ROR1 -specific chimeric antigen receptor. Blood. 2010 Nov 25;116(22):4532- 41. PMID: 
20702778.  
Ibrutinib Investigator Brochure, Pharmacyclics 2021. Ida L, Yamaguchi T, Yanagisawa K, Kajino T, Shimada Y, Suzuki  M, Takahashi T. Receptor 
tyrosine kinase -like orphan receptor 1, a target of NKX2- 1/TTF -1 lineage- survival oncogene, 
inhibits apoptosis signal -regulating kinase 1- mediated pro -apoptotic signaling in lung 
adenocarcinoma. Cancer Sci. 2016 Feb;107(2):155- 61. PMID: 26661061.  
 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 90 of 115  Version 7 ( 15 April  2022 ) Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N, George B, James D, Kantarjian H, 
Burger J, O'Brien S. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015 Mar 26;125(13):2062- 7. PMI D: 25573991.  
Janovska P, Poppova L, Plevova K, Plesingerova H, Behal M, Kaucka M, Ovesna P, Hlozkova M, Borsky M, Stehlikova O, Brychtova Y, Doubek M, Machalova M, Baskar S, Kozubik A, Pospi[INVESTIGATOR_302533] S, Pavlova S, Bryja V. Autocrine signaling by [CONTACT_512967] -5a dereg ulates chemotaxis of 
leukemic cells and predicts clinical outcome in chronic lymphocytic leukemia. Clin Cancer Res. 2016 Jan 15;22(2):459- 69. PMID: 26240275.  
Kamel S, Horton L, Ysebaert L, Levade M, Burbury K, Tan S, Cole -Sinclair M, Reynolds J, 
Filshie R, Schischka S, Khot A, Sandhu S, Keating MJ, Nandurkar H, Tam CS. Ibrutinib inhibits collagen -mediated but not ADP -mediated platelet aggregation. Leukemia. 2015 Apr;29(4):783- 7. 
PMID: 25138588.  
Katoh M, Katoh M. Comparative genomics on ROR1 and RO R2 orthologs. Oncol Rep. 2005 
Nov;14(5):1381- 4. PMID: 16211313.  
Khan WN. Regulation of B lymphocyte development and activation by [CONTACT_512968]'s tyrosine kinase. Immunol Res. 2001;23(2 -3):147- 56. PMID: 11444380. 
Kil LP, de Bruijn MJ, van Hulst JA, Langerak AW, Yuvaraj S, Hendriks RW. Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia. Am J Blood Res. 2013;3(1):71- 83. PMID: 23359016. 
Kotašková J, Pavlová Š, Greif I, Stehlíková O, Plevová K, Janovs ká P, Brychtová Y, Doubek M, 
Pospíšilová Š, Bryja V. ROR1- based immunomagnetic protocol allows efficient separation of 
CLL and healthy B cells. Br J Haematol. [ADDRESS_664148];175(2):339- 342. PMID: 26567475.  
Laffargue M, Ragab -Thomas JM, Ragab A, Tuech J, Missy K , Monnereau L, Blank U, Plantavid 
M, Payrastre B, Raynal P, Chap H. Phosphoinositide 3- kinase and integrin signalling are 
involved in activation of Bruton tyrosine kinase in thrombin- stimulated platelets. FEBS Lett 
1999;443:66- 70. PMID: 9928954. 
Lee HJ, Ch oi MY, Siddiqi T, Wierda WG, Barrientos JC, Lamanna N, Goldenberg A , Isufi  I, 
Tuscano  JM, Subbiah S , Weihe EK , Ianopulos  X, Breitmeyer  JB, Hsu  FJ, Wang  M, Jamieson  
CHM , Kipps  TJ. Clinical Activity of Cirmtuzumab, an Anti- ROR1 Antibody, in Combination 
with Ibrutinib; Interim Results of a Phase 1b/2 Study in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL). J Clin Oncol . 2020; 38(15_suppl): 8036 (abstract).  
Leong DP, Caron F, Hillis C, Duan A, Healey JS, Fraser G, Siegal D. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta -analysis. Blood. 2016 Jul 
7;128(1):138- 40. PMID: 27247135. 
Levade M, David E, Garcia C, Laurent PA, Cadot S, Michallet AS, Bordet JC, Tam C, Sié P, Ysebaert L, Payrastre B. Ibrutinib treatment a ffects collagen and von Willebrand 
factor -dependent platelet functions. Blood. 2014 Dec 18;124(26):3991- 5. PMID: 25305202.  
Li P, Harris D, Liu Z, Liu J, Keating M, Estrov Z. Stat3 activates the receptor tyrosine kinase like orphan receptor -1 gene in chroni c lymphocytic leukemia cells. PLoS One. 2010 Jul 
29;5(7):e11859. PMID: 20686606.  
Lipsky AH, Farooqui MZ, Tian X, Martyr S, Cullinane AM, Nghiem K, Sun C, Valdez J, 
Niemann CU, Herman SE, Saba N, Soto S, Marti G, Uzel G, Holland SM, Lozier JN, Wiestner 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 91 of 115  Version 7 ( 15 April  2022 ) A. Incidence and risk factors of bleeding- related adverse events in patients with chronic 
lymphocytic leukemia treated with ibrutinib. Haematologica. 2015 Dec;100(12):1571- 8. PMID: 
26430171. 
Liu J, Fitzgerald ME, Berndt MC, Jackson CW, Gartner TK. Bruton tyrosine kinase is essential 
for botrocetin/VWF -induced signaling and GPIb- dependent thrombus formation in vivo Blood 
2006;108:2596- 2603. PMID: 16788103.  
Liu TM, Woyach JA, Zhong Y, Lozanski A, Lozanski G, Dong S, Strattan E, Lehman A, Zhang X, Jones JA, Flynn J, Andritsos LA, Maddocks K, Jaglowski SM, Blum KA, By[CONTACT_9063], Dubovsky JA, Johnson AJ. Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib- resistant 
CLL confers BTK independency upon B -cell receptor activation. Blood. 2015 Jul 2;126(1):61- 8. 
PMID: 25972157.  
Liu Y, Yang H, Chen T, Luo Y, Xu Z, Li Y, Yang J. Silencing of receptor tyrosine kinase ROR1 inhibits tumor -cell proliferation via PI3K/AKT/mTOR signaling pathway in lung 
adenocarcinoma. PLoS One. 2015b May 15;10(5):e0127092. PMID: 25978653. 
Lyashenko N, Weissenböck M, Sharir A, Erben RG, Minami Y, Hartmann C. Mice lacking the 
orphan receptor ror1 have distinct skeletal abnormalities and are growth retarded. Dev Dyn. 2010 Aug;239(8):2266- 77. PMID: 20593419.  
Maddocks K, Christian B, Jaglow ski S, Flynn J, Jones JA, Porcu P, Wei L, Jenkins C, Lozanski 
G, By[CONTACT_9063], Blum KA. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non -Hodgkin lymphoma. Blood. 2015a Jan 8;125(2):242-
8. PMID: 25355819.  
Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, 
Blum KA, Grever MR, Johnson AJ, By[CONTACT_9063], Woyach JA. Etiology of ibruti nib therapy 
discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015b Apr;1(1):80- 7. PMID: 26182309.  
Manne BK, Badolia R, Dangelmaier C, Eble JA, Ellmeier W, Kahn M, Kunapuli SP. Distinct pathways regulate Syk protein a ctivation downstream of immune tyrosine activation motif 
(ITAM) and hemITAM receptors in platelets. J Biol Chem. 2015 May 1;290(18):[ZIP_CODE]- 68. 
PMID: 25767114.  
Marostica E, Sukbuntherng J, Loury D, de Jong J, de Trixhe XW, Vermeulen A, De Nicolao G, O'Brien S, By[CONTACT_9063], Advani R, McGreivy J, Poggesi I. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. Cancer Chemother Pharmacol. 2015 Jan;75(1):111- 21. doi: 10.1007/s00280- 014-2617- 3. PMID: 
25381051.  
Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner -Johnston N, Rule S, Advani R, 
Iberri D, Phillips T, Spurgeon S, Kozin E, Noto K, Chen Z, Jurczak W, Auer R, Chmielowska E, 
Stilgenbauer S, Bloehdorn J, Portell C, Williams ME, Dreyling M, Ba rr PM, Chen -Kiang S, 
DiLiberto M, Furman RR, Blum KA. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016 Mar 24;127(12):1559- 63. PMID: 26764355.  
Maruyama D, Nagai H, Fukuhara N, Kitano T, Ishikawa T, Shibayama H, Choi I, Hatake K, Uchida T, Nishikori M, Kinoshita T, Matsuno Y, Nishikawa T, Takahara S, Tobinai K. Efficacy 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol:  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 92 of 115  Version 7 (15 April  2022) and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma. 
Cancer Sci. 2016 Sep 12. PMID: 27616553.  
Masiakowski P, Carroll RD. A novel family of cell surface receptors with tyrosine kinase- like 
domain. J Biol Chem. 1992 Dec 25;267(36):[ZIP_CODE]-90. PMID: 1334494.  
Mato, AR, Lamanna N, Ujjani CS, Brander DM, Hill BT, Howlett C, Skarbnik AP, Cheson B, 
Zent CS, Pu JJ, Kiselev P, Bachow SH, Winter AM, Cruz A-L, Claxton DF, Daniel C, Isaack K, Kennard KH, Timlin C, Yacur M, Fanning M, Strelec L, Landsburg D, Nasta SD, Schuster SJ, Porter DL, Nabhan C, Barr P. Toxicities and outcomes of ibrutinib- treated patients in the united 
states: large r etrospective analysis of 621 real world patients. Blood 2016 Dec 2;128(22):3222 
(abstract).  
Matsuda T, Nomi M, Ikeya M, Kani S, Oishi I, Terashima T, Takada S, Minami Y. Expression of the receptor tyrosine kinase genes, Ror1 and Ror2, during mouse development. Mech Dev. 2001 Jul;105(1-2):153-6. PMID: 11429290.  
McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases the risk 
of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014 Dec 11;124(25):3829-30. PMID: 25498454. 
MD Anderson Cancer Center (MDACC). Tumor lysis in adult patients. 2016 May 31. Available 
at: http://www.mdanderson.org/education- and-research/resources -for-professionals/clinical-
tools- and-resources/practice- algorithms/clin -management -tumor- lysis-web-algorithm.pdf  
(accessed 2016 Dec 23). 
Mohamed AJ, Yu L, Bäckesjö CM, Vargas L, Faryal R, Aints A, Christensson B, Berglöf A, 
Vihinen M, Nore BF, Smith CI. Bruton's tyrosine kinase (BTK): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev. 2009 Mar;228(1):58-73. PMID: 19290921. 
National Cancer Institute (NCI). Common Terminology Criteria for Adverse Events (CTCAE), 
Version 4.03. 2010 Jun 14. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf  (accessed 2016  Dec 20). 
NCCN (National Comprehensive Cancer Network). NCCN clinical practice guidelines in oncology: chronic lymphocytic leukemia/small lymphocytic lymphoma. Version 1.2017. 2016a Sep 28. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf  
(accessed 17 Dec 2016). 
NCCN (National Comprehensive Cancer Network). NCCN clinical practice guidelines in 
oncology: B-cell lymphomas. Version 1.2017. 2016b Dec 7. Available at: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf  (accessed 17 Dec 2016). 
Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F, Collins GP, Ma S, Coleman M, Peles S, Smith S, Barrientos JC, Smith A, Munneke B, Dimery I, Beaupre DM, 
Chen R. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood. 2017 Apr 20;129(16):2224-2232. doi: 10.1182/blood-2016-10-747345. Epub 2017 Feb 6. 
Noy A, de Vos S, Coleman M, Martin P, Flowers CR, Thieblemont C, Morschhauser F, Collins 
GP, Ma S, Pe les S, Smith SD, Barrientos JC, Chong E, Wu S, Cheung LW, Kwei K, Hauns B, 
Arango-Hisijara I, Chen R. Durable ibrutinib responses in relapsed/refractory marginal zone 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol:  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 93 of 115  Version 7 (15 April  2022) lymphoma: long- term follow -up and biomarker analysis. Blood Adv. 2020 Nov 24;4(22):5773-
5784. doi: 10.1182/bloodadvances.[PHONE_10653].  
O'Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, Österborg A, Siddiqi T, Thirman 
MJ, Furman RR, Ilhan O, Keating MJ, Call TG, Brown JR, Stevens-Brogan M, Li Y, Clow F, James DF, Chu AD, Hallek M, Stilgenbauer S. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open- label, 
multicentre study. Lancet Oncol. [ADDRESS_664149];17(10):1409-1418. PMID: 27637985. 
O'Connell MP, Marchbank K, Webster MR, Valiga AA, Kaur A, Vultur A, Li L, Herlyn M, 
Villanueva J, Liu Q, Yin X, Widura S, Nelson J, Ruiz N, Camilli TC, Indig FE, Flaherty KT, Wargo JA, Frederick DT, Cooper ZA, Nair S, Amaravadi RK, Schuchter LM, Karakousis GC, Xu W, Xu X, Weeraratna AT. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov. 2013 Dec;3(12):1378-93. PMID: 24104062. 
Oda A, Ikeda Y, Ochs HD, Druker BJ, Ozaki K, Handa M, Ariga T, Sakiyama Y, Witte ON, 
Wahl MI. Rapid tyrosine phosphorylation and activation of Bruton's tyrosine/Tec kinases in platelets induced by [CONTACT_512969]32 cross-linking Blood. 2000;95:1663-1670. PMID: 10688822. 
Oishi I, Takeuchi S, Hashimoto R, Nagabukuro A, Ueda T, Liu ZJ, Hatta T, Akira S, Matsuda Y, 
Yamamura H, Otani H, Minami Y. Spatio -temporally regulated expression of receptor tyrosine 
kinases, mRor1, mRor2, during mouse development:  implications in development and function of the nervous system. Genes Cells. 1999 Jan;4(1):41-56. PMID: 10231392.  
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity 
and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55. PMID: 7165009. 
Paganoni S, Bernstein J, Ferreira A. Ror1 -Ror2 complexes modulate synapse formation in 
hippocampal neurons. Neuroscience. 2010 Feb 17;165(4):1261-74. PMID: 19958813.  
Pharmacyclics. Imbruvica™ (ibrutinib) prescribing information. 2020 Dec. Available at: 
https://imbruvica.com/files/prescribing -information.pdf (accessed 2022 Mar  22). 
Ponader S, Burger JA. Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. J Clin Oncol. 2014 Jun 10;32(17):1830-9. PMID: 24778403. PMID: 24778403. 
Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O'Brien S, 
Chiorazzi N, Burger JA. The Bruton tyrosine kinase inhibitor PCI-[ZIP_CODE] thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012 Feb 2;119(5):1182-9. PMID: 22180443. 
Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of 
chronic lymphocytic leukemia. Blood. 1975 Aug;46(2):219-34. PMID 1139039. 
Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson 
MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Heitner Enschede S, Humerickhouse RA, Wierda WG, Seymour JF. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016 Jan 28;374(4):311-22. PMID: 26639348. 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 94 of 115  Version 7 ( 15 April  2022 ) Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, Hernández -Rivas JÁ, Qi K, Deshpande S, 
Parisi L, Wang M. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: 
extended 3.5- year follow up from a pooled analysis. Haematologica. 2019;104(5):e211- e214. 
PMID: 30442728.  
Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, Cavazos N, Liu B, Yang S, Clow F, Goldberg JD, Beaupre D, Vermeulen J, Wildgust M, Wang M. Outcomes in 370 patients  with 
mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open -label studies. Br 
J Haematol. 2017;179(3):430- 438. PMID: 28832957. 
Shanafelt TD, Parikh SA, Noseworthy PA, Goede V, Chaffee KG, Bahlo J, Call TG, Schwager SM, Ding W, Eichhorst B, Fischer K, Leis JF, Chanan- Khan AA, Hallek M, Slager SL, Kay NE. 
Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2016 Nov 25:1- 10. [Epub ahead of print]. PMID: 27885886.  
Simon R. Optimal two -stage designs f or phase II clinical trials. Control Clin Trials. 1989 
Mar;10(1):1 -10. PMID: 2702835. 
Stephens DM, Spurgeon SE. Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opi[INVESTIGATOR_1649]. Ther Adv Hematol. [ADDRESS_664150];6(5):242- 52. PMID: 26425337.  
Thom pson PA, Lévy V, Tam CS, Al Nawakil C, Goudot FX, Quinquenel A, Ysebaert L, 
Michallet AS, Dilhuydy MS, Van Den Neste E, Dupuis J, Keating MJ, Meune C, Cymbalista F. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study. Br J Haematol. 2016a  Nov;175(3):462- 466. PMID: 27611233. 
Thompson PA, Wierda WG. Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. Blood. 2016b Jan 21;127(3):279- 86. PMID: 
26576865. 
Uhrmacher  S, Schmidt C, Erdfelder F, Poll -Wolbeck SJ, Gehrke I, Hallek M, Kreuzer KA. Use 
of the receptor tyrosine kinase -like orphan receptor 1 (ROR1) as a diagnostic tool in chronic 
lymphocytic leukemia (CLL). Leuk Res. [ADDRESS_664151];35(10):1360- 6. PMID: 21531460.  
Vihinen M, Mattsson PT, Smith CI. Bruton tyrosine kinase (BTK) in X -linked 
agammaglobulinemia (XLA). Front Biosci 2000;5:D917- D928. PMID: 11102316. 
Vose JM. Mantle cell lymphoma: 2015 update on diagnosis, risk- stratification, and clinical 
management. Am J Hematol. 2015 Aug;90(8):739- 45. PMID: 26103436.  
Vrontikis A, Carey J, Gilreath JA, Halwani A, Stephens DM, Sweetenham JW. Proposed algorithm for managing ibrutinib- related atrial fibrillation. Oncology (Williston Park). 2016 Nov 
15;30(11). pii: 219802. PMID:  27848243.  
Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Zhang L, Baher L, Cheng M, Lee D, Beaupre DM, Rule S. Long- term follow -up of MCL patients treated with single -agent ibrutinib: updated safety 
and efficacy results. Blood. 2015 Aug 6;126(6):739- 45. PMID: 26059948.  
Wang ML, Lee H, Chuang H, Wagner -Bartak N, Hagemeister F, Westin J, Fayad L, Samaniego 
F, Turturro F, Oki Y, Chen W, Badillo M, Nomie K, DeLa Rosa M, Zhao D, Lam L, Addison A, 
Zhang H, Young KH, Li S, Santos D, Medeiros LJ, Champlin R, Romaguera J, Zhang L. 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 95 of 115  Version 7 ( 15 April  2022 ) Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma : a single -
centre, open -label, phase 2 trial. Lancet Oncol. 2016 Jan;17(1). PMID: 26640039.  
Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, 
Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyli ng M, 
Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA. Targeting BTK with ibrutinib in relapsed or refractory mantle -cell lymphoma. N Engl J Me d. 2013 Aug 
8;369(6):507- 16. PMID: 23782157. 
Widhopf GF 2nd, Cui B, Ghia EM, Chen L, Messer K, Shen Z, Briggs SP, Croce CM, Kipps TJ. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ -TCL1 transgenic mice. Proc 
Natl Acad Sci U S A. 2014 Jan 14;111(2):793- 8. PMID: 24379361.  
Winqvist M, Asklid A, Andersson PO, Karlsson K, Karlsson C, Lauri B, Lundin J, Mattsson M, Norin S, Sandstedt A, Hansson L, Österborg A. Real -world results of ibrutinib in patients with 
relapsed or refractory chronic lymphocyti c leukemia: data from 95 consecutive patients treated in 
a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group. Haematologica. 2016 Dec;101(12):1573 -1580. PMID: 27198718.  
Woosley RL, Romero KA. QTdrugs List, 2015 Jul 3, AZCERT, Inc., Available at: www.Crediblemeds.org (accessed 27 Dec 2016).  
Woyach JA, Bojnik E, Ruppert AS, Stefanovski MR, Goettl VM, Smucker KA, Smith LL, Dubovsky JA, Towns WH, Macmurray J, Harrington BK, Davis ME, Gobessi S, Laurenti L, Chang BY, Buggy JJ, Efremov DG, By[CONTACT_9063], Johnson AJ. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood. 2014a Feb 20;123(8):1207- 13. PMID: 24311722. 
Yamaguchi T, Yanagisawa K, Sugiyama R, Hosono Y, Shimada Y, Arima C, Kato S, Tomida S, Suzuki M, Osada H, Takahashi T. NKX2 -1/TITF1/TTF -1-induced ROR1 is required to sustain 
EGFR survival signaling in lung adenocarcinoma. Cancer Cell. 2012 Mar 20;21(3):348- 61. 
PMID: 22439932.  
Yoda A, Oishi I, Minami Y. Expression and function of the Ror -family receptor tyrosine kinases 
during development: lessons from genetic analyses of nematodes, mice, and humans. J Recept Signal Transduct Res. 2003 Feb;23(1):1 -15. PMID:  12680586. 
Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J, Bandyopadhyay N, de Vries R, Balasubramanian S, Hellemans P, Smit JW, Fourneau N, Oki Y. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R -CHOP) for treatment -naive patients with CD20- positive B -cell 
non-Hodgkin lymphoma: a non- randomised, phase 1b study. Lancet Oncol. 2014 
Aug;15(9):1019- 26. PMID: 25042202.  
Yu J, Chen L, Cui B, Wu C, Choi MY, Chen Y, Zhang L, Rassenti LZ, Widhopf GF, Kipps TJ. Cirmtuzumab inhibits Wnt5a -induced Rac1- activation in chronic lymphocytic leukemia treated 
with ibrutinib. Leukemia. 2017 Jun;31(6):1333- 1339. PMID: 27904138.  
Yu J, Chen  Y, Chen L, Zhang L, Rassenti  L, Widhopf GF, Kipps, TJ.  Cirmtuzumab inhibits 
ibrutinib -resistant, Wnt5a -induced Racl activation and proliferation in mantle cell lymphoma. 
Oncotarget 2018; 9: [ZIP_CODE]- [ZIP_CODE]. PMID: 29872501.  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 96 of 115  Version 7 ( 15 April  2022 )  
Yun S, Vincelette ND, Acharya U, Abraham I. Risk of atrial fibrillation and bleeding diathesis 
associated with ibrutinib treatment: a systematic review and pooled analysis of four randomized controlled trials. Clin Lymphoma Myeloma Leuk. 2016 Sep 19. [Epub ahead of print]. PMID:  27780690.  
Zhang H, Qiu J, Ye C, Yang D , Gao L, Su Y, Tang X, Xu N, Zhang D, Xiong L, Mao Y, Li F, 
Zhu J. ROR1 expression correlated with poor clinical outcome in human ovarian cancer. Sci Rep. 2014a Jul 24;4:5811. PMID: 25056203.  
Zhang S, Chen L, Cui B, Chuang HY, Yu J, Wang -Rodriguez J, Tang L, Chen G, Basak GW, 
Kipps TJ. ROR1 is expressed in human breast cancer and associated with enhanced tumor -cell 
growth. PLoS One. 2012a;7(3):e31127. PMID: 22403610.  
Zhang S, Chen L, Wang- Rodriguez J, Zhang L, Cui B, Frankel W, Wu R, Kipps TJ. The onco-
embryonic antigen ROR1 is expressed by a variety of human cancers. Am J Pathol. 2012b 
Dec;181(6):1903 -10. PMID: 23041612.  
Zhang S, Cui B, Lai H, Liu G, Ghia EM, Widhopf GF 2nd, Zhang Z, Wu CC, Chen L, Wu R, 
Schwab R, Carson DA, Kipps TJ. Ovarian cancer stem cells express ROR1, which can be targeted for anti -cancer -stem -cell therapy. Proc Natl Acad Sci U S A. 2014b Dec 
2;111(48):[ZIP_CODE]- 71. PMID: 25411317.  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 97 of 115  Version 7 ( 15 April  2022 ) 12. APPENDICES  
 
12.1 ECOG Performance Status  
12.2 Cockcroft -Gault Method for Estimating Creatinine Clearance  
12.3 Potent Inhibitors and Inducers of CYP3A4  
12.4 RAI Staging System for CLL/SLL  
12.5 Efficacy Assessments - CLL  
12.6 Efficacy Assessment – Lymphoma  
 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 98 of 115  Version 7 ( 15 April  2022 ) 12.1. ECOG Performance Status  
Grade  Description  
0 Fully active, able to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or 
sedentary nature, eg,  light housework , office work  
2 Ambulatory and capable of all self -care but unable to carry out any work activities. Up and about 
more  than 50% of waking  hours  
3 Capable of only limited self -care, confined to bed or chair more than 50% of waking hours  
4 Completely disabled. Cannot carry on any self -care. Totally confined to bed or chair  
5 Dead  
Reference: [ Oken 1982]  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 99 of 115  Version 7 ( 15 April  2022 ) 12.2. Cockcroft -Gault Method for Estimating Creatinine Clearance  
Formulas for calculating the estimated creatinine clearance ( eClCR) are provided below. The 
formula appropriate to the units in which serum creatinine was mea sured and the patient ’s sex 
should be used. 
Cockcroft -Gault Formulas for Calculating Estimated Creatinine Clearance  
Serum  
Creatinine Units  Sex Formula  
     
 mg/dL  Males  eCl CR 
[mL/min]  = (140-patient  age [years]) × patient  weight [kilograms] × 1.0 
72 × patient  serum creatinine [mg/dl]  
    
    
Females  eCl CR 
[mL/min]  = (140-patient  age [years]) × patient  weight [kilograms] × 0.85 
72 × patient  serum creatinine [mg/dl]  
     
     
µM/dL  Males  eCl CR 
[mL/min]  = (140-patient  age [years]) × patient  weight [kilograms] × 1.23 
Patient  serum creatinine [µM/dL]  
    
    
Females  eCl CR 
[mL/min]  = (140-patient  age [years]) × patient  weight [kilograms] × 1.04 
Patient  serum creatinine [µM/dL]  
     
Abbreviation: eCl CR=estimated creatinine clearance 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 100 of 115  Version 7 ( 15 April  2022 ) 12.3. Potent  Inhibitors and Inducers of CYP3A4  
Effect on 
CYP3A  Drug Class  Medications  
Moderate to 
Strong CYP3A 
Inhibitors  Antibiotics  chloramphenicol, ciprofloxacin, clarithromycin, erythromycin, 
telithromycin  
Antiemetic  aprepi[INVESTIGATOR_512927], fluconazole, itraconazole, posaconazole, 
voriconazole  
Antiviral protease inhibitors  amprenavir, atazanavir, boceprevir, cobicistat, darunavir, 
elvitegravir, fosamprenavir, indinavir, lopi[INVESTIGATOR_054], nelfinavir, 
ritonavir, saquinavir, telaprevir, tenofovir, tipranavir  
Calcium -channel blockers  diltiazem, mibifradil, verapamil  
Foods/herbs  grapefruit, grapefruit juice, Seville oranges  
Serotonin antagonist  nefazodone  
Tyrosine kinase inhibitor  imatinib  
Vasopressin antagonist  conivaptan  
Moderate to 
Strong CYP3A 
Inducer s 
 Antibiotics  nafcillin,  rifampin  
Anticonvulsants  carbamazepi[INVESTIGATOR_050], phenobarbital, phenytoin  
Antiviral reverse 
transcriptase inhibitor s efavirenz, etravirine  
Endothelin receptor 
antagonist  bosentan  
Foods/herbs  St. John’s wort  
Wakefulness -promoting 
agent  modafinil  
Reference: [ FDA 2014 ] 
Abbreviation:  CYP=cytochrome P450 enzyme  
 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 101 of 115  Version 7 ( 15 April  2022 ) 12.4. RAI Staging System for CLL/SLL  
Grade  Disease Manifestations  
0 • Absolute lymphocytosis (>15 × 109/L) 
• No lymphadenopathy, splenomegaly, hepatomegaly, anemia  (hemoglobin <11 g/dL) , or 
thrombocytopenia  (platelet count <100 × 109/L) 
1 • Lymphadenopathy  with or without absolute lymphocytosis (>15 × 109/L) 
• No splenomegaly, hepatomegaly, anemia (hemoglobin <11 g/dL), or thrombocytopenia 
(platelet  count <100 × 109/L) 
2 • Absolute lymphocytosis (>15 × 109/L) 
• Splenomegaly and/or  hepatomegaly  with or without absolute lymphocytosis (>15 × 109/L) 
and/or lymphadenopathy  
• No anemia  (hemoglobin <11 g/dL)  or thrombocytopenia  (platelet  count <100 × 109/L) 
3 • Absolute lymphocytosis (>15 × 109/L) 
• Anemia  (hemoglobin <11 g/dL) with or without absolute lymphocytosis (>15 × 109/L), 
lymphadenopathy, splenomegaly, and/or hepatomegaly  
• No thrombocytopenia (platelet  count <100 × 109/L) 
4 • Thrombocytopenia (platelet  count <100 × 109/L) with or without absolute lymphocytosis 
(>15  × 109/L), lymphadenopathy, splenomegaly, hepatomegaly,  and/or anemia 
(hemoglobin  <11 g/dL)  
Reference: [ Rai 1975 ] 
 
12.5. Efficacy Assessment s – CLL /SLL  
The determination of CLL/SLL response and progression will be based on standardized criteria 
[Hallek 2008], as recently updated [ Hallek 2018;  Cheson 2012].  
12.5.1.  Identification and Measurement of Tu mor Lesions and Organomegaly  
[IP_ADDRESS].   Index Lesions  
At screening, up to 6 lymph nodes should be selected as index lesions that will be used to quantitate the status of the disease during study treatment. Ideally, the index lesions should be located in disparate r egions of the body. Only peripheral nodes need be selected as index lesions. 
However, it is optimal if mediastinal and retroperitoneal areas of disease are assessed whenever these sites are involved.  
Index lesions will be measured and recorded at screening and at the stipulated intervals. The cross -sectional dimensions (the largest cross -sectional diameter, ie, the LD × LPD) will be 
recorded (in  cm) for each index lesion. The product of the perpendicular diameters ([COMPANY_003]) (in 
cm
2) for each index lesion and SP D (in cm2) for all index lesions will be calculated and recorded. 
The screening SPD will be used as references by [CONTACT_512970]. The nadir LD of individual lesions and the nadir SPD will be used as re ferences by [CONTACT_512971]/SLL progression will be characterized. All LD and LPD 
diameters will be reported in centimeters and all [COMPANY_003]s and SPDs will be reported in centimeters squared.  
A nodal mass may be selected as a nodal index lesion if it is both abnormal  and measurable at 
screening. A lymph node lesion is considered abnormal if it has a single diameter that is > 1.5 cm 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 102 of 115  Version 7 ( 15 April  2022 ) and is considered measurable if it has 2 perpendicular diameters that can be accurately measured 
in cross section with the LD being ≥ 1.0 cm  and the LPD also being ≥ 1.0 cm.  
Index lesions measuring >1.[ADDRESS_664152] one or both diameters >0 cm and 
<1.0 cm cannot be reliably measured, a default value of 1.0 cm will be assigned for each 
diameter that meets these criteria and the resulting [COMPANY_003] will be used in SPD calculations. Based 
on this convention, a CR may be achieved even if an SPD value is >0 cm2, (ie, if all lymph nodes 
measure <1.0 cm2). 
A new node that measures  ≥1.5 cm in any  diameter will be considered progressive disease 
[Hallek 2018] . 
In cases in which a large lymph node mass has split into multiple components, only those 
elements that are > 1.0 cm in ≥ [ADDRESS_664153] the default [COMPANY_003] of 
1.0 cm2 (1.0 cm  × 1.0 cm) stored only for the purposes of calculating the nadir SPD value. 
If lesions merge, a boundary between the lesions will be established so the LD of each individual 
lesion can continue to be measured. If the lesions have merged in a way that they can no longer be separated by [CONTACT_320205], the newly merged lesion will be measured bi -dimensionally. 
[IP_ADDRESS].   Spleen and Liver  
Both the spleen and liver will be assessed by [CONTACT_4654]/MRI scan at screening and at the stipulated intervals during treatment. The screening and nadir values for the longest vertical dimension (LVD) of each organ will be used as reference to further characterize the objective tumor response of the measurab le dimensions of the CLL/SLL during treatment. All spleen and liver 
LVD measurements should be recorded in centimeters.  
By [CONTACT_9661], the spleen will be considered enlarged if it is >13 cm in LVD [ Bezerra 2005 ; 
Asghar 2011], with the LVD being obtained by [CONTACT_512972] (eg, if the spleen is seen in 14 contiguous cross -sectional images with 0.5 -cm thickness, the L VD is recorded as 7 cm).  
For patient s with splenomegaly at screening or at the splenic LVD nadir, respective response and 
progression evaluations of the spleen will consider only changes relative to the enlargement of the spleen (ie, the portion of the LV D that is >1 3 cm by [CONTACT_9661]) at screening or nadir, not 
changes relative to the total splenic LVD.  
A 50% decrease from screening (minimum decrease of 2 cm) in the enlargement of the spleen in its LVD or to 
≤13 cm by [CONTACT_512973] a splenomegaly response. 
Conversely, an increase in splenic enlargement by ≥ 50% (minimum increase of 2 cm) from nadir 
is required for declaration of splenic progression. Patient s with a normal spleen LVD (ie, a LVD 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 103 of 115  Version 7 ( 15 April  2022 ) of ≤12 cm by [CONTACT_9661]) at nadir will only be considered to have progressed if the spleen attains a 
LVD of >14 cm by [CONTACT_9661]. 
There is no firmly established international consensus of the size of a normal liver. For this 
study, an increase in the liver size of ≥50% of the extent enlargement of the liver below the costal margin defined by [CONTACT_23302], or the de novo appearance of hepatomegaly by [CONTACT_512974]. However, given the impact of numerous medical conditions, liver size by [CONTACT_512975] i s not a reliable measure of hepatic 
involvement by [CONTACT_512976]  [Hallek 2018] . 
A 50% decrease from screening (minimum decrease of 2 cm) in the enlargement of the liver in its LVD or to 
≤18 cm by [CONTACT_512973] a hepatomegaly response. 
Conversely, an increase in liver enlargement by ≥ 50% (minimum increase of 2 cm) from nadir is 
required for declaration of hepatic progression.  
[IP_ADDRESS].   Non -Index Lesions  
Any other measurable and abnormal nodal lesions not selected for quantitation as index lesions may be considered non- index lesions. In addition, non- measurable evidence of CLL/SLL such as 
nodal lesions with both diameters <1.0 cm, extranodal lesions, bone lesions, leptomeningeal 
disease, ascites, pleural or pericardial effusions, lymphangitis of the skin or lung, abdominal masses that are not confirmed and followed by [CONTACT_410357], cystic lesions, previously 
irradiated lesions, and lesions with artifacts may be co nsidered as non- index disease.  
The presence or absence of non -index disease should be recorded at screening and at the 
stipulated intervals during treatmen t. If present at screening, up to 6 non- index lesions should be 
recorded. The non -index disease at screening will be used as a general reference to further 
characterize regression or progression of CLL/SLL during assessments of the objective tumor response  during treatment. Measurements are not required, and these lesions should be followed 
as “present” or “absent”.  
[IP_ADDRESS].   Bone Marrow  
Bone marrow  assessments will be based on morphologic evaluation of bone marrow biopsies. 
Immunohistochemistry may be used to asse ss response if the sample is indeterminate by 
[CONTACT_5293].  
12.5.2.   Definitions of Tumor Response and Progression  
Responses will be categorized as complete response (CR), complete response with incomplete 
blood count recovery (CRi), partial response (PR), partia l response with lymphocytosis (PR -L), 
stable disease (SD), or progressive disease (PD). In addition, a response category of nonevaluable (NE) is provided for situations in which there is inadequate information to otherwise categorize response status. A sum mary of response criteria  is provided in Table [ADDRESS_664154] response recorded from the start of treatment until PD/recurrence. The screening measurement wil l be 
taken as a reference for determinations of response. The nadir measurement will be taken as a reference for PD; this measurement constitutes the smallest measurement recorded, including the 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol:  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 104 of 115  Version 7 (15 April  2022) screening measurement if this is the smallest measurement. Wh ere imaging data are available, 
these data will supersede physical examination data in determining tumor status. 
Table  5: Summary of Response Criteria  for CLL/SLL Patients  
Group  Parameter  CR PR PD SD 
A Lymph nodes  None ≥1.5 cm  Decrease ≥50% 
(from baseline)*  Increase ≥50%  
from baseline or 
from response  Change of  
‒49% to +49%  
Liver and/or spleen 
size†  Spleen size <13 cm; 
liver size normal  Decrease ≥50% 
(from baseline)  Increase ≥50%  
from baseline or 
from response  Change of  
‒49% to +49%  
Constitutional 
symptoms  None  Any Any Any 
Circulating 
lymphocyte count  Normal  Decrease ≥50% 
from baseline  Increase ≥50%  
over baseline  Change of  
‒49% to +49%  
B Platelet count  ≥100 × 109/L  ≥100 × 109/L or 
increase ≥50% 
over baseline  Decrease of ≥50% 
from baseline 
secondary to CLL  Change of  
‒49% to +49%  
Hemoglobin  ≥11.0 g/dL 
(untransfused and 
without 
erythropoietin)  ≥11 g/dL or 
increase ≥50% over baseline  Decrease of ≥2 g/dL 
from baseline secondary to CLL  Increase <11.0 
g/dL or <50% over baseline, or 
decrease <2 g/dL  
Marrow  Normocellular, no 
CLL cells, no B -
lymphoid nodules  Presence of CLL 
cells, or of B -
lymphoid nodules, 
or not done  Increase of CLL cells 
by ≥50% on successive biopsies  No change in 
marrow infiltrate  
Source: Hallek 2018  
*Sum of the products of 6 or fewer lymph nodes (as evaluated by [CONTACT_512977]).  
†Spleen size is considered normal if <13 cm. There is no firmly established international consensus of the size of a normal l iver; therefore, liver 
size should be evaluated by [CONTACT_512978] a study protocol.  
CR, complete remission (all of the criteria have to be met); PD, progressive disease (at leas t 1 of the criteria of group A or group B has to be 
met); PR, partial remission (for a PR, at least 2 of the parameters of group A and 1 parameter of group B need to improve if previously abnormal; if only 1 parameter of both groups A and B is abnormal before therapy, only 1 needs to improve); SD, stable disease (all of the criteria have to be met; constitutional symptoms alone do not define PD).  
[IP_ADDRESS].   Complete Response and Complete Response with Incomplete Blood Count 
Recovery  
To satisfy criteria for CR or CRi , all of the following conditions must be attained:  
• No evidence of new disease 
• ALC in peripheral blood of <4 x 109/L 
• Regression of all index nodal masses to normal size <1.5 cm in the LD  
• Normal spleen and liver size 
• Regression to normal of all nodal non-i ndex disease and disappearance of all detectable 
non-nodal, non-index disease 
• Morphologically negative bone marrow defined as <30% of nucleated cells being lymphoid cells and no lymphoid nodules in a bone marrow sample that is normocellular for age  
• Peripheral blood meeting all of the following criteria: 
o ANC ≥ 1.5 x 10
9/L without need for exogenous growth factors (eg, G- CSF)  
o Platelet count ≥ 100 x 109/L without need for exogenous growth factors 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 105 of 115  Version 7 ( 15 April  2022 ) o Hemoglobin ≥ 110 g/L (11.0 g/dL) without red blood cell transfusions or need for 
exogenous growth factors (eg, erythropoietin)  
Note: Patients who fulfill all the criteria for a CR (including bone marrow criteria) but who 
have a persistent anemia, thrombocytopenia, or neutropenia or a hypocellular bone marrow that is related to prior or ongoing drug toxicity (and not to CLL/SLL) will be considered as a CRi.  
[IP_ADDRESS].   Partial Response  
To satisfy criteria for a PR, all of the following conditions must be attained:  
• No evidence of new disease  
• A change in disease status meeting ≥ 2 of the following criteria, with 2 exceptions in which only 1 
criterion is needed: (1) Only lymphadenopathy is present at screening; or (2) only 
lymphadenopathy and lymphocytosis are present at screening; in these [ADDRESS_664155] improve to the extent specified below:  
o Decrease in peripheral blood ALC by ≥ 50% from screening  
o A decrease by ≥ 50% from the screening in the SPD of the index nodal lesions  
o In a patient  with enlargement of the spleen at screening, a splenomegaly response as 
defined in Section [IP_ADDRESS] 
o In a patient  with enlargement of the liver at screening, a hepatomegaly response as 
defined in Section [IP_ADDRESS] 
o A decrease by ≥ 50% from screening in the CLL/SL L bone marrow infiltrate or in 
B-lymphoid nodules  
• No index, splenic, liver, or non- index disease with worsening that meets the criteria for 
definitive PD  
• Peripheral blood meeting ≥ 1 of the following criteria:  
o ANC ≥ 1.5 x 109/L or ≥ 50% increase over screenin g without need for exogenous 
growth factors (eg, G -CSF)  
o Platelet count ≥ 100 x 109/L or ≥ 50% increase over screening without need for 
exogenous growth factors  
o Hemoglobin ≥ 110 g/L (11.0 g/dL) or ≥ 50% increase over screening without red blood 
cell transfusion s or need for exogenous growth factors (eg, erythropoietin)  
[IP_ADDRESS].   Partial Response with Lymphocytosis  
To satisfy criteria for a PR -L, the following conditions must be attained:  
• No evidence of new disease  
• All criteria for PR achieved (per  Section [IP_ADDRESS]) except for the lack of a decrease in 
peripheral blood ALC by ≥ 50% from screening  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 106 of 115  Version 7 ( 15 April  2022 ) [IP_ADDRESS].  Stable Disease 
To satisfy criteria for SD, the following conditions must be attained:  
• No evidence of new disease  
• There is neither sufficient evidence of tumor shrinkage to qualify for PR nor sufficient 
evidence of tumor growth to qualify for definitive PD  
[IP_ADDRESS].   Progressive Disease  
The occurrence of any of the follow ing events indicates PD:  
• Evidence of any new disease:  
o A new node that measures >1.5 cm in any diameter  
o New splenomegaly as defined in Section [IP_ADDRESS] 
o New hepatomegaly as defined in Section [IP_ADDRESS] 
o New non -index disease (eg, effusions, ascites, or other organ abnormalities related to 
CLL/SLL)  
Note: Isolated new effusions, ascites, or other organ abnormalities are not sufficient evidence alone of PD unless histologically confirmed. Thus, a declaration of PD should not be made if this is the only manifestation of apparently new disease. 
• Evidence of worsening of index lesions, spleen or liver, or non- index disease:  
o Increase from the nadir by ≥ 50% from the nadir in the SPD of index lesions  
o Increase from the nadir by ≥ 50% in the LD of an individual node or extranodal mass 
that now has an LD of >1.5  cm and an LPD of > 1.0 cm  
o Splenic progression as defined in Section [IP_ADDRESS] 
o Hepatic progression as defined in Section [IP_ADDRESS] 
 Unequivocal increase in the size of non -index disease (eg, effusions, ascites, or 
other organ abnormalities related to CLL/SLL)  
 Transformation to a more a ggressive histology (eg, Richter syndrome) as 
established by [CONTACT_37409] (with the date of the lymph node biopsy being considered the date of CLL/SLL progression if the patient  has no earlier objective 
documentation of CLL/SLL progression)  
• Decrease in platelet count or hemoglobin that is attributable to CLL/SLL, is not 
attributable to an autoimmune phenomenon, and is confirmed by [CONTACT_512979]/SLL cells  
o The current platelet count is <100  x 10
9/L and there has been a decrease by >50% 
from the highest on- study platelet count  
o The current hemoglobin is <110 g/L (11.0 g/dL) and there has been a decrease by 
>20 g/L (2  g/dL) from the highest on- study hemoglobin  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol:  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 107 of 115  Version 7 (15 April  2022) Note: If there is uncertainty regarding whether there i s true progression, the patient should 
continue study treatment and remain under close observation (eg, evaluated at 4- week 
intervals) pending confirmation of progression status. In particular, worsening of 
constitutional symptoms in the absence of objective evidence of worsening CLL/SLL will not be considered definitive disease progression; in such patient s, both CLL/SLL -related and 
non- CLL/SLL-related causes for the constitutional symptoms should be considered. 
Worsening of disease during temporary interr uption of study treatment (eg, for intercurrent 
illness) is not necessarily indicative of resistance to study treatment. In these instances, CT/MRI or other relevant evaluations should be considered in order to document whether definitive disease progression has occurred. If subsequent evaluations suggest that the patient has experienced persistent definitive CLL/SLL progression, then the date of progression should be the timepoint at which progression was first objectively documented.  
[IP_ADDRESS].   Nonevaluable 
In a patient  who does not have evidence of PD, the response status of NE will be assigned when 
there are no images or inadequate or missing images to visualize index, non-index or splenic disease.  
In addition, the following occurrence indicates a response status of NE:“Clinically significant” 
contemporaneous period of interruption of study drug administration or other event that in the 
opi[INVESTIGATOR_512928]. 
Note: When  there is uncertainty of true progression, the response  status of NE should not be 
used more than one time in succession . The  prior and subsequent  tumor assessment s must not 
demonstrate PD for the NE assessment to stand. I f the radiographic response is PD for the 
subsequent  evaluation, even if there was an interruption to study drug administration  or 
uncertainty remains about true progression , PD will be assessed (not NE)  in both cases. The 
date of PD should be the date the progression was first suspected. These cases should be 
discussed in advance with the Sponsor.  
[IP_ADDRESS].   Lymphocytosis during Therapy  
Lymphocytosis early in cirmtuzumab or ibrutinib therapy may not represent disease progression in patient s who have persistent control of other CLL/SLL- related sign s and symptoms 
[Cheson 2012]. In the absence of other objective evidence of disease progression, 
lymphocytosis alone will not preclude patient s from meeting the criteria for PR if other criteria 
for PR are met and will not be considered evidence of PD if occurring in isolation.  Patient s 
with lymphocytosis should be continued on study drug until the occurrence of definitive disease progression (ie, disease progression that is manifest by [CONTACT_512980]/SLL-related signs other than lymphocytosis alone), or the occurrence of another reason to discontinue study therapy as described in Section  7.1.  
12.6.   Efficacy Assessment – Lymph oma 
The determination of response and progression for MCL and MZL will be based on standardized criteria [ Cheson 2007] as recently updated [ Cheson 2014
]. A summary of updated response 
criteria is provided in Table 6 . 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol:  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 108 of 115  Version 7 (15 April  2022) 12.6.1.   Identification and Follow-up of Tumor Lesions and Organomegaly 
[IP_ADDRESS].   Index Lesions  
Up to 6 lesions (eg, lymph nodes, liver or spleen nodules, and/or other circumscribed extranodal 
masses) should be selected as index lesions that will be used to quantitate the status of the disease during study treatment. Ideally, the index lesions should be located in disparate regions of the body and include mediastinal, abdominal, and retroperitoneal areas of disease whenever these sites are involved. For patient s with FDG-avid lymphomas undergoing PET, selection of 
FDG -avid lesions is preferred. The IWG criteria for reviewing PET scans were based on visual 
interpretation and intended for end-of-treatment evaluation, using mediastinal blood pool as the comparator. The current recommendation is to use the Deauville 5-point scale, both for clinical trials including interim analysis and for end-of- treatment assessment . 
Index lesions will be measured and recorded at screening and at the stipulated intervals during treatment. The largest cross -sectional dimensions (ie, the LDi × shortest dimension [SDi] will be 
recorded (in  cm) for each index lesion. Using the LD and SDi, the product of the pe rpendicular 
diameters ([COMPANY_003]) for each index lesion will be calculated. The [COMPANY_003]s and the SPDs for all index lesions will be calculated and recorded. The screening and nadir [COMPANY_003]s of individual lesions and the screening and nadir SPDs will be used as references by [CONTACT_512981]. All [COMPANY_003] and SPD measurements will be reported in centimeters squared. 
[IP_ADDRESS].   Nodal Index Lesions 
A nodal mass may be selected as a nodal index lesion if it is measurable at screening. A lymph 
node lesion is considered measurable if it has 2 perpendicular diameters (LDi and SDi) that can be accurately measured in cross section . A measurable node must have an LDi greater than 1.5 
cm [Cheson 2014].
 Nodal index lesions measuring >1.5 cm in the LD, regardless of the 
measurement of the LPD, will be prioritized during screening index lesion selection. 
At follow -up timepoints, the [COMPANY_003]s for individual nodal lesions and the SPD of all nodal index 
lesion s will be considered. 
A new node that measures >1.5 cm in any diameter will be considered PD. Criteria for response 
assessments are detailed below and in Table 6  [Cheson 2014]. 
In cases in which a large lymph node mass has split into multiple components, the individual 
[COMPANY_003]s of the nodes will be summed together to represent the [COMPANY_003] of the split lesion; this [COMPANY_003] will be added to the sum of the [COMPANY_003]s of the remaining lesions to measure response. If subsequent growth of any or all of these discrete nodes occurs, the nadir of each individual node will be used to determine PD (as if each individual node was selected as a target lesion at baseline).  
If nodal lesions merge, the [COMPANY_003] of the current confluent mass will be compared with the sum of the [COMPANY_003]s of the individual nodes, with >50% increase in the [COMPANY_003] of the confluent mass compared with the sum of individual nodes necessary to indicate PD.  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol:  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 109 of 115  Version 7 (15 April  2022) [IP_ADDRESS].   Extranodal Index Lesions  
An extranodal ma ss may be selected as an index lesion if it is measurable at screening. It is 
considered measurable at screening if it has 2  perpendicular diameters that can be accurately 
measured in cross section with the LD being >1.[ADDRESS_664156] one or 
both diameters < 0.5 cm and >0  cm cannot be reliably measured, a default value of 0.5  cm will be 
assig ned for each diameter that meets these criteria and the resulting [COMPANY_003] will be used in SPD 
calculations. If an extranodal lesion is no longer clearly visible, it will be considered resolved 
and its [COMPANY_003] will be defined as 0 cm2.  
If an extranodal lesion that had resolved (ie, had a [COMPANY_003] of 0 cm2) subsequently reappears and 
reaches  >1.[ADDRESS_664157] PD. Criteria for response 
assessments are detailed below and in Table 6  [Cheson 2014]. 
[IP_ADDRESS].   Non -Index Lesions  
Any other measurable and abnormal nodal or extranodal lesions not selected for quantitation as index lesions may be considered non-index lesions. In addition, non- measurable evidence of 
lymphoma such as abnormal, non-measurable nodal lesions, extranodal lesions with both diameters <1.0  cm, bone lesions, leptomeningeal disease, ascites, pleural or pericardial effusions, 
lymphangitis of the skin or lung, abdominal masses that are not confirmed and followed by [CONTACT_15218], cystic lesions, previously irradiated lesions, or lesions with artifacts may be considered as non- index disease.  
If present at screening,  up to 10 non-index lesions should be recorded. Measurements are not 
required .  
Non-index disease will be used as a general reference to further characterize regression or 
progression of lymphoma during assessments of the objective tumor response during tr eatment. 
These lesions should be followed as “present” or “absent”. 
[IP_ADDRESS].   Spleen  
Assessments of the sizes of the spleen will be performed. For patient s with splenomegaly at 
screening or at the nadirs for assessments of the spleen, evaluations will consider only changes 
relative to the enlargement of the organ (ie, the portion of the LVD that is >13 cm by [CONTACT_512982]) at screening or nadir, not changes relative to the total splenic LVD. 
By [CONTACT_9661], the spleen will be considered enlarged if it is >13 cm in LVD [ Cheson 2014].  In the 
setting of splenomegaly, the splenic length must increase by > 50% of the extent of its prior 
increase beyond the LVD  normal of 13 cm (e g, a 15-cm spleen must increase to > 16 cm). If no 
prior s plenomegaly, must increase by [CONTACT_2669] 2 cm from baseline.  
[IP_ADDRESS].   Bone Marrow  
Bone marrow assessments will be based on morphologic evaluation of bone marrow biopsies. Immunohistochemistry or flow cytometry may be used to assess response if the sample is indeter minate by [CONTACT_5293]. The recommendation for bone marrow response is that 
histologically normal bone marrows with a small (< 2%) clonal B -cell population detected by 
[INVESTIGATOR_47933]: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 110 of 115  Version 7 ( 15 April  2022 ) flow cytometry should be considered normal, given that definitive clinical studies that 
demonstrate an inferior outcome are lacking [ Cheson 2007] . (Note: Blinded independent review 
may be used to determine responses .) 
In a patient  who has a screening bone marrow biopsy showing bone marrow lymphoma or does 
not have a screening bone marrow examination, declaration of an on- study CR requires bone 
marrow biopsy documentation of the absence of bone marrow lymphoma. In a patient  who has a 
screening bone marrow biopsy showing no evidence of lymphoma, declaration of an on- study 
CR does not require bone marrow examination as long as other criteria for CR are met. Of note, in patient s with an FDG- PET avid lymphoma, declaration of an on- study CR can be based on 
FDG -PET documentation of the absence of bone marrow involvement, even if a bone marrow 
biopsy is not available , or if by [CONTACT_11136], independent pathologic review a marrow is reported as 
normal or indeterminant . 
[IP_ADDRESS].   Lymph Node Biopsy  
During study participation, a patient  who has a lymph node biopsy indicating transformation to a 
more aggressive lymphoma (eg, DLBCL) will be considered to have PD even in the absence of other evidence of PD. If the patient  has no earlier objective documentation of PD, the date of the 
lymph node biopsy will be considered the date of PD.  
12.6.2.   Definitions of Tumor Response and Progression  
Responses will be categorized as complete response (CR), partial response (PR), stable disease 
(SD), or progressive disease (PD). In addition, a response category of nonevaluable (NE) is provided for situations in which there is inadequate information to otherwise categorize response status.  
The best overall response will be determined. The best overall response is the best on- treatment 
response from screening recorded from the start of treatment until PD/recurrence. The screening measurement will be taken as a reference for determinations of response. The nadir measurement will be taken as a reference for PD; this measurement constitutes the smallest measurement recorded, including the screening measurement if this is the smallest measurement. For FDG -avid tumors, metabolic criteria for response by [CONTACT_10052] -CT will take precedence over 
anatomic criteria for response by [CONTACT_314480] w hen assessing CR. 
[IP_ADDRESS].   Complete Response 
To satisfy criteria for CR, all of the following conditions must be attained:  
• No evidence of new disease  
• Regression of all index nodal lesions to ≤1.5 cm in the LDi 
• Regression to ≤1.5 cm of all nodal non- index disease  
• Disappearance of all detectable extranodal index and non- index disease  
• Normal spleen size by [CONTACT_20521]  
• If PET performed, no evidence of residual disease – ie, score of 1 (no uptake above 
background), 2 (uptake ≤mediastinum), or 3 (uptake > mediastinum but ≤liver) on the 
Deauville 5 -point scale , with or without a residual mass [ Cheson 2014] . [Note : In 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 111 of 115  Version 7 ( 15 April  2022 ) Waldeyer’s ring or in extranodal sites (eg, gastrointestinal tract, liver, bone marrow), 
FDG uptake may be greater than in  the mediastinum with complete metabolic response, 
but should be no higher than surrounding normal physiologic uptake (eg, with marrow activation as a result of chemotherapy or myeloid growth factors)] . 
• Negative for bone marrow involvement by [CONTACT_512983] a PET -avid tumor or by 
[CONTACT_512984] a unilateral core biopsy; if the bone marrow biopsy is indeterminate by [CONTACT_5293], it should be negative by [CONTACT_330413] . Due to its greater accuracy, in this study priority is given to flow cytometry 
analyses when available.  The recommendation for bone marrow response is that 
histologically normal  or indeterminant  bone marrows with a small (< 2%) clonal B -cell 
population detected by [CONTACT_512985], given that definitive clinical studies that demonstrate an inferior outcome are lacking [ Cheson 2007].  
• A compl ete metabolic response (CMR) based on PET -CT would be attained if a score of 
1, 2, or 3 with or without a residual mass on the Deauville 5- point scale  is observed in 
lymph node or extralymphatic sites, no new lesions, and no evidence of FDG -avid 
disease in  marrow.  
[IP_ADDRESS].   Partial Response  
To satisfy criteria for PR, all of the following conditions must be attained:  
• No evidence of new disease  
• A ≥50% decrease from screening in the SPD of the index nodal and extranodal lesions  
o When a lesion is too small to measure on CT, assign 5 mm x 5 mm (0.25 cm2) as the 
default value  
o When no longer visible, 0 x 0 mm  
o For a node > 5 mm x 5 mm, but smaller than normal, use actual measurement for calculation  
• No increase from the nadir in the size of non -index disease  
• In a patient  with enlargement of the spleen at screening, a splenomegaly response as 
defined in Section [IP_ADDRESS]  
• If PET performed:  
o Typi[INVESTIGATOR_897], FDG -avid lymphoma: S core of 4  or 5 on the Deauville 5- point scale with 
reduced uptake compared with baseline and residual mass(es) of any size.  
o Variably FDG -avid lymphoma/FDG -avidity unknown: if no pretreatment PET scan 
or if the pretreatment PET scan was negativ e for lymphoma, CT criteria should be 
used in assessing the tumor during treatment. If the PET scan was positive before 
therapy, the on- treatment PET is positive in ≥ 1 previously involved site.  
 Bone Marrow: If PET performed, residual uptake should be higher than uptake in normal 
marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed)  [Cheson 2014 ]. 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 112 of 115  Version 7 ( 15 April  2022 ) [IP_ADDRESS].   Stable Disease 
To satisfy criteria for SD, all of the following conditions must be attained:  
• No evidence of new disease  
• Neither sufficient tumor shrinkage from screening to qualify for PR nor sufficient 
evidence of tumor growth to qualify for PD  
• If PET performed, the results show a score of 4 (uptake moderate ly >liver) or score of 5 
(uptake markedly >liver) on the Deauville 5- point scale with no significant change in 
uptake compared with screening or end of treatment [ Cheson 2014] . 
[IP_ADDRESS].   Progressive Disease  
The occurrence of any of th e following events indicates progressive disease (PD):  
• Evidence of any new disease that was not present at screening:  
o A new node that measures >1.5 cm in any diameter  
o Reappearance of an extranodal lesion that had resolved (ie, had previously been assigned a [COMPANY_003] of 0 cm
2) 
o A new extranodal lesion >1.0 cm . If < 1.[ADDRESS_664158] be attributable to lymphoma. 
o New non -index disease (eg, effusions, ascites, or other organ abnormalities) of any 
size unequivocally attribut able to lymphoma (usually requires PET, biopsy, 
cytology, or other non- radiologic confirmation to confirm disease attributable to 
lymphoma). Note: Isolated new effusions, ascites, or bone lesions are not sufficient evidence alone of PD unless histologicall y confirmed. In patient s with no prior 
history of pulmonary lymphoma, new lung nodules identified by [CONTACT_512986]. Thus, a declaration of PD should not be made if this is the only manifestation of an apparently new lesion.  
o New FDG- avid foci consis tent with lymphoma rather than another etiology (eg, 
infection, inflammation). If there is uncertainty regarding the etiology of new lesions, biopsy or interval scan may be considered. 
o New or recurrent bone marrow involvement with lymphoma by [CONTACT_512987]. 
• Evidence of worsening of nodal or extranodal index lesions:  
o Increase from the nadir by ≥ 50% in the SPD of index lesions  
o Evidence of worsening of individual index lymph nodes or nodal masses with an 
increase from the nadir by ≥ 50% in the [COMPANY_003] for any individual node if the node now 
has an LDi of >1.5 cm, an increase by ≥50% from the nadir [COMPANY_003], and an increase in LDi or SDi from the nadir by:  
 ≥0.5 cm for lesions measuring ≤2.0 cm (in LDi or SDi) or  
 ≥1.0 cm for lesions measuring >2.0 cm (in LDi or SDi)  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol :  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 113 of 115  Version 7 ( 15 April  2022 ) o Unequivocal increase in the size of non -index disease  
o Unequivocal worsening in the size of the spleen as defined in Section [IP_ADDRESS]  
• Transformation to a more aggressive NHL histology as established by [CONTACT_37409] 
• If PET performed, there is a score of 4 (uptake moderately >liver) or score of 5 (uptake 
markedly >liver) on the Deauville 5- point scale with an increase in uptake compared with 
the nadir in conjunction with an anatomic increase in lesion size consistent with PD.  
Note: Study patient s undergoing PET for lymphoma assessment can experience transient 
disease flare on imaging before having subsequent therapy -induced tumor regression. 
Worsening of constitutional symptoms or performance status in the absence of objective evidence of worseni ng lymphoma (eg, due to infection) may not represent definitive disease 
progression. Further, transient worsening of disease during temporary interruptions of study therapy (eg, for drug- related toxicity or inter -current illness) may not indicate definitiv e 
progressive lymphoma. If there is uncertainty regarding whether there is true lymphoma progression and if medically appropriate, the patient  may continue or resume study treatment 
and remain under close observation (eg, evaluated at 4- week intervals) whi le relevant 
radiographic, clinical, and/or laboratory assessments are performed to document whether tumor control can be maintained or whether disease progression has truly occurred. If subsequent evaluations suggest that the patient  has experienced persis tent definitive disease 
progression, then the date of progression will be the timepoint at which progression was first objectively documented.  
[IP_ADDRESS].   Nonevaluable  
In a patient  who does not have evidence of PD, the response status of NE will be assigned when 
there are no images or inadequate or missing images to visualize index, non- index, or splenic 
disease.  
In addition, the following occurrence indicates a response status of NE:  “Clinically significant” 
contemporaneous period of interruption of study drug admi nistration  or other event that in the 
opi[INVESTIGATOR_512929].  
Note: When there is uncertainty of true progression, the response  status of NE should not be 
used more than one ti me in succession. The prior and subsequent tumor assessments must not 
demonstrate PD for the NE assessment to stand. I f the radiographic response is PD for the 
subsequent  evaluation, even if there was an interruption to study drug administration  or 
uncerta inty remains about true progression , PD will be assessed (not NE)  in both cases . The 
date of PD should be the date the progression was first suspected. These cases should be discussed in advance with the Sponsor.  
 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol:  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 114 of 115  Version 7 (15 April  2022) Table 6: Summary of Response Criteria for MCL  and MZL  Patients  
 
 
  
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37
Investigational Product: Cirmtuzumab (UC -961)  
Study Protocol:  CIRM -0001 Oncternal Therapeutics, Inc.  
CONFIDENTIAL  Page 115 of 115  Version 7 (15 April  2022)  
Source: Cheson 2014  
 
DocuSign Envelope ID: 79119608-04B8-451D-8A29-573F49B08D37